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Abstract 
 
 
Introduction: Chronic heart failure (CHF) is associated with an increased incidence of 
atrial fibrillation (AF) and elevated levels of catecholamines and endothelin-1 (ET-1), each 
of which affects the atrial L-type calcium current (ICaL) and consequently action potentials. 
 
Hypotheses: ET-1 modulates the effects of isoproterenol (ISO) on ICaL and action potentials 
in human atrial myocytes. 
 
Methods: Atrial myocytes were isolated enzymatically from samples of right atrial 
appendage obtained from consenting patients in sinus rhythm undergoing cardiac surgery. 
The nystatin-perforated whole cell patch clamp technique was used at 37ºC to record ICaL 
and action potentials in voltage-clamp and current-clamp mode respectively. 
  
Results: The current-voltage relationship of ICaL was bell-shaped, peaking at +10 mV with 
a current density of -4.8±0.4 pA/pF (mean± s.e.m., n=89 cells, 34 patients). ISO, 0.1 nM to 
1 µM, increased peak ICaL in a concentration-dependent manner (n=4-46 cells) with a 
maximum response of 250± 53% above control and an approximate EC50 of 0.06 µM. 
Isoproterenol at 0.05 µM significantly increased peak ICaL from -4.7± 0.4 to -12.2± 0.9 
pA/pF (P<0.05, Students t-test; n=64 cells). This adrenergic effect was reversed by ET-1 at 
all concentrations tested from 0.01 to 10 nM and was partially reversible upon ET-1 
washout and in the presence of the specific ET-A receptor antagonist, FR139317 (n=5-12 
cells). Neither ET-1 alone nor the ET-B receptor agonist Sarafotoxin S6c, at 10 nM, had an 
effect on ICaL.  
 
 
  iii 
Isoproterenol (0.05 µM) prolonged the action potential duration at 50% repolarisation 
(APD50) from 30± 7 to 46± 7 ms (P< 0.05, n=15 cells), but had no effect on APD90 nor the 
cellular ERP. These adrenergic effects on APD50 and SDs were also abolished by ET-1 at 
10 nM (P< 0.05, n=15 cells). Superfusion with ET-1 (10 nM) alone had no significant 
effect on APD50, APD90, nor ERP (n=21 cells). There were no significant interactions 
between these electrophysiological effects and diseases states or chronic pre-operative drug 
therapy. 
 
Spontaneous activity, defined as a depolarisation occurring during phase 3 of action 
potential repolarisation or a depolarisation of greater than 3 mV amplitude during phase 4, 
frequently interrupted action potential recordings during, but not prior to, superfusion with 
ISO. Using a repetitive stimulation protocol, ISO at 0.05 µM produced spontaneous 
depolarisations in 5 of 7 cells studied (P< 0.05, χ2 test). Endothelin-1 at 10 nM abolished 
these depolarisations in all 5 cells (P< 0.05). Superfusion with ET-1 (10 nM) alone was 
associated with spontaneous depolarisations in significantly fewer cells (P< 0.05, n=2 of 
13 cells). 
 
In a retrospective univariate analysis, patient comorbidity and pre-operative drug therapy 
were not found to influence the electrophysiological effects observed. 
 
Conclusions: ET-1 reversed adrenergically induced increases in peak ICaL, APD50 and SDs 
in human atrial myocytes. This anti-adrenergic effect may be expected to influence the 
occurrence of AF in patients irrespective of comorbidity or pre-operative drug therapy.                 
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1 GENERAL INTRODUCTION 
1.1 Atrial Fibrillation- the clinical problem 
 
Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia in humans 
and epidemiological studies have demonstrated that the incidence of AF is 
increasing1. Characterised by multiple electrical wavelets spreading chaotically 
throughout the atrium resulting in rapid irregular stimulation of the ventricles via 
the atrioventricular node (AVN), AF causes an irregular tachycardia. Ventricular 
contraction in AF is both irregular in frequency and force of contraction as a result 
of the Frank-Starling mechanism2. This may produce an unpleasant sensation of 
palpitation, and in addition, the  tachycardia, if prolonged, results in atrial 
contractile dysfunction, a pro-thrombotic state predisposing to thrombo-embolic 
disease and a reduction in cardiac output which can precipitate heart failure3;4.  
Patients who develop AF suffer increased morbidity and an approximate doubling 
of mortality compared with aged-matched controls5. Treatment has traditionally 
aimed at either terminating the arrhythmia by cardioverting the patient back to 
sinus rhythm, ‘rhythm control’, or slowing the ventricular rate in AF via drugs which 
increase the refractory period of the AVN, ‘rate control’. Recent evidence has 
demonstrated that the increased morbidity and mortality in AF is maintained in 
both rhythm and rate control strategies due to the combination of anti-arrhythmic 
drug toxicity, insufficient anti-coagulation to prevent thromboembolism and the 
high relapse rate of AF6-8. 
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1.2 Fundamental mechanisms of arrhythmogenesis in 
human atria 
 
The three fundamental mechanisms underpinning arrhythmogenesis are triggered 
activity, reentry and abnormal automaticity the occurrence of which is promoted by 
several pathophysiological remodelling processes (Figures 1.1-1.4). In order to 
understand any potential effects on human atrial arrhythmogenesis a brief 
description of the ionic flux during a normal human atrial action potential will be 
followed by a discussion of each of the three fundamental mechanisms in turn. 
 
Under normal circumstances the rapid upstroke of the human atrial myocyte action 
potential (phase 0), mediated by INa, occurs as an all or none response if the cell is 
depolarised to threshold (-50 mV) by its neighbour from the resting potential of 
approximately -75 mV. This rapid upstroke reaches positive potentials (+40 to +60 
mV) and is immediately followed by transient repolarisation comprised of rapidly 
inactivating fast sodium current (INa) and activation of the repolarising  transient 
outward and ultra-rapid rectifying potassium currents Ito and IKur (phase 1)
9. 
Membrane depolarisation (above -40 mV to peak activation at +10 mV) activates 
L-type calcium current (ICaL) which maintains the action potential plateau (phase 2) 
providing the electrochemical driving force for K+ efflux, and as ICaL inactivates, the 
rapid and delayed rectifier repolarising currents IKur, IKr, IKs and IKATP predominate 
returning the membrane voltage back towards the resting potential (phase 3)9. The 
atrial myocyte is relatively quiescent during phase 4, in readiness for subsequent 
stimulation (Figure 1.4). 
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Figure 1.1 Schema indicating the complex inter-relationships between the fundamental mechanisms 
of arrhythmogenesis, human atrial electrophysiological remodelling and atrial pathophysiologies 
known to be associated with AF in humans. 
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Figure 1.2 Representations of A) EADs and B) DAD in human atrial myocytes adapted from 
Workman et al, Heart Rhythm 2008;5:S1-S6. Typical human atrial action potentials in bold with 
shaded lines indicating the impact of early or late depolarisations on action potential morphology and 
subsequent generation of triggered activity, indicated by star symbol. 
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Figure 1.3 Schema displaying the formation of a 2 dimensional reentrant circuit. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Schema displaying abnormal automaticity due to accelerated depolarisation of phase 4 of 
a stylised action potential. 
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1.2.1 Triggered Activity 
Triggered activity, by definition, are abnormal afterdepolarisations dependent on 
the preceding action potential for their generation which, if reaching threshold, 
trigger a subsequent action potential. These diastolic oscillations in the membrane 
potential are classified according to the phase of the preceding action potential 
during which they occur (Figure 1.2). 
 
Early depolarisations (EADs), which by definition disrupt repolarisation in phase 2 
or 3 of the action potential, are associated with prolongation of repolarisation and 
bradycardia or pause dependent mechanisms10. Delayed afterdepolarisations 
(DADs), however, which occur during phase 4 of the action potential are often 
associated with tachycardia. In the presence of β- adrenergic stimulation both 
EADs and DADs may occur at physiological heart rates due to cellular calcium 
loading albeit by differing mechanisms10;11. If an EAD is sufficiently large it can 
cause the cell to reach threshold and result in a new subsequent action potential 
manifesting as an ectopic beat on the surface electrocardiogram (ECG) or, as a 
result of electrotonic interaction with surrounding myocardial cells in various 
stages of refractoriness, can result in initiation of a reentrant arrhythmia12;13. 
Triggered activity has been almost exclusively studied in ventricular preparations, 
although occasional atrial experiments have been reported14-16. 
 
EADs are associated with a reduction in rapid and slow activating delayed rectifier 
currents IKr and IKs combined with augmentation of ICaL and late INa which prolongs 
the APD sufficiently to allow ICaL to recover from inactivation and reactivate during 
the plateau of the action potential10;11;17-20. EADs have consistently been induced 
by stimulation of beta-adrenoceptors (β-AR) by ISO21;22 resulting in 
aftercontractions22;23. EADs were initially thought to be particular to the conducting 
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tissue or Purkinje network24 but more recently have been demonstrated in atrial 
preparations although their clinical relevance remains to be determined15;20;25. 
 
DADs are a result of spontaneous SR calcium release at the end of the action 
potential which activates the transient inward current (Iti) comprised primarily of the 
sodium-calcium exchange current (INaCa) and the calcium activated chloride 
current (ICa(Cl)) under conditions that favour cellular calcium overload
11;16;20;26-29. 
Under normal circumstances calcium entry via ICaL and reverse mode INaCa acts as 
the trigger for calcium induced calcium release (CICR) from the sarcoplasmic 
reticulum (SR) resulting in a calcium transient30-33. The local control theory34 
linking the close proximity of the ICaL pores with the ryanodine receptors of the SR 
in the dyadic cleft explains how calcium sparks can be graded and both temporally 
and spatially summated into global calcium transients depending on the magnitude 
of the whole cell ICaL, SR calcium content and ryanodine receptor status
35-43. The 
direction and magnitude of INaCa is dependent on the myocyte membrane potential 
and the local concentration gradients across the plasmalemma of Ca2+ and Na+ 
and the stoichiometry of the reverse mode INaCa results in a net inward current 
prolonging myocyte repolarisation and APD44. 
 
Confocal microscopy has demonstrated differing spatial features of EADs as 
compared with DADs45, with greater homogeneity demonstrated following an EAD, 
as expected with membrane bound electrophysiological mechanisms, as opposed 
to the focal spontaneous SR calcium release resulting in a DAD, although 
significant overlap may exist10;22;45-47. Indeed recent evidence has identified a 
potential role for INaCa in EAD formation both as conditioning agent and as charge 
carrier10;11;17;48;49. 
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ET-1 was, at first, thought likely to predispose to EADs and DADs by reducing IK 
and causing increased intracellular calcium loading50 via augmenting ICaL. The 
Pulmonary Vein sleeves, thought by many to be the predominant driver behind 
most AF51, may be particularly prone to triggered arrhythmia52;53. Although results 
from initial experiments investigating potential arrhythmogenic effects of ET-1 in 
cardiac tissue remain difficult to interperet54-60, several groups reported focal 
‘arrhythmia’ or spontaneous contractions following acute exposure to ET-156;61-64. 
The potential for ET-1 to have arrhythmogenic effects in human atrium remains to 
be determined. 
 
1.2.2 Intra-atrial Reentry 
Intra-atrial reentry occurs when a depolarising wavefront being propagated 
between atrial myocytes encounters an area of unidirectional block. If the aetiology 
of block is functional, should the wavefront travel in another direction and return to 
this refractory tissue when it is no longer refractory it will now conduct creating a 
circuit (2 dimensional circuit represented in Figure 1.3). Conduction within the 
circuit will be maintained if in the intervening period neighbouring myocytes have 
regained excitability. If the wavefront travels along the entire circuit (Conduction 
Time) sufficiently slowly (Conduction Velocity) that all points within the circuit (Path 
Length) recover from refractoriness the circuit may be maintained indefinitely. The 
wavelength is the product of refractory period and conduction velocity and as such 
it represents the distance traveled by an impulse in one refractory period. The 
wavelength determines the shortest circuit that may accommodate functional 
reentry. Thus any factor that reduces conduction velocity and refractoriness or 
increases path length or conduction time will promote reentry and ultimately AF. 
Decreased INa and upstroke velocity (Vmax), decreased ICaL or increased IK, 
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decreased action potential duration (APD) and effective refractory period (ERP), 
atrial dilation and stretch all promote reentry. 
 
Traditionally considered in terms of the “leading-circle model”, as illustrated in 
Figure 1.3, recent developments in biophysical theory have suggested the utility of 
a “spiral wave model” of reentry65;66. In cardiac tissue, a spiral wave of reentry can 
occur following an ectopic beat, howsoever generated, that initiates a depolarising 
wavefront which traverses the trajectory of a previous sinus beat and encounters 
tissue in various stages of repolarisation. This second wavefront blocks in 
refractory tissue, however is able to propagate across non refractory tissue, albeit 
tangentially in 3-dimensions, curving towards newly excitable myocytes65. The 
major difference between the leading-circle and spiral wave models of reentry, 
other than level of complexity, is the improved correlation of the impact of INa 
blockade on re-entrant circuit characteristics predicted by the spiral wave model. 
 
1.2.3 Abnormal Automaticity 
Abnormal automaticity in the atrium occurs when atrial or pulmonary vein 
myocytes, which are not normally pacemaker cells, begin to spontaneously fire as 
a result of accelerated phase 4 depolarisation (See Figure 1.4). If the rate at which 
these cells reach threshold exceeds that of the sino-atrial node (SAN), then an 
ectopic rhythm will supervene. This form of regular tachycardia may act as a 
trigger to atrial tissue that is vulnerable to reentry which may fractionate, or may 
result in fibrillatory conduction because the atrial myocardium is not capable of 
maintaining 1:1 conduction for some reason (see below). Although the primary 
phase 4 depolarising current, If, is expressed in atrial tissue from patients suffering 
AF and in porcine CHF models no direct evidence for a role of abnormal 
automaticity has been identified to date in human patients67-69. 
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1.3 AF begets AF: electrophysiological remodelling 
It has long been established that the longer the duration of AF the lower the 
likeliehood of successful cardioversion and subsequent maintainance of sinus 
rhythm indicating that the arrhythmia itself is associated with changes which result 
in perpetuation of the arrhythmia70;71. More recently in animal models using rapid 
atrial pacing to induce AF and in observational clinical studies, atrial 
electrophysiological and cellular changes have been shown to rapidly occur 
favouring the arrhythmia becoming permanent72-74. The electrical changes, 
collectively termed electrophysiological remodelling, result in a shortened atrial 
action potential duration (APD) and an abbreviated atrial effective refractory period 
(ERP)73. In addition the normal physiological rate adaptation of human atrial APD 
and ERP which results in proportional shortening of the APD and ERP with 
increasing heart rate is lost73. Combined with decreases in conduction velocity75-77 
and increased heterogeneity in atrial repolarisation78 these AF induced changes in 
APD and ERP create a substrate for the multiple wavelet circuit re-entry necessary 
to perpetuate AF.  
 
Isolated human atrial myocyte electrophysiology experiments corroborate these 
changes in APD and ERP and indicate that the ionic mechanisms which underpin 
electrophysiological remodelling can be attributed, at least in part, to alterations in 
the L-type calcium current (ICaL)
79;80. Reductions in human atrial myocyte peak ICaL 
current density have been associated with chronic atrial fibrillation in a number of 
studies81-84 ranging from 50% (Christ), 63% (Workman) to 75% (Skasa) in the 
presence (Christ) and absence (Workman) of a change in current voltage 
relationship79 and have been attributed to various protein expression 
downregulation of the pore forming α-1c subunit
85-87, although this remains 
controversial88;89. More recently the interaction of intracellular kinases and 
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phosphatases have been implicated84;90-92. These observations only partly explain 
AF induced remodelling however. 
 
1.4 AF begets AF: cellular remodelling 
The multiple re-entry circuits of AF produce very high frequency electrical activity 
in the atrium in vivo, typically up to 600 beats per minute93. Rapidly increasing 
rates of electrical stimulation of human atrial myocytes in vitro are associated with 
large increases in calcium influx contributing to calcium overload94. In chronic rapid 
atrial pacing models of AF, calcium overload has been implicated in alterations in 
atrial myocyte subcellular apparatus; sarcoplasmic reticulum disruption, 
mitochondrial swelling74;95, dedifferentiation and hypertrophy resulting in apoptotic 
cell death96. Similar ultrastructural changes have been described in human atrial 
myocytes from patients in AF97. During the first few days of AF the time course of 
the development of atrial contractile dysfunction parallels that of electrical 
remodelling98, suggesting that these two processes share similar or common 
mechanisms. However the offset kinetics are different in that although electrical 
remodelling reverses within days, atrial mechanical dysfunction persists for some 
weeks99. Down regulation of synthesis of calcium handling and ICaL channel 
proteins have been reported85;100-102 in response to calcium overload. The time 
course of mRNA regulation and ultimately expression of calcium handling 
apparatus is in the order of 3 months, many times longer than that of 
electrophysiological remodelling100;102. Experimental evidence supports the pivotal 
role of ICaL in these maladaptive processes. The calcium channel blocking drug 
verapamil reduced both electrical remodelling and contractile dysfunction while, in 
contrast, calcium loading of the cell with the dihydropyridine agonist BAY 8644 had 
the opposite effect103;104. The administration of intracellular calcium lowering 
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agents to patients has been demonstrated to reduce the AF recurrence rate 
following successful DC cardioversion105. 
 
1.5 Atrial Fibrillation and Chronic Heart Failure  
AF does occur in the absence of structural heart disease, however it is more 
commonly associated with cardiac disease, particularly chronic heart failure 
(CHF). Observational studies have associated CHF with an approximate six fold 
increase in the development of AF, and AF is positively correlated with the severity 
of CHF5;106. The incidence of AF and CHF doubles for every successive decade of 
age and is estimated to increase, in part, due to an ageing population1;107-110. In 
patients with CHF the development of AF is associated with a further deterioration 
in morbidity and mortality4. Atrial Fibrillation induced atrial contractile dysfunction 
combined with the irregular tachycardia immediately compromises ventricular 
filling and if the tachycardia persists can lead to dilated cardiomyopathy111. 
 
1.6 CHF induced atrial electrophysiological and 
structural remodelling 
 
Several possible contributing pathophysiological mechanisms link AF and CHF. 
Rapid ventricular pacing induced CHF in dogs and was associated with 
electrophysiological remodelling in atrial myocytes112;113. These ventricular-paced 
CHF-induced reductions in atrial ICaL (~30%) are smaller than those reported in 
rapid atrial pacing induced ionic remodelling (~70%)113. However in human atrial 
myocytes from patients with CHF reductions in ICaL (~80%)
114 are similar in 
magnitude to those associated with AF (~65%)79;81. CHF causes elevated filling 
pressures resulting in haemodynamic stretch producing atrial dilatation which is 
also associated with diminished atrial ICaL
115 and the development of AF116. 
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Histological examination of atrial myocytes from patients with CHF demonstrated 
myocyte hypertrophy with evidence of local atrial conduction slowing, interstitial 
fibrosis and apoptosis, creating a suitable substrate for arrhythmia117;118. Such 
changes in the atria of animals with heart failure have been shown to be effective 
substrates of anisotropic and/ or very slow conduction which could permit the 
development of multiple circuit re-entry even within very small areas of the 
atrium119. These results demonstrate that the electrophysiological changes 
associated with AF/ rapid atrial pacing and CHF share the common mechanism of 
ICaL remodelling. 
 
1.7 CHF induced neurohormonal activation 
The publication of a large number of negative results from trials examining 
haemodynamic interventions in heart failure stimulated investigation of alternative 
pathophysiological mechanisms in CHF. The neurohormonal hypothesis of 
CHF120;121 postulated that a number of neurohormones such as catecholamines, 
Angiotensin II (A-II)122 and Endothelin-1123;124 are elevated acutely during 
myocardial embarrassment in order to preserve cardiac output and maintain vital 
organ perfusion. Initially beneficial, if the reduction in cardiac output is irreversible, 
as in CHF, the ensuing ventricular dysfunction produces persistent atrial stretch, 
baroreceptor dysfunction, excessive adrenergic activation, neurohormonal 
activation125 and a positive feedback cycle resulting in a progressive deterioration 
in cardiac function. The ability of the failing ventricle to respond to endogenous or 
exogenous catecholamines becomes markedly attenuated126 and a new 
cardiovascular equilibrium is reached in which peripheral vasoconstriction and fluid 
overload supervenes. Perfusion of the other vital organs, most notably the kidney, 
is adversely affected resulting in yet further sympathetic activation until cardiac 
output is insufficient to maintain life.  
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Elevation in the serum concentrations of catecholamines and endothelin-1 are 
positively correlated with deteriorating left ventricular systolic function, regardless 
of aetiology122;125;127 and are associated with poor outcome in patients with 
CHF122;128;129. In patients with CHF, elevated serum levels of the endothelin 
precursor big ET-1 are independently predictive of the development of AF130, and 
the onset of AF in these patients is associated with yet further elevation of serum 
levels of ET-1131 and a poorer prognosis4. Interruption of the neurohormonal 
positive feedback cycle by beta-blockers (β-B)132;133, formerly contraindicated in 
patients with CHF due to their adverse haemodynamic impact, are now of proven 
mortality benefit in patients with CHF134-137 and thus are now recommended 
therapy138. Atrial Fibrillation commonly complicates CHF, indeed often causing 
haemodynamic decompensation1;139;140. There is also increasing evidence that 
beta-blockers have a role in both 'rhythm control'141-143 and 'rate control' treatment 
strategies and this is supported by mechanistic evidence for an adaptive atrial 
cellular electrophysiological response to chronic beta blockade in patients termed 
‘pharmacological remodelling’144. 
 
1.8 Endogenous and exogenous catecholamines 
The endogenous catecholamines, dopamine, norepinephrine (NE) and 
epinephrine (E) are sympathomimetic amines derived from L-tyrosine which act as 
neurotransmitters throughout the nervous system in humans.  During periods of 
physiological stress the adrenal medulla acts as a neuroendocrine transducer, 
transforming efferent impulses from the pre-ganglionic sympathetic fibres into 
hormonal signals, releasing NE and E into the peripheral blood to mediate the 
“fight or flight” response. Under normal conditions the neurohormones E and NE 
are both detectable in low concentration in peripheral blood. However in CHF 
patients the concentrations of catecholamines in peripheral blood are chronically 
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elevated and correlate with CHF severity122. Catecholamines acting as 
neurohormonal first messengers bind to membrane bound alpha (α-AR) and beta 
(β-AR) adrenoceptors throughout the body. These two types of adrenoceptors can 
be differentiated by their sensitivity to agonists. α-AR are most sensitive to NE; β-
AR are most sensitive to the synthetic sympathomimetic amine isoproterenol (ISO) 
and the response to epinephrine is intermediate. Isoproterenol is the isopropyl 
analogue of E and acts almost exclusively at β-AR. β-AR are further classified into 
two types, β1-AR and β2-AR, both of which are expressed on the sarcolemmae of 
human atrial myocytes in the ratio of (β1-AR 4:1 β2-AR)
145 and both employ cAMP 
as a second messenger146.  
 
The binding of ISO with either of the β-ARs produces conformational change in the 
cytosolic membrane bound guanyl-nucleotide regulatory protein (G-protein) 
complex147. In human atrial myocytes there are two types of heterotrimeric G 
proteins associated with the β-AR: Gs and Gi, which stimulate and inhibit 
adenylylcyclase catalysing the formation of cyclic AMP (cAMP) from adenosine 
triphosphate (ATP), respectively. This enzyme cascade is further extended by the 
action of cAMP to activate protein kinase A (PKA), which phosphorylates 
intracellular effector proteins and this is counter-balanced by cellular 
phosphatases and phosphodiesterases (PDE) which degrade cAMP. 
 
1.9 The positive inotropic effect of Isoproterenol  
The force frequency relationship is similar in human atrium and ventricle, however, 
important differences in atrial microarchitecture148 and intracellular calcium 
processing exist149;150. In isolated strips of human ventricle selective stimulation of 
β2-AR results in at most 50% of the maximal positive inotropic effect
151, whereas 
selective stimulation of β2-AR in human atrial myocardium results in a maximal 
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inotropic response152. Isoproterenol acting via both β1-AR and β2-AR has a 
positive inotropic effect153, maximal in micromolar concentrations, mediated by the 
cAMP second messenger system146;154. ISO induces an increase in intracellular 
calcium, both cytosolic via phosphorylation of ICaL
155 and within the sarcoplasmic 
reticulum (SR) via PKA dependent phosphorylation of phospholamban156.  
 
This ISO-induced positive inotropic effect can be modified by a range of 
physiological, pathophysiological and therapeutic processes. Increased 
senescence was associated with impaired responsiveness to ISO in the absence 
of altered receptor expression and a combination of reduced catalytic activity of 
adenylate cyclase and increased Gi in human atria
157 in contrast to human 
ventricular myocytes in which reduced β1-AR and Gs expression were 
demonstrated158. In atrial tissue obtained from patients with CHF the maximal 
positive inotropic effect of ISO was preserved despite reduced levels of beta 
adrenoceptors expression158;159 in contrast to human ventricular papillary muscle 
in which the positive inotropic effect of ISO was blunted in association with 
reduced beta adrenoceptor expression159. The positive inotropic effect of 
catecholamines is greater in atrial tissue obtained from patients receiving selective 
β1-AR antagonists
152 despite a lack of effect on β2-AR density or affinity,  due to 
enhanced β2-AR Gs-protein coupling
160. 
 
1.10 The effect of ISO on ICaL and action potentials 
Influx of calcium ions via ICaL depolarises the atrial myocyte contributing to the 
action potential plateau161 and stimulates calcium-dependent-calcium-release from 
the sarcoplasmic reticulum thereby permitting excitation:contraction coupling162. A 
wide number of hormones and second messengers acting via the cAMP/ PKA 
pathway can phosphorylate the calcium channel and thus modulate inward 
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calcium current. At physiological temperature ICaL is larger with more rapid 
activation and inactivation161 than at room temperature155. ISO, on binding to β-
AR, activates Gs-protein adenylylcyclase and via temperature-dependent enzyme 
cascades culminates in the phosphorylation of dihydropyridine-sensitive calcium 
channels resulting in increased ICaL
90;147;161. No changes in ICaL single channel 
conductance, reversal potential, or the numbers of channels available have been 
observed in response to β-AR stimulation with ISO90. In human atrial myocytes 
ISO at 1µM almost doubled ICaL current density and resulted in an elevation in the 
action potential plateau161. Relatively little is known regarding the effects of ISO on 
APD and ERP in human atrial myocytes, and there have been no reports in the 
literature of the impact of pre-cardiac surgery β-B therapy or heart failure on the 
effects of ISO on ICaL, APD and ERP with respect to arrhythmogenesis. 
 
1.11 The pro-arrhythmic effects of ISO 
Increased adrenergic stimulation alone or in combination with increased rates of 
electrical stimulation causes an increase in the frequency and amplitude of 
diastolic calcium sparks162. If the SR calcium load is sufficiently enhanced, waves 
of calcium-induced-calcium-release propagate in cardiac myocytes, activating 
pacemaker currents and stimulating delayed afterdepolarisations and triggered 
arrhythmia162. Increased cytosolic calcium concentration accelerates ICaL 
inactivation161;163 which predisposes to early afterdepolarisations. In addition to 
effects on calcium handling in human atria, ISO has effects on outward 
repolarising currents. ISO reversibly increased, in a concentration dependent 
manner, the delayed rectifier potassium currents IK
164 and the ultrarapid delayed 
rectifier potassium current Ikur
165. Furthermore ISO increased the pacemaker 
current (If) amplitude, shifting the voltage of activation towards more positive 
values in human atrial cells166 which in combination would increase the probability 
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of delayed afterdepolarisations and predispose to re-entry in human atrium. The 
ability of catecholamines to induce afterdepolarisations in human ventricle and 
animal atrium is well recognised167. However despite the many reports of the 
effects of ISO on isolated currents in human atrium, the pro-arrhythmic effects of 
isoproterenol to induce afterdepolarisations in isolated human atrial myocytes has 
not been previously demonstrated. 
 
1.12 Endothelin-1  
Endothelin-1 is a relatively short 21 amino-acid peptide first isolated from the 
cultured supernatant of porcine aortic endothelial cells, unrelated to previously 
identified vasoconstrictor peptides168. The first and most abundant of the three 
endogenous isoforms to be identified, mature ET-1, is generated by the action of 
endothelin converting enzyme (ECE) on big ET-1 which has previously been 
cleaved from intrinsic or circulating preproET-1, a 200 amino acid polypeptide. 
Endothelin-1 has been demonstrated to have vasoconstrictive effects in several 
vascular beds in numerous mammalian species including humans168-171 and has a 
multitude of other effects; stimulating the release of NO and prostacyclin from 
vascular endothelial cells172, stimulating proliferation in smooth muscle cells173 and 
myocardial cell hypertrophy174, in addition to  positively inotropic175-178 and 
lusitropic179 effects in human atrial myocytes. Endothelin-1 binds with two distinct 
endothelin receptor subtypes, ET-A which has a greater affinity for ET-1
180 and ET-
B
181 which has almost equal affinity for all three endothelins (ET-1, ET-2 & ET-3). 
Both endothelin receptor subtypes, ET-A and ET-B, are seven transmembrane 
domain spanning, Gq-protein-coupled receptors (GPCR) that are widely expressed 
throughout the normal and diseased human heart182-184. In human right atrial 
specimens the endothelin receptor subtype expression ratio ET-A: ET-B was 
approximately 2:1184. In patients with CHF, levels of ET-1 are elevated
123. In atria 
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from failing hearts ECE mRNA was upregulated and ET-1 peptide levels were 
increased, while ET-A mRNA was unaltered and ET-B mRNA was downregulated 
in failing hearts185. The human atrial endothelin system is also altered in AF131. 
The amount of ET-A and ET-B receptor proteins were significantly reduced in 
patients with AF, as was ET-B mRNA when compared with tissue from patients in 
sinus rhythm186. In human right atrial myocytes ET-1, via ET-A receptors, inhibits 
adenylate cyclase via Gi protein and also activates protein kinase C (PKC) via Gq-
protein coupled phospholipase C (PLC)184;187. This is in contrast to human 
ventricular myocytes in which ET-A receptors are not coupled to Gi inhibition of 
adenylate cyclase188. In human right atrial strips, ET-1 in concentration dependent 
manner from 0.1 nMol to 1 µMol, increased inositol tri-phosphate (IP3) 
accumulation but had no effect on cAMP under basal conditions187.  
 
1.13 The positive inotropic effect of endothelin-1 
An endothelin system has been described in human atrial and ventricular 
myocardium185;189. Evidence for an autocrine or paracrine effect of ET-1 in the 
human heart is growing56;57;190. In human cardiac tissue nanoMolar concentrations 
of ET-1 had a greater positive inotropic effect via ET-A receptors in right atrial than 
in ventricular preparations175;188;191. The positive inotropic effect of ET-1 is 
maintained191 or enhanced188 in atrial tissue from failing compared to non-failing 
hearts. The positive inotropic effect of ET-1 results from an ET-A mediated 
activation of PKC increasing intracellular calcium concentrations and an increased 
myofilament sensitivity to calcium via PKC activated increases in Na/H exchanger 
activity177;178;188;191-194. Initially it was speculated that the increased cytosolic 
calcium concentration required to create the positive inotropic effect of ET-1 was 
due to an ET-1 induced increase in ICaL. However, subsequently it has been shown 
that ET-1 can produce a positive inotropic effect in the absence of an increase in 
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ICaL
195-197. In rat atrium ET-1 had a powerful positive inotropic effect raising 
intracellular calcium concentration by 50% in the presence of the ICaL blocker PN 
200-110197. ET-1, although positively inotropic, was significantly less positively 
inotropic than ISO193 in human right atrial tissue. The positive inotropic effect of 
ET-1 but not ISO was abolished when PKC or Na/ H exchange was inhibited177. 
ET-1 did not activate adenylate cyclase and therefore appears to have a positive 
inotropic effect independent of cAMP. Thus the positive inotropic effect of ET-1 is 
mediated differently to that of ISO and potentially independent of ICaL in human 
atrial tissue.  
 
1.14 The effect of ET-1 on ICaL and action potentials 
A direct effect of ET-1 on inward calcium current was suggested in the original 
paper isolating ET-1 as, in porcine coronary artery, the vasoconstrictor effect of 
ET-1 was inhibited in the absence of extracellular calcium ions and in the 
presence of Nicardipine, a selective dihydropyridine calcium channel blocker168. 
Endothelin-1 at 10 nM had no effect on the affinity or density of dihydropyridine 
binding sites and at 100 nM failed to displace bound radio-labelled calcium 
channel agonists in rat cardiac membranes suggesting that ET-1 does not interact 
with the dihydropyridine calcium channel at the level of the membrane receptor198. 
The effect of ET-1 on human atrial ICaL is controversial. In two studies, at room 
temperature employing the ruptured patch method, ET-1 has been found to 
increase199, decrease199;200 and have no effect199 on human atrial ICaL. The 
stimulatory effect of ET-1, where detected, was antagonised by the ET-A receptor 
antagonist BQ-123 and the inhibitory effect of ET-1 antagonised by the ET-B 
receptor antagonist BQ-788199. However the ET-A receptor antagonist BQ-123 can 
directly modulate ICaL in animal experiments
201. It is recognised that temperature 
affects ICaL and that results from ruptured patch experiments can be difficult to 
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interpret because of a lack of reversibility of effect and 'rundown' of ICaL. The 
perforated patch technique permits a more physiological intracellular milieu, 
prolonging the ability of the cell to respond to neurohormones and avoiding 
disruption of the normal intracellular calcium buffering mechanisms202. Previously 
apparent controversy in the literature relating to results from animal experiments 
were resolved by utilisation of the perforated patch technique demonstrating that 
ET-1 alone under more physiological recording conditions did not modulate basal 
ICaL
203. The absence of any effect of ET-1 on basal ICaL is supported by the lack of 
effect of ET-1 on cAMP under basal conditions in human atrium187;203.  
 
1.15 The proarrhythmic effect of ET-1 
In human cardiac myocytes ET-1 was found to induce arrhythmic contractions in 
right atrial trabeculae, and those occurred more frequently in tissues excised from 
patients receiving, when compared with those not receiving, β-B preoperatively191. 
In one small study, ET-1 had no appreciable effect on action potentials in human 
atrial trabeculae despite the positive inotropic effect remaining intact176. However 
the separation of a vasoconstriction induced ischaemic arrhythmic effect from an 
intrinsic effect on arrhythmogenesis remains controversial59;204. Yorikane61 first 
demonstrated that ET-1 causes APD prolongation in the right bundle branch of 
canine myocardial tissue and that this APD prolongation is followed by early 
afterdepolarisations, suggesting a direct arrhythmogenic effect of ET-1 on cardiac 
cells. The direct arrhythmogenic effect of ET-1 has not been studied in human 
atrial myocytes. 
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1.16 The interaction of ISO and ET-1 on ICaL and action 
potentials 
 
In contrast to the differing effects observed of ET-1 alone on basal ICaL in both 
previous studies in isolated human atrial myocytes, ET-1 (10 nM) had a consistent 
ET-A receptor mediated, pertussis toxin sensitive, anti-adrenergic effect to 
decrease ICaL following pre-stimulation of ICaL with ISO
199;200. This effect was 
irreversible and no data are available to determine whether the effect of ET-1 
could be overcome with increasing concentrations of ISO. ET-1, via ET-A receptors 
has been shown to have an anti-adrenergic effect on other currents in human atrial 
myocytes. The cAMP-activated chloride current (ICl, cAMP) which is controversial as 
it can only be demonstrated under conditions of adrenergic stimulation in some 
atrial myocyte preparations, was activated with 1µM ISO and subsequently was 
significantly inhibited by ET-1 (30 nM) by 75%± 6%205. This anti-adrenergic effect 
of ET-1 could be explained by the effect of nanoMolar concentrations of ET-1 to 
decrease ISO/ forskolin induced increases in cAMP in human right atrial strips. 
There have been no previous reports examining the interaction of effects of ISO 
and ET-1 on APD and ERP in human atrial myocytes, and there have been no 
reports in the literature of the impact of 'pharmacological remodelling' nor CHF on 
the interaction of effects of ISO and ET-1 on ICaL, APD and ERP. 
 
1.17 The potential mechanisms for ISO and ET-1 to affect 
arrhythmogenesis in human atrial myocytes 
 
Atrial Fibrillation has been described as multiple re-entrant waves conducted 
chaotically throughout the atria. Electrical heterogeneity in the atria, whether due 
to ischaemia, structural heart disease or heart failure is central to the phenomenon 
of re-entry. Re-entrant waves are formed when electrically coupled tissue has 
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differing properties of refractoriness or structural discontinuities produce lines of 
unidirectional conduction block. When a wavefront meets refractory tissue the 
direction of the impulse changes traversing around these refractory areas of tissue 
and thus may either be extinguished if the tissue encountered is completely 
refractory or electrically inert, or propagating daughter wavelets and yet further 
fibrillatory waves resulting in arrhythmia perpetuation. 
 
Cardiac arrhythmogenesis, however, requires a trigger to initiate an electrical 
impulse in addition to a substrate of conducting tissue capable of maintaining the 
arrhythmia. More recently, at the level of the whole heart in vivo, the trigger for AF 
has been identified in patients as originating in the pulmonary veins51. At the 
cellular level, triggered activity such as early afterdepolarisations (EAD), which are 
secondary depolarisations occurring prior to full repolarisation of the action 
potential, or delayed afterdepolarisations (DAD), initiated after myocyte 
repolarisation is complete, can result in impulse propagation and formation of 
wavelets capable of being conducted throughout the atria and thus compete with 
the sinus node for non refractory atrial myocytes. 
 
Prolongation of the APD has been implicated in the generation of EADs206. A 
number of mechanisms have been demonstrated to contribute to this prolongation- 
a reduction in repolarising K+ currents resulting in more slowly inactivating 
INa
207;208. Also small calcium transients may result in complete ICaL inactivation 
increasing the likeliehood of inward ICaL reactivation in the AP and thus EADs
11;209. 
 
Abnormalities in calcium handling have a pivotal role in the generation of DADs. 
Activation of β-adrenoceptors augments ICaL and increases SR calcium uptake 
resulting in intracellular calcium overload which in turn increases calcium-
dependent-calcium-release from the SR activating arrhythmogenic transient 
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inward current Iti
210;211. Atrial myocyte calcium loading is further potentiated in 
heart failure due to tachycardia and increased ‘reversed’ sodium-calcium 
exchange current (INCX) combined with decreased IK1, thus for any given SR 
calcium release more INCX will result in more calcium activated Iti and hence 
DADs162;210. Indeed for a given Iti a greater DAD will result, as a reduced IK1 results 
in a less stable Em
210. Thus in heart failure approximately 50% of the normal SR 
calcium release is required to initiate a DAD of sufficient magnitude to reach 
threshold and trigger an action potential which may be propagated into an 
arrhythmia162. 
 
1.18 Hypothesis 
It is my hypothesis that endothelin-1 modulates the effects of isoproterenol on ICaL 
and consequently action potentials in human atrial myocytes. Such modification 
may occur at the level of the ligand-receptor complex or via interaction of 
secondary messenger systems. Any such modification of ICaL by endothelin-1, 
whether alone or in combination with isoproterenol will have implications for 
arrhythmogenesis in the human atrium. 
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2 METHODS 
2.1  Ethical Approval 
 
Ethical approval was obtained from the Ethics Committee of Glasgow Royal 
Infirmary for the use of human atrial tissue for electrophysiology studies from 
consenting patients undergoing cardiac surgery. This investigation conformed with 
the principles established in the Declaration of Helsinki 212. Patients were identified 
from the cardiac surgery theatre schedule and their consent to participate was 
obtained.  
 
2.2 Patient Characteristics 
 
Clinical characteristics of all patients from whom samples of right atrial appendage 
were obtained were recorded in a database (Microsoft Access). Information was 
obtained from the clinical case sheets relating to age, gender, operative procedure 
and comorbidity. Data retrieval was complete in more than 97% of instances. In a 
small number of cases incomplete data was collected due to non availability of 
complete records. This thesis is based on all available information in order to 
maximise utility, thus small variabilities in sample size will be presented. Pre-
operative drug therapy was assessed from prescription charts. Patients who had 
been receiving beta-adrenoceptor blocking drugs for less than 30 days pre-
operatively were excluded from further analysis. None of the patients had 
undergone previous cardiac surgery, ablation procedures or were prescribed 
Amiodarone or Sotalol preoperatively.  
 
Information on cardiac rhythm and rate was assessed using the pre-operative 
ECG. Only those patients in sinus rhythm with no documented episodes of atrial 
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fibrillation in the preceding 6 months prior to surgery were included. 
Postoperatively, case records were later re-examined for evidence of AF up to 
seven days postoperatively. 
 
2.3 Cell Isolation 
 
 
The tip of the right atrial appendage was removed at the time of cardiac 
cannulation for aortopulmonary bypass. The tissue sample was immediately 
transported to the laboratory, within five minutes of excision, immersed in 50 ml 
oxygenated warmed modified Tyrode's solution (NaCl 150 mM, KCl 5.4 mM, 
MgCl2 1.2 mM, NaHEPES 5 mM, glucose 10 mM, CaCl2 1 mM; titrated to pH 7.4 
with HCl 1M solution). Atrial cells were isolated by enzymatic dissociation and 
disaggregation using a modified 'chunk' method first described by Escande213 and 
subsequently modified by Harding158 and Workman79. 
 
Excised tissue was blotted dry and weighed (mass 0.386 ±0.03 g n= 63) then 
placed on a glass slide, cleaned of visible connective tissue and fat and chopped 
with scalpels into ~1 mm3 chunks. These chunks were then transferred to a beaker 
which was placed into a water bath maintained at 37°C, shaken at 130 strokes per 
minute and continuously oxygenated in 40 ml nominally Ca-free solution 'B' (NaCl 
120 mM, KCl 5.4 mM, MgSO4 5 mM, pyruvate 5 mM, glucose 20 mM, taurine 20 
mM, NaHEPES 10 mM, nitrilotriacetic acid 5 mM and titrated to pH 7.0 with NaOH 
1 M solution). The 'chunks' were hand filtered through nylon gauze (200 µm mesh, 
Barr & Wray, Lanark, UK) and transferred to another beaker containing a fresh 
sample of 40 ml oxygenated solution ‘B’ at three minute intervals in order to 
prevent hypoxia and remove any toxic metabolites. After a total of 12 minutes 
agitation the sample was transferred to another beaker containing 15 ml of 
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solution ‘C’ (NaCl 120 mM, KCl 5.4 mM, MgSO4 5 mM, pyruvate 5 mM, glucose 20 
mM, taurine 20 mM, NaHEPES 10 mM, nitrilotriacetic acid 5 mM, CaCl2 50 µM 
and titrated to pH 7.0 with NaOH 1M solution) with protease (Type XXIV, Sigma, 4 
IU/ml) added and were incubated under identical conditions for a further 45 
minutes. 
 
This semi-digested sample was then placed in another 12 ml of modified solution 
‘C’ with collagenase (CLS 1 Type 1, Worthington 330 IU/ml) added in the absence 
of protease and incubated for consecutive periods of 15, 15 and 20 minutes. Each 
of these three cell suspensions were filtered through nylon gauze, as before. 
These three “filtrates” formed three consecutive aliquots which were then 
centrifuged (Model PK110, A.L.C. International) for two minutes at 40 g. The 
resulting supernatant was aspirated by hand and discarded and the remaining 
cells were re-suspended for a maximum of 10 minutes in 1 ml of Kraftbrühe (KB) 
solution214 (KOH 70 mM, KCl 40nM, L-glutamic acid 50 mM, taurine 20 mM, 
KH2PO4 20 mM, MgCl2 3 mM, glucose 10 mM, NaHEPES 10 mM, EGTA 0.5 mM 
and titrated to a pH of 7.2 with 1M KOH solution) in order to wash off any 
remaining enzymes. 
 
The centrifugation process was then repeated and after removing as much of the 
KB solution as possible the cells were re-suspended in 1 ml of a low calcium 
solution (NaCl 130 mM, KCl 4 mM, CaCl2 0.2 mM, MgCl2 1 mM, NaHEPES 10 
mM, glucose 10 mM and titrated to a pH of 7.4 with 1M NaOH solution). Each of 
the three aliquots was transferred to a separate petri-dish for storage at room 
temperature prior to use in experiments. Cells were examined under high power 
(x40) light microscopy (Nikon TMS microscope) and cells which were isolated, 
striated, elongated, straight-edged and stable in the perfusion chamber were 
selected for electrophysiological recordings (Photograph 1 Figure 2.1). 
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2.4 Electrical Recording Techniques 
 
2.4.1 Patch clamp recording 
The extracellular patch clamp method, first described by Neher and Sakmann215, 
permits the observation and recording of ionic currents from biological 
membranes. This technique employs a small highly polished glass pipette 
containing a predetermined specific ‘internal’ solution surrounding a silver filament 
electrode attached to an amplifier and recording equipment. The pipette was 
advanced into the external solution containing the cell to be examined under 
positive pressure to prevent contamination. The tip of the pipette was pressed 
gently against the cell membrane in order to form an electrical seal. The electrical 
resistance of the pipette-membrane seal obtained by this technique was increased 
from 50 MΩ215 to approximately 100 GΩ, using micro-pipettes of smaller tip 
diameter and the application of negative pressure to the cell membrane as contact 
was achieved as advised by Hamill et al216. The advantage of a pipette-membrane 
seal of greater resistance, termed a giga-seal, is that background electrical noise 
or interference is reduced, less current ‘leaks’ around the pipette into the perfusion 
chamber reducing inaccuracy of measurements and the mechanical stability is 
improved.  
 
However, this ‘standard’ ruptured patch whole cell recording technique, also called 
the continuous single electrode voltage clamp (cSEVC), has been shown to suffer 
two major drawbacks when investigating ICaL. The cell membrane is physically 
disrupted, or intentionally ruptured, using negative pressure permitting washout 
and disruption of intracellular calcium buffering mechanisms resulting in rapid 
rundown of ICaL magnitude, alteration of the I: R relationship and desensitisation to 
adrenergic receptor activated second messengers202;217-219. This problem was 
overcome by adding the polyene antibiotic, nystatin, to the internal solution (see 
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below) in the pipette. Nystatin containing pipette solutions have previously been 
demonstrated to form voltage independent, highly selective monovalent cationic 
pores of 0.4 nM diameter in cell membranes without compromising the cell’s 
integrity202, increasing the signal to noise ratio,  preventing ICaL rundown
220;221 and 
maintaining sensitivity to isoproterenol for up to 90 minutes recording221. The 
combination of a high seal resistance around the pipette with the small 0.4 nM 
pores within the pipette permit only monovalent ions and substances up to 200 D 
molecular weight to dialyse with the internal pipette solution, establishing stable 
electrical access with preservation of the normal intracellular cytoplasm. Nystatin 
itself does not enter the cell nor does it cross the glass membrane seal, however it 
is not without its disadvantages. Nystatin solution loses its pore-forming ability 
within 4 hours at room temperature requiring fresh stock solutions during an 
experimental day. This becomes obvious by the inability to obtain satisfactory 
series resistance within approximately 20 minutes. Successful pore formation 
precludes any manipulation of the intracellular constituents of the cell under 
investigation via the patch pipette, limiting opportunities for experimentation. In 
addition the formation of junction potentials and subsequent intracellular 
hypertonicity during long experimental protocols can occur202. This can be 
minimised by ionic substitution in the internal pipette solution, use of electrodes of 
low resistance and effective delivery of sufficient nystatin to the tip of the pipette to 
ensure excellent seal and low series resistance202. 
 
Thus the nystatin-perforated whole cell patch clamp technique202 was employed 
both to limit ICaL rundown
221 and also preserve the internal milieu of the myocyte202 
during experimental protocols. In order to limit vibration artefact cells were 
permitted to sediment in the perfusion bath (RC-24E fast exchange perfusion 
chamber, Warner instruments) (Figure 2.1) positioned on an air suspension table 
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(Wentworth laboratories) (Figure 2.2) coupled with an Axopatch-1D amplifier 
(Axon instruments) (Figure 2.3). 
 
2.4.2 Micropipette electrodes 
Fine borosilicate glass pipette microelectrodes (Clark Electromedical) were 
constructed by hand during cell sedimentation using a vertical micropipette puller 
(Narishige PP-83) using a two stage thinning process and then heat polished to 
resistances (Rp) of 2-5 MΩ (mean Rp= 2.7 ±0.1 MΩ n= 148). First the capillary was 
loaded onto the micropipette puller and thinned at high power increasing capillary 
length by approximately 8 to 10 mm. Then the thinned capillary was re-centred at 
the heating element and low power heating used until the capillary split into two 
identical pipettes. Each of these pipettes was then loaded in turn onto the heat 
polisher under direct visualization via light microscopy. The tip of the pipette was 
manoeuvred close to the glowing filament for a few seconds causing a subtle 
change in shape and a darkening of the silhouette. Pipettes with resistances in the 
range of 2- 5 MΩ have an internal opening diameter of ≤1 µm216. The optimal 
shape of the micropipette is depicted in Figure 2.4A. The Rp associated most 
frequently with successful electrical access to the atrial myocyte was found to be 2 
MΩ as depicted in Figure 2.4B.  
 
The electrode was formed from a silver wire which was polished to ensure a clean 
surface prior to being coated by silver chloride (Ag/AgCl) by anodising in a solution 
of sodium hypochlorite (NaOCl) prior to loading on the head stage (Figure 2.3). 
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2.4.3 Solutions- Internal 
Micropipettes were back-filled with a caesium based ‘internal’ solution (Cs-
methanesulphonic acid 100 mM, NaCl 5 mM, CsCl 30 mM, MgCl2 1 mM, 
NaHEPES 5 mM, pH 7.4 with 1 M CsOH) in order to block K+ currents during 
voltage clamp experiments recording ICaL. For action potential recordings with the 
amplifier in current clamp mode micropipettes were back-filled with a potassium 
based internal solution (K methanesulphonic acid 100 mM, NaCl 5 mM, KCl 30 
mM, MgCl2 1 mM, NaHEPES 5 mM, pH 7.4 with 1 M CsOH). Nystatin (Sigma 184 
µM) was dissolved in DMSO (Sigma 120 µL) and added to fresh internal pipette 
solution at hourly intervals in order to maintain the selective pore forming ability of 
the Nystatin solution202. 
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Figure 2.1 Schemata of the perfusion chamber apparatus with a photograph of human atrial 
myocyte (not to scale) 
 
 
2.4.4 Solutions- External 
Cells were superfused in the sedimentation chamber with a physiological ‘external’ 
salt solution (NaCl 130 mM, KCl 4 mM, CaCl2 2 mM, MgCl2 1 mM, NaHEPES 10 
mM, glucose 10 mM, titrated to pH 7.4 with a 1 M NaOH) at 1.5 ml/ min 
maintained at 37ºC via an in-line heater (SH27-B, Warner instruments) as 
determined by a digital thermometer (Model 410, Rapid electronics). Reagents 
were stored in lightproof sealed containers in a commercial refridgerator as per the 
manufacturers’ recommendations. On the morning of the experiment pre-specified 
amounts of reagent were weighed and dissolved in de-ionised water which had 
been micro-pipetted to the required volume. Reagent solutions were then diluted 
to the desired concentration using de-ionised water and stored in lightproof sealed  
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Figure 2.2. Schemata representing electrophysiology recording rig with photographic image. 
1   Micromanipulators 
2   Microscope 
3   In-line heater 
4   Solution reservoirs 1-5 
5   Thermometer 
6   Head stage 
7   Micropipette 
8   Air table 
9   Light source 
10 Salt bridge 
11 Signal out to Digidata 
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Figure 2.3 Schemata representing digital recording equipment. 
1 Digidata Interface 
2 Oscilloscope 
3 Axopatch 1-D amplifier 
4 Microcomputer and VDU 
1 
2 
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Figure 2.4 Schemata of Micropipette manufacture and frequency distribution of pipette resistance 
(Rp) 
A Schemata to scale of longitudinal and end on appearances of optimal micropipette 
B Frequency distribution of pipette resistance (Rp) associated with successful electrical access to the 
cell (Mean Rp of successful seal formation 2.7 ±0.1 MΩ n= 148 pipettes). 
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containers attached to the perfusion chamber for the duration of the experiment at 
room temperature. During superfusion the in-line heater ensured that the ambient 
temperature within the perfusion chamber was maintained at 37oC (as above). 
 
2.4.5 Liquid Junction Potentials 
 
Using this configuration of solutions with the earth electrode maintained in a 3M 
KCl bath connected via an agar salt bridge to the perfusion chamber a liquid 
junction potential (LJP) of +5 mV (±0.1 mV n=5) was measured (bath relative to 
pipette) using the method described by Neher222 as follows. The patch clamp rig 
was prepared as above with both the micropipette and perfusion chamber filled 
with internal solution. The Axopatch amplifier was switched to current-clamp 
mode, held at 0 pA, and the offset voltage nulled manually. The perfusion chamber 
was then evacuated and refilled with external solution. The voltage reading was 
permitted to stabilise and this solution specific LJP was recorded in the lab book. 
This recorded liquid junction potential was compared with other work performed in 
this laboratory79;223 and found to correlate well. This method of calculating the LJP 
permits a priori compensation, prior to seal formation, of the LJP by WinWCP 
software by inserting a junction potential correction of equal size but opposite 
polarity, however it mandates that the 3M KCl solution in which the salt bridge is 
bathed is refilled at frequent intervals during the experimental process. 
 
2.4.6 Myocyte selection 
 
The perfusion chamber was thoroughly examined with the microscope, initially on 
low power, to determine the most suitable myocyte for patch clamp recordings. 
Myocytes were selected as suitable for recordings if positioned in the perfusion 
chamber within reach of the pipette and if they remained geographically stable. 
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Cells which remained isolated, elongated, and striated under high power 
microscopy during superfusion with control solution containing 2 mM calcium (a 10 
fold increase from the low calcium storage solution) were selected. Myocytes were 
approached obliquely under light microscopy maintaining slight positive pressure 
in the pipette in order to avoid surface contaminants increasing the resistance of 
the microelectrode and consequently inhibiting seal formation. The pipette was 
advanced to within micrometres of the sarcolemma using a micromanipulator 
(Narishige NW-3) under gentle positive pressure per orum via a small rubber tube 
with two O rings attached to the micropipette mounting and then when optimally 
positioned vis a vis the myocyte gentle negative pressure was applied to attach 
the tip of the pipette to the cell membrane until a gigaohm seal was obtained. The 
giga-seal was not lost on any occasion when the negative pressure on the pipette 
was released prior to electrical compensation. 
 
2.4.7 Series Resistance (Rs) and Capacitance (C) Compensation 
 
When the membrane potential was manipulated, there was a significant current 
transient required to charge the membrane capacitance during which it is 
impossible to record meaningful data. The settings of the whole-cell capacitance 
controls to eliminate this capacitative transient are unique to the cell being 
clamped. The values of the cell membrane capacitance and the access resistance 
can be directly read from the Axopatch amplifier controls. The absolute value of 
the membrane capacitance was displayed on the whole-cell capacitance dial after 
the whole-cell current transient has been eliminated. This value may be used to 
estimate the surface area of the cell assuming that the membrane capacitance per 
unit area is 1 µF/cm2. Capacitance compensation was used to reduce the effective 
value of any remaining capacitance error. The Axopatch amplifier injected ‘extra’ 
current into a capacitor connected to the input. At the ideal setting of the amplifier 
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gain, the current injected is exactly equal to the current that passes through the 
stray capacitance to ground hence eliminating error. However, this compensation 
must be implemented cautiously for if the amplifier gain is increased beyond the 
ideal setting, the current injected back will cause the input signal to overshoot 
resulting in circuit oscillation and mycocyte death. 
 
When electrical access to the cell was gained the internal pipette solution formed 
an electrical continuity with the interior of the myocyte. However, this continuity 
was imperfect and there remained a small electrical resistance across the pipette 
of the order 1-10 MΩ. This resistance is termed the series resistance Rs and is 
electronically compensated in a positive feedback loop by increasing the 
command potential proportional to the potential drop across the pipette. The Rs 
must be minimised as it introduces both a voltage error and also lowers the 
temporal resolution of the voltage clamp. In the steady state, the amplifier will 
clamp the potential across the pipette while one is aiming to clamp the potential 
across the cell membrane resulting in an error which can be minimised by 
maintaining as small a Rs as possible. During depolarisation, rapid step changes 
(see below) in potential initiated by command from the amplifier will produce 
changes in cellular Vm with a time lag potentially of milliseconds duration. In order 
to overcome this problem the patch clamp amplifier continuously computes the 
potential drop across the pipette and injects a correction signal to the command, 
effectively reducing the error by a factor of (1- correction factor) thus Rs of 80% 
correction results in an 80% reduction in voltage error and an 80% reduction in 
time lag. Caution must be exercised, however, as compensation was increased 
the stability of the electrical circuit decreased and oscillations occurred resulting in 
myocyte death above 80% Rs compensation. 
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The Series Resistance (Rs) (mean Rs= 7.2± 0.2 MΩ n= 255 cells from 67 patients) 
and Capacitance (C) (mean C= 82.9± 0.8 pF n= 255 cells from 67 patients) of 
these selected myocytes were measured and electronically compensated (mean 
Rs% compensation = 68.2± 0.2% n= 161) following the formation of the perforated 
patch and prior to recording. 
 
Cells were rejected if, after stabilisation, the Rs was >20 MΩ  due to potential 
voltage errors in recording accuracy within the Axopatch 1D amplifier. The 
software programme utilised, WinWCP (J. Dempster, Strathclyde University) on a 
microcomputer (Gateway microcomputers with Pentium III microprocessor) 
permitted simultaneous stimulation and recording. Current and voltage data were 
low passed filtered at 5 kHz and digitised at a rate of 15 kHz (Digidata 1200 A-D 
converter, Axon instruments) prior to storage on compact discs. 
 
2.4.8 Resting Membrane Potential (Vm) 
 
Following Rs and C compensation the cell was permitted approximately 60 
seconds quiescence following which the resting membrane potential under control 
conditions (Vm) was recorded in current clamp mode. This was performed by 
nulling the voltage clamp and recording the potential difference across the 
myocyte membrane prior to recording ICaL or action potentials. The mean Vm for all 
cells was -19± 4 mV (n= 81 cells from 23 patients). 
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2.5 Experimental Protocols 
 
2.5.1 Voltage Clamp: ICaL current: voltage relationship 
 
During voltage clamp experiments the membrane voltage of the myocyte under 
investigation is held constant and the trans-membrane current required to maintain 
that voltage across the cell membrane is measured. This artificial process, if 
performed carefully, eliminates the capacitive current bar the immediate voltage 
step and permits control of activation and inactivation of voltage dependent ICaL. 
The resultant recorded current is directly proportional to the membrane 
conductance of ICaL. 
 
Once a giga-seal was obtained and electrically stable access to the cell achieved 
the cells were voltage clamped at a holding potential (HP) of -40 mV. This was 
chosen in order to avoid contamination of ICaL by rapid and large inward Na
+ 
currents which might be present at more negative potentials. The current-voltage 
(IV) relationship of ICaL was determined using repeated stepwise incremental +10 
mV depolarising pulse steps of 350 ms duration every 3 seconds from the holding 
potential of -40 mV up to a maximum of +60 mV at physiological temperature 
(37°C) (See Figure 2.5). This physiological temperature was chosen as it has 
previously been shown that ICaL has temperature dependent time course of 
activation and inactivation161. Previous work examining ICaL has demonstrated that 
a depolarising stimulus frequency of 0.33 Hz permits full recovery of ICaL prior to 
the next depolarising pulse94. 
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2.5.2 Voltage Clamp: peak ICaL time course effects 
Experiments examining the time course of the effects of both ISO and ET-1 were 
performed using a -40mV Holding Potential with repeated identical voltage steps 
from a HP of -40 mV to +10 mV of 350 ms duration at a fixed frequency of 0.2 Hz 
while the perfusion chamber was maintained at 37°C (Figure 2.6). This step 
potential was chosen as the previously obtained ICaL IV relationship peaked at +10 
mV which is consistent with other reports in the literature using similar 
experimental conditions 79;161. 
 
2.5.3 Current Clamp: action potential recordings 
During a current-clamp experiment a constant or pre-specified time-varying current 
is applied to the myocyte and the resultant change in membrane potential is 
measured. Technically more challenging than voltage clamping in the laboratory, 
current clamping recreates the response of a myocyte to electrical stimulation or 
depolarisation in vivo, that is, the generation of action potentials. 
 
Myocytes in the resting state were current clamped to -80± 5 mV and 
subsequently the holding current was maintained <150 pA thereafter. Action 
potentials were stimulated at 75 beats per minute (bpm) using 5 ms current pulses 
of 120% threshold strength. The stimulus threshold was initially determined by 
repetitively stimulating the cell with a train of three 5 ms current pulses, the first 
and second stimuli being of equal supra-threshold amplitude and the third pulse of 
lesser amplitude increasing in 50 pA increments from 0 pA until a regenerative 
action potential was stimulated. 
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Figure 2.5 Diagram of the protocol for determining the current voltage relationship of ICaL. 
 
 
 
 
 
 
 
 
 
Figure 2.6 Diagram of the protocol for determining the time course of effects on peak ICaL. 
 
This threshold was then increased by a factor of 1.2 and this ‘supra-threshold’ 
stimulus was maintained constant throughout the experiment in that cell (See 
Figure 2.7). The entire train of stimulated action potentials was visible on the 
oscilloscope, however, in order to maximize resolution, only the final two S1 action 
potentials and the S2 action potential were recorded. The APD was calculated as 
the interval between the action potential upstroke and repolarisation to the level of 
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50% (APD50) and 90% (APD90) of the upstroke amplitude (See Chapter 5 Methods 
section).  
 
2.5.4 Current Clamp: Measurement of the effective refractory 
period (ERP) 
 
The ERP of each cell was determined using a standard S1-S2 protocol consisting 
of an 8 pulse conditioning train of 5 ms pulses at 75 bpm (S1) followed by one 
pulse of equal magnitude and duration which was delivered at 10 ms progressively 
shorter intervals (S2) (See Figure 2.7). The cellular ERP was defined as the 
shortest S1-S2 interval which elicited a regenerative action potential of amplitude 
greater than 80% of the preceding S1 action potential.  
  
2.5.5 Current Clamp: Spontaneous depolarisations 
During ERP experiments it was noted on the oscilloscope that following 
superfusion with 0.05 µM ISO a number of cells became electrically unstable. On 
inspection of this phenomenon it appeared that during the train of S1 stimuli the 
appearance of 'spontaneous depolarisations' preceded electrical instability. The 
ERP protocol was modified to a repetitive protocol ('REP') in which the final S2 
stimulus was replaced with another S1 stimulus and the entire train was recorded 
(See Figure 2.7). 
2.6 Data Analysis and Statistics 
 
 
WinWCP raw data records were analysed visually and an absolute value of ICaL for 
every record was obtained by subtraction of the steady state current at the end of 
the depolarising step from the peak inward current. The magnitude of peak ICaL 
absolute current (pA) was corrected for cell capacitance (pF) and the consequent 
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ICaL current density (pA/pF) was used to control for variation in cell size. This 
current density value measured in WinWCP was recorded and stored in Microsoft 
Excel and transferred into the data records of Graphpad Prism software. Mean 
data pertaining to individual myocyte recordings in WinWCP traces were obtained 
using this Prizm software and related mean data graphs constructed. 
 
Myocytes, wherever possible, acted as their own control. Sample size was 
primarily determined by number of myocytes, however the number of human 
subjects required to provide samples of right atrial appendage from which these 
cells were isolated was also recorded. Data relating to ICaL were expressed as 
mean± standard error of the mean (s.e.m.) with nc= number of cells studied and 
np= number of patients from whom these cells were obtained. The mean values 
were compared using a two-tailed paired or unpaired Student’s t-test as 
appropriate. A Chi-squared (χ2) test was used to assess the level of significance of 
differences in the incidence of events between groups. Statistical significance was 
predetermined at a level of P< 0.05 throughout. 
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A  APD & ERP protocol 
 
 
 
 
 
B REP protocol 
 
Figure 2.7 Diagrammatical representations of the current clamp protocols. 
A Schemata of the protocol used to record Action Potentials and the Effective Refractory Period. 
B Schemata of the protocol used to record Action Potentials and Spontaneous Depolarisations. 
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3 RESULTS (i) 
L-type calcium current recordings 
3.1 Introduction and aims 
 
L-type calcium current (ICaL) is the large, voltage and time dependant, long-lasting 
inward current, by convention designated with a negative polarity, which enters 
atrial myocytes during the plateau phase of the action potential. L-type calcium 
channels are heterotrimeric proteins which span the plasmalemma and are 
activated by the voltage changes occurring during the initial depolarisation phase 
of the action potential under physiological conditions. In human atrial myocytes the 
inward calcium current contributes to the plateau phase of the action potential and 
this calcium entry triggers calcium-induced-calcium-release from the sarcoplasmic 
reticulum resulting in myofilament contraction158;162. Numerous roles have been 
attributed to ICaL in the human cardiovascular system and this current is of 
particular interest because of its role in excitation-contraction coupling and 
arrhythmogenesis224;40;162;163. 
 
Although extensively studied in human ventricular myocardium fewer studies have 
sought to characterise this current in human atrium and the majority of those have 
investigated current characteristics at room temperature. Modification of the 
function or density of human atrial ICaL has been associated with chronic drug 
therapy94;114;155 and disease states113;115;158 and these altered electrophysiological 
characteristics have been postulated to be both protective against and contributing 
factors in altered contractile function and arrhythmogenesis162.  
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Human atrial ICaL has been described by a small number of groups who have used 
the ruptured patch clamp technique either at room114;155;163;225 or physiological 
temperature79;144;161;223, and although broadly similar results have been reported 
important differences in current characteristics have emerged161. 
 
The effects of adrenoceptor agonism by ISO in human right atrium both in vivo226 
and in vitro146;227-233 have long been recognised as a potential mechanism for 
investigation of human ion current characteristics234, indeed many early reports 
describe augmenting inward calcium current in order to reproducibly identify 
calcium currents155;235. The increase in ICaL inward current flow due to β-AR 
stimulation is accepted to be due to an increase in the probability of a calcium 
channel being open as a result in an increase in the fraction of calcium channels 
available to open during depolarisation in the absence of increased single channel 
conductance, altered reversal potential or the total number of channels per unit 
membrane236-239. In contrast, the stimulatory effect of catecholamines on ICaL at 
physiological temperature with the perforated patch 
technique92;114;155;161;163;199;224;240 has not previously been studied and differences 
in temperature and recording techniques have previously been shown to alter ion 
current characteristics considerably161. 
 
Endothelin, a 21 amino-acid peptide, was first discovered in 1988 as a potent 
vasoconstrictor in the supernatant of cultured porcine aortic endothelial cells168. 
Acting in concert with other neurohormones, such as Angiotensin II (A-II) and 
adrenergic stimulation, ET-1 released either in an autocrine or paracrine manner, 
has direct and indirect effects on inotropy241-243, chronotropy241-243, myocyte 
hypertrophy244 and ICaL
245-249.  
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Initial experiments with intra-aortic endothelin infusions resulted in a concentration 
dependent reduction in coronary perfusion and thereafter induced a concentration 
dependent negative chronotropic and inotropic effect on Langendorff mounted rat 
hearts. The threshold effect of ET-1 was in the nanoMolar range but even with 
nanoMolar concentrations, experimental models have struggled to divorce the 
electrophysiological effects of ischaemia resulting from ET-1 induced coronary 
vasoconstriction from any direct intrinsic inotropic effect250. 
  
It has long been noted that plasma endothelin levels are elevated in 
CHF123;125;128;132;251;252 and correlate with poor functional status and 
prognosis123;125;128;129;251;253;254. Circulating levels of ET-1 in plasma from patients 
with CHF can be as high as 10 pg/ml253;255 and have been demonstrated to be 
similar in right and left atria256. In human patients with CHF circulating plasma ET-
1 concentrations correlate with right atrial pressure and decrease in response to 
BB therapy132 occasionally returning to normal levels if treatment renders the 
patient asymptomatic123;125;252;254;257. Whether elevated circulating levels in plasma 
or local concentrations of ET-1 are primarily important in determining the 
physiological effects of ET-1 remains open to debate. Intuitively, as ET-1 is 
thought to act in an autocrine or paracrine matter, local concentrations are 
deterministic. The time course of neurohormonal activation in patients with CHF is 
not known.  
 
Endothelin-1 has been shown in animal models to be both pro and anti-arrhythmic 
depending on the physiological setting and animal model under investigation. 
Initial reports described stimulatory196;248;258;259, inhibitory195;196;248;260-263 or no 
effect203;247;249;264 of ET-1 on ICaL, with an EC50 between 1 and 10 nM, mediated via 
ET-A receptors in animal models
195;196;203;248;249;258-264. In addition to the possible 
effects on calcium current, activation of the Sodium-Hydrogen exchange current 
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(NHE)265 and Sodium Calcium Exchange current (NCX)266-268 via PKC, inhibition of 
K+ outward currents62;269-272 and ICl via inhibition of PKA/ adenylate cyclase
273 have 
been described.  
 
Despite promising results from trials of long term ET-A receptor blockade in 
animals274;275, results of trials in human patients with CHF have been 
disappointing276 indeed two larger studies identified an unexpected increase in 
atrial277 and ventricular278 arrhythmia prior to early termination.  
 
CHF is associated with systemic circulating elevated ET-1 levels, although the 
local levels in the human atria during CHF are not known. ET-1 is reported to have 
potential direct and indirect electrophysiological actions but further study is 
required. CHF is also associated with progressive cellular and electrophysiological 
remodelling that predisposes to AF. We sought to identify the acute 
electrophysiological effects of ET-1 on human atrial myocyte ICaL and, later, action 
potentials to determine whether this could in part explain CHF induced 
electrophysiological remodelling. 
 
The aims of these experiments were as follows: 
• To determine the range of concentrations of ISO which would reproducibly 
augment ICaL under the recording conditions being used and define the 
concentration: response relationship. 
• To select a concentration of ISO approximate to the EC50 which would 
reliably ‘pre-stimulate’ peak ICaL resulting in a sufficiently stable peak current 
to permit interpretation of any subsequent effect(s) of ET-1 or its analogues 
on peak ICaL. 
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• To assess the impact of the nystatin-perforated as compared to the 
nystatin-ruptured patch technique of electrical access on the stimulatory 
effect of ISO on ICaL. 
• To investigate whether patient senescence, chronic preoperative drug 
therapy or pre-existent comorbidity were associated with an altered 
adrenergic stimulatory effect of ISO on ICaL. 
• To investigate the effect(s), if any, of ET-1 on ICaL and to determine the ET-
1 receptor(s) subtypes involved in mediating any ET-1 effect on ICaL. 
• To investigate the effect(s) on ICaL of ET-1 and ISO in combination. 
 
3.2 Methods 
The nystatin-perforated whole cell patch clamp technique was used to record ICaL 
as described in detail in Methods section 2.4. Data were obtained with the patch 
clamp amplifier in voltage clamp mode using a Caesium based ‘internal’ solution in 
order to block K+ currents. 
 
Following examination of the ICaL traces obtained in the early experiments it was 
apparent that stable recordings obtained with a sufficiently good seal were 
associated with a greater inward current than ‘leak’ tail current. The ratio of leak 
tail current to peak inward current was assessed first subjectively and then 
calculated objectively and if this ‘leak to peak’ ratio (LtP ratio) was greater than 1 
the cell was excluded as shown in Figure 3.1A. 
 
Figure 3.1B illustrates an acceptable recording of ICaL under control conditions. 
Following a voltage step of 350 msec duration at 0.2 Hz from the holding potential 
-40 mV to +10 mV, while the cell and the superfusate are maintained at 37°C, a 
rapid and reproducible increase in inward calcium current occurred which reached 
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a maximum in less than 5 ms and which appeared to decay in a bi-exponential 
fashion. Subtraction of the steady state current at the end of the depolarising step 
from the peak inward current permitted estimation of the absolute magnitude of 
ICaL for any given record. Recordings from cells were excluded from further 
analysis if this LtP ratio was ≤ 1, such as that depicted in Figure 3.1A. 
 
In early experiments electrical artefact and rapid ICaL rundown in addition to ‘leak to 
peak’ ratio suggested a time cut off of March 2002, approximately two months 
(eight experiments) into the project. This date was selected as, in retrospect, 
stable recordings associated with a ‘leak to peak ratio’ of less than 1 were in the 
minority until that date and is taken to reflect the author’s ‘learning curve’. 
 
Cells were not immediately excluded, pending subsequent analyses, if electrical 
access to the cell was formed abruptly, i.e. ruptured, as opposed to perforated, 
patch clamping (Figure 3.2). Cells in which the Rs dropped so rapidly as to 
preclude simultaneous Rs compensation (Figure 3.2A) were designated as 
Nystatin Ruptured (NR) cells and comprised 29% of the total myocyte recordings. 
A comparison between the time courses of ruptured and perforated seals can be 
seen in Figure 3.2. The mean time course of the drop in series resistance (Rs) 
during the formation of perforations in all cells is depicted in Figure 3.3. 
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A 
Figure 3.1 Variability of ICaL recordings: demonstration of leak to peak exclusion criterion. 
A peak ICaL current trace from human atrial myocyte depolarised for 350 msec from a holding 
potential of -40 mV to +10 mV at physiological temperature using the nystatin perforated patch clamp 
method demonstrating a peak ICaL which when corrected for leak current is less than or equal to 1.  
B ICaL current trace obtained using identical methodology exhibiting leak to peak ratio greater than 1 
and hence excluded from further analysis. 
 
Leak to Peak ratio = peak current (pA) 
              leak current (pA) 
 
200 pA 
10 ms 
peak 
peak 
leak 
B 
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Figure 3.2 Representative examples of the time course of electrical access to the cell.  
A Nystatin ruptured patch (NR), in 29% of myocytes there was no drop in Rs prior to electrical 
access (n= 74 cells from 39 patients). 
B Nystatin perforated patch (NP), in 71% of myocytes Rs compensation was constantly adjusted 
during pore formation prior to electrical access (n= 181 cells from 60 patients). 
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Figure 3.3 The mean time course of the formation of nystatin perforated patch electrical access to 
atrial myocytes as indicated by the falling electrical resistance (Rs) with time mean ± s.e.m. (n= 165 
cells from 55 patients). 
 
3.3 Protocols 
Recordings of ICaL were made using both the stepwise voltage pulse protocol to 
determine the current:voltage (IV) relationship and the repetitive time course peak 
ICaL protocol as described in Methods section 2.4.1..  Figure 3.1B illustrates a 
typical recording of ICaL under control conditions using the stepwise voltage pulse 
protocol. Following a voltage step from the holding potential (-40 mV) in 
incremental +10 mV depolarising pulses of 350 ms duration at 0.2 Hz, the cell and 
the superfusate were maintained at 37°C, a rapid and reproducible increase in 
inward calcium current occurred which reached a maximum in less than 5 ms and 
which appeared to decay in a bi-exponential fashion (Figure 3.1B) consistent with 
previous reports of human atrial ICaL
161. 
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3.4 Statistics & data analysis 
Data were recorded and analysed off-line as described in Methods section 2.5.1.. 
Subtraction of the steady state current at the end of the depolarising step from the 
peak inward current permitted estimation of the absolute magnitude of ICaL for any 
given record. In order to assess the effect of ISO and ET-1 on the time constants 
of ICaL inactivation the WCP traces were scaled and transposed into pCLAMP 
version 10 software Clampfit data analysis tables (Axon Instruments). 
 
In order to determine the most appropriate statistical tests to employ, the 
distribution of values of peak ICaL was assessed. As can be seen from Figure 3.4 
the distribution of the direct observations of ICaL current density was not Gaussian, 
with a leftward skew. However after logarithmic transformation of ICaL current 
density the data did have a normal distribution and, therefore, the unpaired 
Student’s t test was employed to determine the degree of difference between sub-
analysed samples of ICaL under control conditions. This test was selected as it is 
the most valid test with which to assess the probability of a similar or more 
extreme result being arrived at by chance in samples of small size. This precedent 
has been set in other published work examining the electrophysiology of human 
atrial myocytes79;144;161;223. Where a comparison between two differing populations 
of data are presented the variance of the two groups has been assessed to permit 
the use of the unpaired Student’s t test, and if paired data are being compared the 
distribution of the variable being assessed was recorded and the paired Students’ t 
test was employed. This report is based on all available information in order to 
maximise utility. In a small number of cases incomplete data was collected from 
patient records, comprising <3% data points, resulting in small variability in sample 
size depending on analysis undertaken. 
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Figure 3.4 Frequency distribution graphs of peak ICaL (n= 176 cells from 49 patients). 
A Observed peak ICaL current density under control conditions 
B Logarithmic transformation of the magnitude of peak ICaL current density under control conditions. 
 
 
B 
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3.5 Results 
3.5.1 Patients’ clinical characteristics and methodological 
considerations 
 
Clinical characteristics of all patients from whom samples of right atrial appendage 
were obtained are illustrated in Table 3.1. Post operative Atrial Fibrillation (AFpcs) 
occurred in 19 of 65 patients (29%) within 7 days. None of the patients’ clinical 
characteristics were significantly associated, by univariate analysis, with the 
development of AFpcs and the data is presented in Table 3.2. 
 
Cells from patients who were receiving ACE-inhibitor (ACE-I) therapy pre-
operatively were associated with a significantly greater Rs, 7.66± 0.36 MΩ (n= 114 
cells from 32 patients, mean± s.e.m.) as compared with those from patients who 
were not receiving ACE-I therapy, 6.73± 0.28 MΩ (n=130 cells from 33 patients, 
mean± s.e.m., p< 0.05). There were no other significant associations between 
patients’ clinical characteristics and Rs C nor Vm demonstrated. 
 
While there were no significant univariate associations between patients’ clinical 
characteristics and mode of electrical access (Table 3.3), it can be seen from 
Figure 3.5 that fewer periods of enzymatic incubation of cells and greater myocyte 
capacitance are associated with successful perforated patch recordings in the 
absence of any significant effect on Vm (NR myocytes 75.3± 2.6 pF n=74 cells 
from 39 patients v. NP myocytes 86.4± 2.3 pF n=181 cells from 63 patients, 
mean± s.e.m., p< 0.05, Figure 3.5). 
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        Table 3.1 Patients’ clinical characteristics. 
  np % 
Male 52 80 
Age (years) 63.9± 1.2  
Female 13 20 
Patient demographics 
Age (years) 67.3± 2.2  
Beta-Blocker 48 72 
Calcium Channel Blocker 21 32 
Drug Therapy 
ACE- Inhibitor 32 49 
CABG 58 89 
AVR 6 9 
Operative Procedure 
CABG & AVR 1 2 
None (Normal) 32 50 
Mild  12 19 
Moderate 16 25 
LVSD 
Severe 4 6 
Hypertension 37 58 Comorbidity 
Previous MI 33 51 
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  Post-op AF 
yes 
np (%) 
Post-op AF 
no 
np (%) 
Male 13 (25) 39 (75) 
Female 6 (46) 7 (54) 
Age <75 (years) 14 (25) 42 (75) 
Age ≥75 (years) 5 (56) 4 (44) 
Pre-op HR <60 (bpm) 10 (33) 20 (67) 
Patient 
demographics 
Pre-op HR ≥60 (bpm) 8 (24) 26 (76) 
Beta-Blocker 13 (28) 34 (72) 
No Beta-Blocker 7 (39) 11 (61) 
Calcium Channel Blocker 5 (24) 16 (76) 
No CCB 14 (32) 30 (68) 
ACE- Inhibitor 8 (25) 24 (75) 
Drug Therapy 
No ACE- Inhibitor 11 (33) 22 (67) 
CABG 15 (26) 43 (74) Operative 
Procedure AVR 3 (50) 3 (50) 
Mild or None 12 (27) 32 (73) 
Moderate or Severe 6 (30) 14 (70) 
Ischaemic LVSD 6 (30) 14 (70) 
LVSD 
Non-ischaemic LVSD 3 (30) 7 (70) 
Hypertension 11 (30) 26 (70) 
No Hypertension 8 (30) 19 (70) 
Previous MI 9 (27) 24 (73) 
Comorbidity 
No Previous MI 10 (31) 22 (69) 
Table 3.2 Patients’ clinical characteristics and univariate analysis for post-op AF. 
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  Ruptured 
Patch 
nc (%) 
Perforated 
Patch 
nc (%) 
Male 53 (29) 130 (71) 
Female 20 (33) 41 (67) 
Age <75 (years) 65 (30) 150 (70) 
Patient 
demographics 
Age ≥75 (years) 9 (23) 31 (77) 
Beta-Blocker 59 (33) 122 (67) 
No Beta-Blocker 15 (20) 59 (80) 
Calcium Channel Blocker 22 (28) 57 (72) 
No CCB 51 (31) 114 (69) 
ACE- Inhibitor 28 (25) 86 (75) 
Drug Therapy 
No ACE- Inhibitor 45 (35) 85 (65) 
CABG 67 (32) 145 (68) Operative 
Procedure 
AVR 4 (15) 23 (85) 
Mild or None 53 (32) 111 (68) 
Moderate or Severe 20 (25) 60 (75) 
Ischaemic LVSD 18 (21) 68 (79) 
LVSD 
Non-ischaemic LVSD 15 (34) 29 (66) 
Hypertension 43 (31) 96 (69) 
No Hypertension 27 (27) 74 (73) 
Previous MI 30 (25) 92 (75) 
Comorbidity 
No Previous MI 43 (35) 79 (65) 
Table 3.3 Patients’ clinical characteristics and univariate analysis for mode of electrical access. 
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Perforated patch recordings (NP) were associated with larger series resistance Rs 
than those obtained with ruptured patch (NR 5.35± 0.28 MΩ n=74 cells from 39 
patients v. NP pipettes 7.97± 0.26 MΩ n=181 cells from 63 patients, mean± s.e.m., 
p< 0.05, Figure 3.5). 
 
Consistent with previous reports202;221;223 nystatin perforations formed consistently 
over a period of thirty minutes, indeed in this study more rapidly than ruptured 
patch seals (time to NR access 768± 67 s n=39 cells from 24 patients v. NP 473± 
25 s n=143 cells from 55 patients, mean± s.e.m., p< 0.05, Figure 3.6). Perforated 
patch recordings were associated with more stable ICaL recordings of longer 
duration as compared to ruptured patch recordings (NR ICaL duration 458± 46 s 
n=48 cells from 26 patients v. NP 657± 39 s n=103 cells from 40 patients, mean± 
s.e.m., p< 0.05, Figure 3.6). 
 
3.5.2 ICaL kinetics 
 
The ICaL activation time was 4.1± 0.12 ms under control conditions (n= 7 cells from 
7 patients). The ICaL inactivation data were confirmed to fit a bi-exponential relation 
with mean time constants of tauf (rapid phase time constant) = 11.8± 2.1 ms, taus 
(slow phase time constant)= 57.2± 5.7 ms n= 7 cells from 7 patients (Figures 3.7 
and 3.8). 
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Figure 3.5 The possible interactions between methodology and cellular characteristics on mode of 
seal formation.  = ruptured patch nystatin present in pipette (NR)   =  perforated patch nystatin 
present in pipette (NP) Values are mean± s.e.m..  
A Effect of increasing 10 minute periods of enzymatic incubation on the mechanism of electrical 
access to the cell. (NR n= 74 cells from 39 patients, NP n= 174 cells from 60 patients) p< 0.05. χ2 
test for incidence of NP access in cells from incubation 2 rather than incubation 1 or 3 p<0.05.  
B Lack of effect of pipette resistance on mode of seal formation. (NR n= 49 cells from 25 patients, 
NP n= 50 cells from 28 patients).  
C Effect of mode of seal formation on steady state series resistance. (NR n= 74 cells from 39 
patients, NP n= 181 cells from 63 patients) p< 0.05.   
D Effect of cell capacitance on mode of electrical access. (NR n= 74 cells from 39 patients, NP n= 
181 cells from 63 patients) p< 0.05.  
E Lack of effect of mode of seal formation on resting membrane potential (NR n= 13 cells from 9 
patients, NP n= 68 cells from 20 patients). 
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Figure 3.6 Effect of the mechanism of electrical access to the myocyte on duration of experiment.  
 = ruptured patch nystatin present in pipette (NR)  =  perforated patch Nystatin present in 
pipette (NP) Values are mean± s.e.m.. 
A Effect of the mechanism of electrical access to the myocyte on time taken to form electrical seal in 
seconds (NR n= 39 cells from 24 patients, NP n= 143 cells from 55 patients) p< 0.05. 
B Effect of method of electrical access on the duration of stable ICaL recordings in seconds.   
(NR n= 48 cells from 26 patients, NP n= 103 cells from 40 patients) p<  0.05. 
 
 
3.5.3 The current: voltage relationship of ICaL 
The mean current: voltage relationship of inward current recorded under control 
conditions at physiological temperature was a characteristic bell shaped curve as 
shown in Figure 3.9A. At potentials more negative than -30 mV and more positive 
than +40 mV little inward current was detectable. Peak inward current was 
recorded at +10 mV with a mean current density of -4.8± 0.4 pA/pF (n= 89 cells 
from 29 patients, mean± s.e.m.) corresponding with previous reports of ICaL
161;163. 
 
 
3.5.4 ICaL peak current density 
 
The peak current density, recorded at +10 mV, was noted in all cells in which ICaL 
was measured. The mean peak current density from all cells (Figure 3.9B) was -
5.1± 0.3 pA/pF (n= 176 cells from 49 patients, mean± s.e.m.) consistent with 
previously published work from this laboratory and others79;144;161;223. The mean 
peak ICaL per patient or ‘patient’ mean was also calculated to be -4.8± 0.4 pA/pF 
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(n= 49 patients, mean± s.e.m.) and there was no significant difference between 
the ‘cell’ mean peak ICaL and the ‘patient’ mean peak ICaL(Figure 3.9B). Unless 
specifically stated to the contrary all mean values will refer to cell mean. 
 
3.5.5 The time course of ICaL rundown under control conditions 
Peak ICaL was recorded repetitively under control conditions in order to ascertain 
the degree of initial rundown (Figure 3.10). Cells which demonstrated irreversible 
rundown under control conditions (Figure 3.10B) were not immediately excluded 
from initial analysis in order to examine whether this property of cells could be 
predicted. Fortunately the number of cells which demonstrated irreversible 
rundown during control was only 12 from 188 recordings (6.4%). The vast majority 
of these recordings were made in the initial stages of the project, eleven in the first 
twenty recordings consistent with the author’s learning curve. There were no 
significant differences in the cellular characteristics of those cells exhibiting 
irreversible rundown. Electrophysiological data relating to these cells is not 
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Figure 3.7 An example of a raw inward current trace (top) obtained using the voltage pulse protocol 
(lower) under control conditions with stepwise depolarisations, increasing in 10 mV increments from 
a holding potential of -40 mV to a maximum of +60 mV demonstrating the rapid inward current with 
biexponential decay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Representative example of peak ICaL under control conditions demonstrating rapid 
activation and biexponential decay of ICaL (tauf = 11.9± 1.4 ms, taus = 57.4± 2.9 ms)  
Mean values± s.e.m. tauf = 11.8± 2.1 ms, taus = 57.2± 5.7 ms (n= 7 cells from 7 patients). 
200 pA 
10 ms 
200 pA 
10 ms 
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Figure 3.9 The I:V relationship of ICaL and comparison of cell v. patient mean. 
A The mean current:voltage relationship obtained in all cells (n= 89 cells from 29 patients mean± 
s.e.m.).  
B Comparison of ‘cell’ mean v ‘patient’ mean peak current density of ICaL in all cells (n= 176 cells 
from 49 patients, mean± s.e.m.) 
B 
A 
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Figure 3.10 Comparison of stable ICaL recordings with ‘run down’. 
A Example of stable ICaL under control conditions with ‘permissible’ rundown with time.  
B Example of unstable ICaL under control conditions with ‘unacceptable’ rundown with time. 
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3.5.6 Impact of the method of seal formation on ICaL 
 
There was no significant difference (Figure 3.11) in the I:V relationship of ICaL in 
those myocytes in which the seal was obtained via a ruptured patch as compared 
with those cells in which the seal was a perforated patch. There was no significant 
difference in the magnitude of peak ICaL in those myocytes in which the seal was 
obtained via a ruptured patch -4.7± 0.4 pA/pF (n= 65 cells from 31 patients, mean± 
s.e.m.) as compared with those cells in which the seal was a perforated patch, -
5.4± 0.4 pA/pF (n=111 cells from 41 patients, mean± s.e.m., Figure 3.12A). Figure 
3.18B illustrates that there was no significant difference in the variance between 
the two groups and therefore the Students’ t test is a valid test to compare the two 
groups. 
3.5.7 Impact of patients’ clinical characteristics on ICaL 
3.5.7.1 Patient age and ICaL characteristics 
 
The mean I: V relationship of ICaL recorded from myocytes isolated from patients 
aged 75 years or older was found to be similar to that obtained from patients aged 
younger than 75 years (Myocytes from patients aged ≥75 years n= 19 cells from 6 
patients, v.  Myocytes from patients aged <75 years n= 70 cells from 23 patients, 
mean ± s.e.m.). Mean peak ICaL under control conditions was not significantly 
different between myocytes isolated from patients aged ≥75 years and that from 
younger patients (Myocytes from patients aged ≥75 years peak ICaL -5.2± 0.8 
pA/pF, n= 33 cells from 8 patients, v.  Myocytes from patients aged <75 years 
peak ICaL -5.1± 0.3 pA/pF, n= 143 cells from 41 patients, mean± s.e.m.). 
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3.5.7.2 Gender and ICaL characteristics 
 
There was no significant difference in the current: voltage relationship of ICaL in 
those myocytes obtained from male as compared with female patients. There was 
no significant difference in peak ICaL in those myocytes obtained from male 
patients when compared with myocytes obtained from female patients. (Male cells 
-5.3± 0.3 pA/pF, n= 143 cells from 40 patients, v.  Female cells -4.5± 0.5 pA/pF, 
n= 33 cells from 9 patients, mean± s.e.m.). 
 
3.5.8 Impact of chronic pre-operative beta-adrenoceptor blocking 
(β-B) therapy on ICaL 
3.5.8.1 Pre-operative heart rate and β-B therapy 
All 48 patients (72% of total) received beta-adrenoceptor blocking drugs (beta-
blockers, β-B) continuously for a minimum of 30 days pre-operatively until the peri-
operative period. The most common agent used was Atenolol (39 patients, 81%) 
in dosages ranging from 25-75 mg daily (mean dose 41 mg, mode 50 mg). Other 
agents were Bisoprolol (4 patients, 9%), Metoprolol (3 patients, 6%) and Carvedilol 
(2 patients 4%). No patient was receiving Sotalol. The preoperative heart rate as 
recorded on the 12 lead electrocardiogram was significantly lower in those patients 
receiving beta blockers (BBY 59± 1 bpm v BBN 76± 1 bpm, n= 48 and 16 patients 
respectively P< 0.05). 
3.5.8.2 β-B therapy and ICaL characteristics 
There was no significant difference in the current: voltage relationship nor peak 
ICaL in those myocytes obtained from patients who had, as opposed to had not, 
received chronic pre-operative β-B therapy (I: V relationship Figure 3.21A: peak 
ICaL: BBY -5.4± 0.3 pA/pF, n= 124 cells from 36 patients, v. BBN -4.5± 0.4 pA/pF, 
n=52 cells from 13 patients, mean± s.e.m.). 
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Figure 3.11 Lack of effect of method of electrical access on L-type calcium current (ICaL) 
current:voltage relationship under control conditions.   = ruptured patch nystatin present in pipette 
(NR) (n= 41 cells from 21 patients)   =  perforated patch Nystatin present in pipette (NP) (n= 48 
cells from 23 patients). Values are mean± s.e.m. 
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Figure 3.12 Comparison of mode of electrical access and peak ICaL.  = ruptured patch nystatin 
present in pipette (NR) (n= 65 cells from 31 patients)   =  perforated patch Nystatin present in 
pipette (NP) (n= 111 cells from 41 patients). Values are mean± s.e.m. 
A Lack of effect of method of electrical access on peak (measured at +10 mV) L-type calcium current 
(ICaL) density under control conditions.  
B Lack of significant difference in variance in the distribution of peak ICaL recordings related to 
method of electrical access. 
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3.5.9 Impact of chronic pre-operative calcium channel blocker 
(CCB) therapy on ICaL 
3.5.9.1 Pre-operative heart rate and CCB therapy 
 
All 21 patients (32% of total) received calcium channel blocking drugs (CCB) 
continuously for a minimum of 3 months pre-operatively and throughout the peri-
operative period. The most common agent used was Amlodipine (15 patients, 
72%) at either 5 or 10 mg. One patient was receiving Nifedipine. The remaining 5 
patients (24%) were prescribed Diltiazem betweem 60 and 300 mg. No patients 
were prescribed Verapamil. The preoperative heart rate as recorded on the 12 
lead electrocardiogram was not significantly different in those patients receiving 
calcium channel blocking drugs from those not receiving CCB drugs pre-
operatively (CCBY 62± 2 bpm v CCBN 64± 1 bpm, n= 21 and 43 patients 
respectively). 
3.5.9.2 CCB therapy and ICaL characteristics 
 
There was no significant difference in either the current: voltage relationship or 
peak ICaL in those myocytes obtained from patients who had received chronic 
calcium channel blocking therapy pre-operatively (CCBY -4.7± 0.4 pA/pF, n= 55 
cells from 17 patients, v.  CCBN -5.4± 0.3 pA/pF, n=121 cells from 32 patients, 
mean± s.e.m.). 
3.5.10 The impact of chronic Angiotensin Converting Enzyme 
Inhibitor (ACE-I) therapy on ICaL 
 
All 32 patients (49% of total) received ACE-I medications continuously for a 
minimum of 3 months pre-operatively until the peri-operative period. In 11 patients 
(34%) this medication was withheld on the last preoperative day. The most 
common agent used was Ramipril (20 patients, 63%) in dosages ranging from 2.5-
10 mg daily (mean dose 7.7 mg, mode 10 mg). Other agents were Lisinopril (8 
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patients, 25%), Enalapril (2 patients, 6%), Perindopril and Trandolapril (1 patient 
each 3%). There was no significant difference in the current: voltage relationship 
of ICaL in those myocytes obtained from patients who had received chronic ACE-I 
therapy. There was no significant difference in peak ICaL in those myocytes 
obtained from patients who had received chronic pre-operative ACE-I therapy 
when compared with myocytes obtained from patients who had not received 
preoperative ACE-I therapy (ACE-I Y -5.4± 0.5 pA/pF, n= 112 cells from 28 
patients, v.  ACE-I N -5.0± 0.3 pA/pF, n=64 cells from 21 patients, mean± s.e.m.). 
3.5.11 Impact of pre-operative left ventricular systolic 
dysfunction (LVSD) on ICaL 
 
There was no significant difference in the current: voltage relationship between 
either normal compared with abnormal Left Ventricular Systolic Dysfunction 
(LVSD), as defined by pre-operative echocardiography, nor between the 
aggregated groups of Normal & Mild LVSD compared with Moderate & Severe 
LVSD. There was no significant difference between the peak current density in 
those cells from patients with normal compared to abnormal LVSD (Normal LV 
systolic function peak ICaL -5.0± 0.4 pA/pF n= 77 cells from 23 patients, v. 
Abnormal LV systolic function peak ICaL -5.1± 0.4 pA/pF n= 77 cells from 21 
patients, Figure 3.13A). However the peak current density recorded from cells with 
moderate and severe LVSD was statistically significantly greater than that 
recorded from cells with normal or mild LVSD (Normal and Mild LVSD peak ICaL -
4.8± 0.3 pA/pF n= 108 cells from 32 patients, v. Moderate and Severe LVSD peak 
ICaL -5.6± 0.6 pA/pF n= 46 cells from 12 patients p< 0.05, Figure 3.13B). 
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Figure 3.13 Impact of LVSD on peak ICaL. Values are mean± s.e.m. 
A Lack of effect of any degree of pre-operative Left Ventricular Systolic Dysfunction (LVSD) on peak 
ICaL under control conditions.   = patients without LVSD (n= 77 cells from 23 patients)   =  
patients with LVSD (n= 77 cells from 21 patients).  
B Effect of moderate or severe pre-operative Left Ventricular Systolic Dysfunction (LVSD) on peak 
ICaL under control conditions.   = patients with mild or no LVSD (n= 108 cells from 32 patients)   
=  patients with moderate or severe LVSD (n= 46 cells from 12 patients). p< 0.05. 
 
A 
B 
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3.5.12 Impact of prior Myocardial Infarction on ICaL 
 
There was no significant difference in the current: voltage relationship between 
patients who had suffered a prior Myocardial Infarction (MI), as recorded in the 
clinical case sheets, and those patients who had not had a documented previous 
MI (Figure 3.14A). In contrast, myocytes isolated from patients who had suffered a 
documented MI pre-operatively had a significantly greater peak ICaL current density 
on comparison with myocytes from patients who had not suffered a prior MI (MIN -
4.52± 0.35 pA/pF, n= 83 cells from 23 patients v. MIY -5.55± 0.36 pA/pF, n= 88 
cells from 25 patients, p< 0.05 Figure 3.14B). 
3.5.13 Impact of aetiology of Left Ventricular Systolic 
Dysfunction (LVSD) on ICaL 
 
There was no significant difference in the current: voltage relationship between 
patients who had ischaemic cardiomyopathy (ICM) and those suffering non-
ischaemic cardiomyopathy (NICM). However, ICaL was of a significantly lower 
density from myocytes isolated from patients with NICM when depolarised to 
potentials more positive than zero. p< 0.05 (Figure 3.15A). Peak ICaL, however, 
was of a significantly lower density from myocytes isolated from patients with 
NICM when compared to myocytes from patients with ischaemic cardiomyopathy 
(NICM -3.52± 0.3 pA/pF, n= 25 cells from 6 patients, ICM -5.87± 0.47 pA/pF, n= 
62 cells from 17 patients, p< 0.05 Figure 3.15B). 
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Figure 3.14 Impact of prior Myocardial Infarction (MI) on ICaL.   = patients who have not sustained 
previous MI (MIN)   = patients who have sustained previous MI (MIY) Values are mean± s.e.m.. 
A Lack of effect of prior MI on ICaL I: V relationship under control conditions. (MIN n= 41 cells from 13 
patients, MIY n= 48 cells from 16 patients). 
B Effect of prior MI on peak ICaL under control conditions (MIN n= 83 cells from 23 patients, MIY n= 
88 cells from 25 patients) p< 0.05. 
B 
A 
Calum Jon Redpath  Chapter 3-77 
 
-40 -30 -20 -10 10 20 30 40 50 60
-5
-4
-3
-2
-1
0
ICaL
(pA/pF)
mV
 
-7
-6
-5
-4
-3
-2
-1
0
ICaL
(pA/pF)
*
 
Figure 3.15 Impact of aetiology of LVSD on ICaL.   = patients who have non-ischaemic 
cardiomyopathy (NICM)   = patients who have ischaemic cardiomyopathy (ICM) Values are mean± 
s.e.m.. 
A Lack of effect of aetiology of LVSD on ICaL I: V relationship under control conditions. (NICM n= 15 
cells from 4 patients, ICM n= 28 cells from 10 patients). 
B Effect of aetiology of LVSD on peak ICaL under control conditions (NICM n= 25 cells from 6 
patients, ICM n= 62 cells from 17 patients).p< 0.05.  
B 
A 
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3.5.14 The effect of ISO on ICaL current: voltage relationship 
Isoproterenol at 0.1 µM significantly increased the magnitude of the inward current 
without altering the current: voltage relationship of ICaL (Figure 3.16A) at 
physiological temperature. (n= 4 cells from 3 patients, paired data, mean± s.e.m. 
p< 0.05.) An example of the paired peak (+10 mV) current traces is depicted in 
Figure 3.16B. 
 
3.5.15 The effect of ISO on activation and inactivation of ICaL 
Isoproterenol at 0.05 µM had no significant effect on the activation time (control 
4.13± 0.15 ms v. 4.3± 0.37 ms n= 4 cells from 4 patients) or time constant of 
inactivation of ICaL (control 54.0± 10.1 ms v. 55.2± 14.8 ms n= 4 cells from 4 
patients). Figure 3.16B is an example of raw current tracings demonstrating this 
lack of effect and mean data are presented in histograms in Figure 3.17. 
 
3.5.16 The effect of ISO on peak ICaL 
3.5.16.1 Time course of ISO effect on peak (+10 mV) current density 
 
There were four differing patterns of change in peak ICaL following acute 
superfusion of ISO which we classified into four response ‘types’ (Figures 3.18 and 
3.19). The type O response, in which there was no discernible effect of ISO on 
peak ICaL, occurred in only 3% of cells (Figure 3.18A). Due to the combination of 
the rarity of this type of response, the early loss of seal, the subjective visible signs 
of cell death (shrinkage, spherication, crenation, loss of discernable striations) and 
the literature describing the consistent positive effect of ISO to increase 
ICaL
81;94;114;144;155;161;199;200;221;225;279-282
 these cells were excluded from further 
analysis. 
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The most common adrenergic response, designated the type 1 response, 
occurred in 60% of cells. This response was characterised by a stable augmented 
ICaL current density persisting as a plateau on the time course curve-plot, see 
Figure 3.18B. 
 
A type 2 response in which the initial increase in peak ICaL current density was 
temporary but an intermediate plateau was reached which was of greater current 
density than that recorded under control conditions but less than the peak initial 
response occurred in 10% of cells (see figure 3.19A). 
  
Finally a type 3 response to ISO was that of an initial increase in ICaL which did not 
reach a plateau and peak ICaL irreversibly ran down to control levels and occurred 
in 30% of cells (Figure 3.19B). 
 
3.5.16.2 ISO effect on peak (+10 mV) current density 
 
An example of the effect of acute superfusion with 0.05 µM ISO on the raw current 
tracings can be seen in Figure 3.20A. The significant mean increase in peak ICaL 
following acute superfusion with 0.05 µM ISO in absolute terms can be seen in 
Figure 3.20 and the relative increase, that is the magnitude of the increase in 
current density expressed as a percentage of the current density under control 
conditions was 218.8± 17.4 % (n= 87 cells from 36 patients, paired data, mean± 
s.e.m. p< 0.05). 
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3.5.16.3 Concentration: response relationship of ISO on peak ICaL 
 
Isoproterenol, at concentrations equal to or less than 10-9 had no significant effect 
on the magnitude of peak ICaL (+10 mV), however at all concentrations tested in 
the range from 10-8 to 10-6 M, acute superfusion with ISO significantly increased 
the magnitude of peak ICaL (Figures 3.21 and 3.22). 
 
An interim concentration: response curve of the maximal initial effects of ISO on 
peak ICaL was constructed during the early stages of the project in order to select a 
suitable concentration of ISO for later experiments (Figure 3.22A). From this curve 
we calculated that the EC50 of ISO was approximately 0.05 µM ISO and that the 
maximal response was likely to occur at approximately 1.0 µM ISO. 
 
As can be seen from the final concentration: response curve of the adrenergic 
effect of ISO on peak ICaL (Figure 3.22B) the true EC50 of ISO was approximately 
0.013 µM ISO, consistent with initial experience with the nystatin perforated patch 
clamp recordings of ICaL
221. 
 
3.5.16.4 Time to maximal ISO effect on peak (+10 mV) current density 
 
The mean time to peak effect of ISO on ICaL was 95± 4 seconds (n= 113 cells from 
39 patients Figure 3.23A). There was no significant difference in the time to peak 
effect of increasing ISO concentration (Figure 3.23A). There was no significant 
difference in the time taken to peak ISO effect of either method of electrical access 
(Figure 3.23B). However, ISO at 0.05 µM, had a significantly more rapid peak 
effect on ICaL in cells from patients who had received chronic pre-operative beta-
adrenoceptor antagonists (Figure 3.23C). 
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Figure 3.16 The effect of acute superfusion of ISO at 0.1 µM on of ICaL. 
A The effect of ISO 0.1 µM on the I: V relationship of ICaL.  = control   =  ISO 0.1 µM ISO (n=4 
cells from 3 patients, paired data, mean± s.e.m. p< 0.05.)  
B Examples of two superimposed raw current tracings of peak ICaL recorded from the same myocyte: 
i) under control conditions ii) following acute superfusion with ISO 0.1 µM. 
10 ms 
100 pA  
i) 
 
ii) 
A 
B 
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Figure 3.17 The effect of acute superfusion of ISO at 0.05 µM on activation and inactivation time 
constants of ICaL.   = control   =  ISO 0.05 µM ISO (n=4 cells from 4 patients, paired data, mean± 
s.e.m.). 
A The lack of effect of ISO 0.05 µM on the activation time of ICaL (ms)  
B The lack of effect of ISO 0.05 µM on the rapid (tauf) time constant of inactivation of ICaL (ms). 
C The lack of effect of ISO 0.05 µM on the slow (taus) time constant of inactivation of ICaL (ms). 
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Figure 3.18 Examples of the type 0 and type 1 time course of effect of ISO on ICaL. 
A Type 0 effect; perpetual rundown from an initial peak ICaL until cell death following superfusion with 
ISO.These cells were excluded from further analysis. 
B Type 1 effect; stable ICaL under both control conditions and following exposure to ISO until 
experiment electively terminated. 
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Figure 3.19 Examples of the type 2 and type 3 time course of effect of ISO on ICaL. 
A Type 2 effect; stable ICaL under control conditions prior to superfusion with ISO, however the 
adrenergic effect was an initial rise in peak ICaL follwed by rundown which stabilised at a plateau 
greater than under control conditions.   
B Type 3 effect; following addition of ISO to the superfusate, an initial rise in peak ICaL was followed 
by irreversible rundown of ICaL until cell death. 
 
A 
B 
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Figure 3.20 Effect of acute superfusion with 0.05 µM isoproterenol on a human atrial 
myocyte.  
A Examples of the raw inward current traces recorded under control conditions (i) and (ii) 
during acute superfusion with 0.05 µM isoproterenol.  
B Representative example of the time course of the adrenergic effect of ISO (0.05 µM) on 
peak ICaL. Timing of the addition of ISO to the superfusate is indicated by the solid black bar. 
B 
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3.5.17 Repetitive applications of ISO 
 
Initial experimental protocols were of a stepwise increase in the concentration of 
ISO in the superfusate following the adrenergic effect reaching a steady state. 
However, this stepwise effect of ISO was achieved in few cells (Figure 3.24). The 
estimation of the magnitude of the effect of second and subsequent applications of 
ISO were hampered by failure of initial plateau formation (type 3 responses), the 
initial rundown prior to plateau formation negating the impact of further adrenergic 
effects with increasing concentrations of ISO (type 2 response) See Figure 3.24B. 
 
3.5.18 Impact of the method of seal formation on the    
adrenergic effect of 0.05 µM ISO on ICaL 
Mode of electrical access, (NR v NP), was not associated with any specific ‘type’ 
of response of human atrial myocyte ICaL following acute superfusion with ISO in 
concentrations ranging from 10-10 to 10-6 M. There was no significant difference 
(NR v NP) in the magnitude of the adrenergic effect of 0.05 µM ISO on peak ICaL 
(NR 176.1± 24.8% v. NP 246± 24.8% increase in peak ICaL, n= 22 cells from 15 
patients and n= 65 cells from 21 patients respectively). 
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Figure 3.21 The significant adrenergic effect of acute superfusion with increasing concentrations of 
ISO on peak ICaL.  = control   =  ISO (varying concentrations as indicated) paired data, values 
are mean± s.e.m. 
A 0.0001 µM ISO (n=  4 cells from 3 patients) 
B 0.001 µM ISO (n=  4 cells from 3 patients) 
C 0.01 µM ISO (n=  5 cells from 4 patients, p< 0.05.) 
D 0.05 µM ISO (n=  87 cells from 36 patients, p< 0.05.) 
E 0.1 µM ISO (n=  20 cells from 13 patients, p< 0.05.) 
F 1.0 µM ISO (n=  17 cells from 10 patients, p< 0.05.) 
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Figure 3.22 Concentration: response curve of the effect of Isoproterenol on ICaL. Data from which an 
unrestrained sigmoidal plot using the Hill equation calculated the EC50 to be 0.06± 0.014 µM ISO, 
the minimal and maximal effects of ISO were estimated to be 16.5± 21% and 199.3± 43% increases 
in ICaL compared to baseline respectively  (n= 4- 46 cells from 3- 22 patients). 
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Figure 3.23 Analysis of time to maximal adrenergic effect of ISO on peak ICaL. 
A The mean time to maximal effect of differing concentrations of ISO on peak ICaL all values are 
paired data mean± s.e.m.  = 0.05 µM ISO (n=  87 cells from 36 patients)   = 0.1 µM ISO (n=  17 
cells from 12 patients)   = 1.0 µM ISO (n=  11 cells from 7 patients) 
B The lack of impact of method of electrical seal on the time to peak ISO effect on ICaL (nystatin 
perforated patch (NR) n= 92 cells from 38 patients v nystatin ruptured patch (NR) n= 21 cells from 13 
patients, mean± s.e.m.) 
C Chronic pre-operative β-B therapy results in an expedited peak response to ISO (mean± s.e.m.). 
n= 97 cells from 37 patients receiving chronic pre-operative β-B therapy (BBY). n= 16 cells from 7 
patients not receiving chronic pre-operative β-B therapy (BBN).  
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Figure 3.24 Differing cellular responses to repetitive applications of increasing concentrations of 
Isoproterenol. 
A Repetitive application of ISO in which subsequent addition of an increased concentration of ISO to 
the superfusate resulted in a stable increase in the magnitude of peak ICaL 
B Increased concentration of ISO did not reverse the onset of ICaL rundown. 
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3.5.19 Impact of patients’ clinical characteristics on the 
adrenergic effect of 0.05 µM ISO on ICaL 
There were no significant differences observed in the magnitude of the mean 
adrenergic effect of 0.05 µM ISO on peak ICaL associated with any recorded patient 
clinical characteristics or pre-operative drug therapy, other than the presence of 
pre-operative hypertension. The mean adrenergic response of peak ICaL to 0.05 
µM ISO was significantly greater in myocytes isolated from patients suffering from 
hypertension pre-operatively as compared to myocytes from patients free from 
hypertension. (Mean adrenergic increase 250.7± 25.3% n= 46 cells from 19 
hypertensive patients v. 173.5± 22.2% n= 38 cells from 15 normotensive patients). 
3.5.19.11 Adrenergic response of peak ICaL to ISO 0.05 µMol is not 
predictive of post operative Atrial Fibrillation (AFpcs) 
 
The mean adrenergic increase in peak ICaL from myocytes isolated from those 
patients who went on to develop post-operative Atrial Fibrillation (AFpcs) was not 
significantly different from the mean adrenergic increase in peak ICaL of myocytes 
from patients who remained in sinus rhythm post-operatively (SRpcs). (Mean 
adrenergic increase (AFpcs) 193.7± 32.7% n= 28 cells from 12 patients v. (SRpcs) 
229.2± 20.1% n= 58 cells from 23 patients). 
 
3.5.20 The lack of effect of Endothelin-1 alone on peak ICaL 
Endothelin-1 alone at the maximal concentration tested of 10 nM had no effect on 
peak ICaL (control -4.8± 0.5 pA/pF v. ET-1 -4.5± 0.7 pA/pF, n= 5 cells from 4 
patients, paired data, p< 0.05 Figure 3.25). An example of this lack of effect of ET-
1 at 10 nM on ICaL is shown in Figure 3.25A and is confirmed by mean data (Figure 
3.25B). 
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3.5.21 The lack of effect of Sarafotoxin-S6c alone on peak ICaL 
Sarafotoxin-S6c, a selective ET-B receptor agonist, at 10 nM had no effect on ICaL 
(control -3.9± 1.1 pA/pF v. S6c -3.3± 0.9 pA/pF, n= 5 cells from 3 patients, paired 
data, p< 0.05 Figure 3.26).  An example of this lack of effect of S-6c on ICaL is 
shown in Figure 3.26A and is confirmed by mean data (Figure 3.26B). 
 
3.5.22 The effect of Endothelin-1 on adrenergically pre-
stimulated peak ICaL 
Peak ICaL was pre-stimulated with ISO at a concentration of 0.05 µM which 
approximated to the EC50 of the adrenergic stimulatory effect of ISO on peak ICaL. 
Once it was apparent in real time that the adrenergic effect had reached a plateau, 
Endothelin-1, in varying concentrations, was added to the superfusate. Endothelin-
1, at the maximal concentration evaluated of 10 nM reversed the adrenergic effect 
of 0.05 µM ISO on peak ICaL, as can be seen in Figure 3.27A (control -4.9± 1.3 
pA/pF v. ISO -16.8± 3.4 pA/pF v. ISO and ET-1 co-application -8.2± 2.1 pA/pF n= 
14 cells from 12 patients, paired data, p= 0.0005 Figure 3.27B). The anti-
adrenergic effect was calculated by first measuring the magnitude of the 
adrenergic effect of ISO on ICaL in absolute terms and then dividing the magnitude 
of the effect of ET-1 in pA/pF permitting the expression of the anti-adrenergic 
effect of ET-1 as a percentage of the initial adrenergic effect (See Figure 3.27). 
 
3.5.23 Partial reversibility of the anti-adrenergic effect of ET-1 
on peak ICaL due to washout 
The anti-adrenergic effect was partially reversible with washout in the majority of 
cells tested (Figure 3.28). In 10 of 16 cells in which the experiment continued into 
a washout period, the effect of ET-1 was partially reversible. During washout of all 
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concentrations of ET-1 ≤1 nM partial reversibility was more frequent than not. In 5 
cells it was not possible to assess reversibility due to premature termination of the 
experiment due to cell death or electrical instability. No correlation between 
preoperative drug therapy or comorbidity could be made as the numbers in each 
group preclude further investigation. 
 
3.5.24 The concentration: response relationship of the anti-
adrenergic effect of ET-1 on peak ICaL 
The magnitude of the anti-adrenergic effect of decreasing concentrations of ET-1 
was assessed in order to determine if there was a relationship between the 
concentration of ET-1 and the magnitude of the anti-adrenergic effect on peak ICaL. 
Endothelin-1 had a significant anti-adrenergic effect on peak ICaL in all 
concentrations tested from 0.01 nM to 10 nM (See Figure 3.29). The beginning of 
a concentration response effect can be determined as the magnitude of the anti-
adrenergic effect decreased with decreasing concentrations of ET-1 in the 
superfusate.  
 
3.5.25 The concentration response relationship of the time 
course of the anti-adrenergic effect of ET-1 on peak ICaL 
The time taken for ET-1 to have an anti-adrenergic effect appeared to be 
concentration dependent. At high concentration, ET-1 at 10 nM completely 
reversed the adrenergic effect of ISO at 0.05 µM in 140± 9 seconds which was 
significantly earlier than lower concentrations (n= 4-14 cells from 2-12 patients P= 
0.0004. Figure 3.30). 
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Figure 3.25 A) Time course of 10 nM ET-1 effect, inset are examples of raw current tracings 
obtained during each phase of the experiment. B) Histograms of mean data of 10 nM ET-1 effect on 
peak ICaL.   = control   =  ET-1 10 nM (n=  5 cells from 4 patients, paired data mean ± s.e.m., p= 
ns). 
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Figure 3.26 A) Time course of lack of effect of 10 nM S6c on ICaL. B) Histograms of mean data of 10 
nM S6c effect on peak ICaL.   = control   =  S6c 10 nM (n= 5 cells from 3 patients, paired data 
mean ± s.e.m., p= ns). 
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Figure 3.27 A) Time course of the anti-adrenergic effect of 10 nM ET-1 on peak ICaL. B) Histogram of 
mean data of the anti-adrenergic effect of 10 nM ET-1 on peak ICaL.   = control    =  ISO 0.05 
µM    = ET-1 10 nM (n=  14 cells from 12 patients, paired data, mean ± s.e.m., * P= 0.0005, # P= 
0.0002). 
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Figure 3.28 Example of the partial reversibility of the anti-adrenergic effect of 0.1 nM ET-1 on peak 
ICaL with washout. 
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Figure 3.29 The concentration response relationship of the magnitude of the anti-adrenergic effect 
of ET-1 (nM) on peak ICaL. 
10 nM ET-1 n = 14 cells from 12 patients P= 0.0002 
1 nM ET-1 n = 4 cells from 2 patients P= 0.017 
0.1 nM ET-1 n = 5 cells from 3 patients P= 0.013 
0.01 nM ET-1 n = 5 cells from 5 patients P= 0.036 
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3.5.26 Partial reversibility due to the blockade of ET-A 
receptors with FR139317 (FRA) 
Using the ET-A antagonist FRA the effect of 10 nM ET-1 was partially reversible in 
6 of 7 seven cells (Figure 3.31). 
 
3.5.27 The blockade of ET-A receptors with FR139317 (FRA) 
prevents the antiadrenergic effect of 10 nM ET-1 on 
adrenergically pre-stimulated peak ICaL 
Superfusion of the myocyte with the ET-A antagonist FRA following exposure to 
0.05 µM ISO prevented the anti-adrenergic effect of 10 nM ET-1 on peak ICaL 
(Figure 3.32). 
 
3.5.28 The lack of effect of Sarafatoxin-S6c on adrenergically 
pre-stimulated peak ICaL 
The selective ET-B receptor agonist Sarafotoxin-S6c at 10 nM had no effect on ICaL 
which had been adrenergically pre-stimulated with 0.05µM ISO (control 4.7± 0.5 
pA/pF v. ISO -19.2± 2.7 pA/pF v. ISO and S6c co-application 18.0± 3.4 pA/pF, 
paired data n=9 cells from 4 patients).  An example of this lack of effect of S-6c on 
ICaL is shown in Figure 3.33 and is confirmed by mean data (Figure 3.34). The 
presence of 10 nM S6-c in the superfusate had no effect on the ability of 10 nM 
ET-1 to reverse the adrenergic effect of 0.05µM ISO on peak ICaL (Figure 3.43B). 
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Figure 3.30 The concentration response effect of the time to peak anti-adrenergic effect of ET-1 on 
peak ICaL. (n= 4-14 cells from 2-12 patients. * P= 0.0004) 
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Figure 3.31 A) The specific ET-A receptor antagonist FR-139317 at 10 nM partially reverses the anti-
adrenergic effect of 10 nM ET-1 on peak ICaL. B) The specific ET-A receptor antagonist FR-139317 at 
10 nM prevents the anti-adrenergic effect of 10 nM ET-1 on peak ICaL. 
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Figure 3.32 The mean effect of 10 nM FR139317 to partially reverse the anti-adrenergic effect of 10 
nM ET-1 on peak ICaL.   = control    =  ISO 0.05 µM    = ET-1 10 nM  = 10 nM FRA (n = 6 
cells from 4 patients mean ± s.e.m. p= ns). 
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Figure 3.33 A) The lack of effect of Sarafotoxin S6-c alone on prestimulated peak ICaL. B) The 
absence of effect of Sarafotoxin S6-c on the anti-adrenergic effect of 10 nM ET-1 on peak ICaL. 
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Figure 3.34 A) Mean lack of effect of sarafotoxin S6-c on adrenergically prestimulated peak ICaL .   
= control    = ISO 0.05 µM    =  S6c 10 nM (n= 9 cells from 4 patients mean ± s.e.m.) B) The 
impact of sarafotoxin S6-c on the anti-adrenergic effect of 10 nM ET-1 on peak ICaL (ET-1 alone n= 
14 cells from 12 patients, ET-1 following exposure to S6-c n= 3 cells from 1 patient mean ± s.e.m. p= 
ns) 
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3.6 Discussion 
3.6.1 Methodological considerations 
These results demonstrate that ICaL can be reliably and reproducibly recorded from 
human atrial myocytes using the nystatin-perforated whole-cell patch clamp 
technique at physiological temperature. This nystatin perforated method had no 
significant effect on activation nor inactivation kinetics, the current: voltage 
relationship nor peak inward calcium current while avoiding the irreversible current 
rundown in the vast majority of cells under control conditions79;161;163;223. 
Additionally these results indicate that the method of electrical access, patient 
gender and chronic preoperative drug therapy had no effect on human atrial ICaL 
under control conditions. In contrast, in cells isolated from patients suffering from 
moderate and severe LVSD, as defined by trans-thoracic echocardiography (TTE), 
there was a significantly greater peak ICaL observed with no significant alteration in 
the I-V relationship. 
 
The clinical characteristics of the patients from whom these atrial myocytes were 
isolated are similar to those reported in recent surgical series283 and on the UK 
central cardiac audit database (www.ccad.org.uk/ccadweb.nsf). Due to the small 
sample size of patients in the present study it was not possible to detect any 
significant associations between clinical characteristics and post-operative AF, 
however this would appear to be a type II error as pooled work from our laboratory 
has recently been published reporting the presence of these associations284. 
 
An association between pre-operative ACE-I therapy and greater Rs has not, as 
far as the author is aware, been previously reported. Angiotensin II has been 
implicated in stretch induced fibrosis, reversible increases in cellular expression of 
connexin 43 and other membrane bound proteins, however, these changes were 
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not associated with alterations in resting membrane potential or action potential 
upstroke285;286. While this possible effect of chronic pre-operative ACE-I therapy on 
human atrial myocyte plasmalemmae cannot be entirely discounted it is likely to 
be a spurious result representing a type I error. This interpretation is supported by 
the publication of pooled data from our laboratory which did not report any 
significant association between ACE-I therapy and greater Rs
284
. 
 
Successful perforated patch recordings were more likely with two periods of 
enzymatic incubation during the myocyte isolation process and also in cells of 
greater capacitance. Nystatin-induced pores in the lipid bilayer permit electrical 
access and in comparison with ruptured patch where the pipette is in direct contact 
with the intracellular milieu it is intuitive that Rs should be greater in NP cf. NR 
recordings. Exactly how nystatin pores, cell size and pre-operative ACE-I therapy 
interact at the plasmalemmae remains a subject for further research. The present 
study confirms that the stability of ICaL recordings can be maintained far beyond 
that which was previously possible with ruptured patch recordings202;220;221.  
 
The majority of previous publications describing ICaL used ruptured patch clamp 
experiments at room temperature 114;155;163;225;281;282;287;288 and all report a bell 
shaped I-V relationship with inward current being detected in the range of >-40 mV 
to <+60 mV, peaking at +10± 10 mV. This ‘peak’ ICaL, measured either at 0 mV or 
at +10 mV in these experiments was in the range of 1.2 pA/pF 225 to 3.2 pA/pF 287. 
Early pioneering work in this area was hampered by ICaL being detected in fewer 
than half of cells studied and often required amplification with dihydropyridine 
agonists (Bay K 8644) in order to become recordable155. 
 
In contrast when physiological temperature conditions were employed, the current 
voltage relationship of ICaL was bell shaped with peak current consistently at +10 
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mV79;161;163;223. One report specifically examined the physiological effect of 
temperature on ICaL
161 demonstrating no shift in the IV relationship but an increase 
in peak ICaL from 2 pA/pF at room temperature increasing to 6 pA/pF from a 
holding potential of -40 mV at physiological temperature. When the effect of raising 
the temperature of the cells during the experiment was tested directly it was 
demonstrated that ICaL had similar I: V relationship but that greater current passed 
at all voltages and that peak current was approximately doubled with more rapid 
activation and inactivation161. Further corroboration has arisen from subsequent 
work reporting that peak ICaL was in the range of 4.8 to 6.8 pA/pF occurring at +10 
mV under control conditions of 370C79;144;161;163;223. 
 
3.6.2 Interaction of patients’ clinical characteristics and human 
atrial isolated myocyte ICaL 
Previous publications have sought to determine whether chronic pre-operative 
drug therapy alters human atrial myocyte electrophysiology. This was suggested 
by reports indicating altered contractile responses and arrhythmogenicity in cells 
from patients who had received chronic preoperative beta-adrenoceptor (BB) 
antagonists 152;289-291.  The data presented are in accordance with previous work, 
including work from our own laboratory, demonstrating that pre-operative therapy 
with BB has no significant effect on human atrial ICaL under control 
conditions144;223;281;287.  
 
Initial assessments of the impact of chronic therapy with calcium channel blockers 
(CCB) pre-operatively reported no effect on the I-V relationship of ICaL but reported 
an association with reduced peak ICaL under control conditions 
155;282. No such 
association was apparent in this study. The association of reduced peak ICaL and 
chronic CCB therapy has not been corroborated since the initial two reports 
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144;223;281;287.  Possible explanations are methodological differences, a type I error 
as both reports contain data from few patients and limited cell sample sizes and 
early experimental difficulties in recording ICaL
155. 
 
Treatment with ACE-Inhibitor drugs, while not considered anti-arrhythmic therapy 
in the traditional sense have recently been associated with preventive292-295 and 
supportive effects in the successful cardioversion of atrial fibrillation296;297. Under 
control conditions there was no significant difference in peak ICaL between cells 
from patients taking ACE-I therapy preoperatively and those not. This corroborates 
previously published data which have not demonstrated a statistically significant 
electrophysiological effect of preoperative ACE-I therapy, implicating structural or 
cellular remodelling processes144;223;281;287. 
 
Gender has been implicated in altered human atrial action potential 
repolarisation298. No gender differences were identified in the measured 
characteristics of ICaL under control conditions in this study nor in the published 
literature describing ICaL in vitro
144;223;281;287. 
 
The same group who published the association between chronic preoperative 
CCB therapy and reduced basal ICaL subsequently described alterations in ICaL 
comparing ‘normal’ to ‘diseased’ human cardiac cells114. Ouadid et al reported that 
myocytes from patients with severe heart failure requiring cardiac transplantation 
had significantly greater capacitance and smaller ICaL current density when 
compared to cells from patients undergoing cardiac surgery for coronary artery 
disease or mitral stenosis114. Although no patients undergoing cardiac 
transplantation were included in this study, both studies enrolled patients with 
CHD undergoing cardiac surgery regardless of LVSD or valvular heart disease. 
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Both studies are in agreement that heart failure, however so defined, was not 
associated with an alteration in the I-V relationship of ICaL. 
 
In contrast, the present study, under more physiological experimental conditions 
and with a much greater sample size, has demonstrated that, under control 
conditions, peak ICaL current density was significantly greater in cells isolated from 
patients with subjectively moderate/ severe LVSD compared with those with 
normal/ mild LVSD and that no significant difference in capacitance existed 
between these two groups. In comparison with Ouadid et al114, when cells from 
patients suffering from severe LVSD were considered alone, the association was 
maintained. However, the subjective presence or absence of LVSD in the present 
study was associated with similar kinetics, I:V relationship and peak ICaL. More 
recent data, again recorded at room temperature299 reported very small peak ICaL 
(some as low as 0.1 pA/pF) in patients with LVSD. The conclusions presented 
herein are based on the largest single experimental dataset published to date and 
are believed to be sufficiently large to permit accurate interpretation and avoidance 
of type II error. 
 
In order to resolve this issue pooled data from our laboratory submitted for 
publication with approximately a threefold sample size, (and work from another 
laboratory279) has indicated that atrial myocytes isolated from patients with LVSD, 
defined objectively by TTE, do have greater capacity and that ICaL has similar 
kinetics of activation and inactivation, I: V relationship and peak current magnitude 
regardless of the presence of LVSD after multivariate analysis300.  
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3.6.3 Adrenergic effect(s) of acute superfusion with ISO 
Isoproterenol, at concentrations ranging from 0.01 to 1 µM, increased the 
magnitude of the long lasting inward calcium current (ICaL) in a concentration-
dependent manner without altering the I:V relationship, activation or inactivation 
kinetics in human isolated atrial myocytes. In the majority of cells studied, this 
adrenergic increase in ICaL was stable with a time to maximal effect of 
approximately 90 seconds. The mode of electrical access did not appear to affect 
the magnitude of the adrenergic effect, however as indicated in Results chapter 1, 
perforated patch recordings were associated with a greater duration of stable 
recordings. Patient senescence and gender did not appear to affect the adrenergic 
increase in ICaL. Pre-operative drug therapy was not associated with an altered 
response to acute superfusion with Isoproterenol at the EC50 (0.05 µM). A 
diagnosis of pre-operative hypertension was associated with a significantly larger 
adrenergic response to 0.05 µM ISO. In contrast, prior MI, the presence of LVSD, 
regardless of severity, and Aortic Valvular Heart Disease were not associated with 
altered adrenergic responses. The magnitude of the adrenergic response of ICaL to 
0.05 µM was not predictive of the development of post-operative Atrial Fibrillation 
(AFpcs). 
 
ISO increased the magnitude of calcium current passing into the cell at all voltages 
recorded in the absence of a detectable change in the current: voltage (IV) 
relationship. The time to peak current recorded at +10 mV was less than 4 
milliseconds in line with one previous report161. The concentration: response curve 
of the effect of ISO on ICaL at physiological temperature using the nystatin 
perforated patch clamp method has not been previously published. However, our 
data is similar in comparison with the concentration: response curve of the 
inotropic effect of ISO in human right atrial preparations153 reporting an EC50 
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between 0.01 and 0.1 µM ISO and a maximal effect at 1 µM ISO. The EC50 of the 
stimulatory effect of ISO on cAMP in human right atrial strips was reported to be 
10-6.23 with a maximal effect between 1 and 10 µM ISO145;146;228;301 resulting in a 
threefold increase in adenylate cyclase activity301. Exposure to ISO resulted in a 
rapid increase cAMP over 60 seconds but the positive inotropic effect developed 
to a maximum over 120 to 240 seconds154. These effects were mediated by both 
β1-AR and β2-AR
153;154 and the increase in cAMP persisted for up to 15 
minutes146;228, similar in time scale to that of the TCC data presented herein. 
 
Ligand binding of β-AR-Gαs stimulates PKA/ cAMP causing phosphorylation of 
serine and threonine residues on the α1c and β2a subunits of L type calcium 
channels augmenting ICaL via an increased mean channel opening time and an 
increased Po
90;238;239;302-307. Calcium entry into the cytosol acts as a negative 
feedback to ICaL although other gating modalities such as voltage inactivation also 
occur161. Although there are at least three types of β-AR expressed in the human 
heart, little is known of the physiological role of the β3-AR in the atrium and 
discussion in this work will be limited to β1-AR and β2-ARs
308. In human atrial 
myocytes β1-ARs couple to solely to Gαs stimulating ICaL via PKA and cAMP, 
however β2-ARs couple to both Gαs and Gαi which can exert negative feedback on 
ICaL and other cellular processes activated by β2-AR stimulation
232;309-313. PKA is 
anchored to the plasmalemma, co-localising with the L type calcium channel and 
being bound by PKA anchoring protein (AKAP) or AHNAK protein314;315. 
 
No data comparing ICaL kinetics obtained using the differing methodologies has 
been published to date. The purpose of the comparison in this project was to 
establish if the formation of a ruptured patch with nystatin present in the pipette 
would preclude further analysis of ICaL so recorded because of the possible 
confounding effect of nystatin entering the myocyte cytosol via a ruptured patch. 
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The increased duration of stable ICaL recordings with nystatin perforated patch 
recordings is consistent with the published literature220;221 and confirmed the 
possibility of subsequently performing further yet more complex experiments. 
 
It has been shown that cardiac β-AR function decreases with increasing age in 
humans316;317. Mean β-AR density, the ratio of β1-AR: β2-AR and Gαs activity was 
unchanged157, however, Gαi levels increase in human right atrium in association 
with ageing and correlate with a significant reduction in adenylyl cyclase activity in 
response to mixed β1-AR: β2-AR agonists resulting in a ten fold increase in the 
EC50 of the positive inotropic response to ISO
157. Animal models of ageing have 
demonstrated that reduced responsiveness to β-AR stimulation in isolated 
myocytes is due to reduced receptor: ligand: second messenger activity with 
preserved calcium handling protein apparatus231. The lack of effect of increasing 
age on ICaL could be explained by a significant reserve in the number of L-type 
calcium channels available for opening or an age related decrease in the activity of 
PDE4 which transduces the Gαi signal to inhibit cAMP. This possibility highlights 
the potential role of second messenger sub-systems and compartmentalisation 
within the atrial myocyte to separate ICaL acting as a trigger for excitation 
contraction coupling from an adrenergic inotropic effect of ISO38;318-321. 
Alternatively the lack of an age related effect may represent a type 2 error due to 
the homogeneity of our sample of patients or indeed provide evidence of 
significant reserve of second messenger coupling to ICaL such that increased 
inward current in response to ISO is maintained despite the reduction in Gαs: Gαi 
ratio present in myocytes isolated from senescent patients. 
 
Gender has been associated with altered repolarisation but no reports of altered 
human ICaL have been published to date
298. Data from this laboratory and others 
have consistently failed to identify any significant difference in ICaL characteristics 
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in human atrial myocytes from male as opposed to female 
patients79;144;223;281;284;287;322. 
 
Pre-operative drug therapy had no discernible effect on ICaL under control 
conditions nor on the adrenergic effect of ISO. Although chronic β-B therapy has 
been associated with reductions in APD90 and ERP these were related to 
reductions in Ito in the absence of an effect on ICaL
144. These electrophysiological 
changes, termed “pharmacological remodelling”, were associated with a reduced 
occurrence of AFpcs, but were identified in vitro, independent of receptor 
occupancy144. 
 
Although a third, and possibly a fourth β-AR have recently been identified, little is 
known of their physiological role in the heart308;323-325. All subtypes of human 
myocardial β-AR are guanine nucleotide protein receptors which bind 
Norepinephrine undergoing conformational change which in turn activates 
membrane bound heterotrimeric G proteins326-328. The ratio of β1-AR to β2-AR 
expression in human right atrium is controversial with several reports suggesting 
that the ratio varies between 65:35 to 80:20145;229;301;329;330. β1-AR activation with 
Norepinephrine and β2-AR binding with Epinephrine can equally maximally 
increase inotropy in human atrial myocardium152;331;332, and the β2-AR selective 
agonist zinterol demonstrates that both β-AR receptors are coupled to the Gαs / 
adenylyl cyclase/ cAMP/ PKA/ PLB phosphorylation/ TnI phosphorylation/ TnC 
phosphorylation system resulting in positive inotropic and lusitropic effects333. 
 
Chronic β1-AR selective β-B therapy sensitised β2-AR in human left and right atrial 
myocytes334-339 resulting in an enhanced inotropic action of mixed and selective β2-
AR agonists in the absence of β1-AR antagonists suggestive of a persistent 
modification of receptors and intracellular messenger systems152;337. 
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However, human atrial β2-AR hyper-responsiveness of up to a 10 fold increase
152 
cannot be explained by increased receptor density alone159;301;340. Following β-B 
therapy in tissue samples335 and myocytes marked increases in β2-AR 
responsiveness152;331;337 and arrhythmia290 were observed. The atrial inotropic 
response to NE via β1-AR 
152;331;337 and E341 was not enhanced following chronic 
BB therapy, however chronic β-B therapy was associated with noradrenalin 
evoked ‘arrhythmia’ mediated via β1-AR
290. 
 
Chronic pretreatment with β-B therapy may330;334;335;337 or may not324 increase β-
AR expression in human atrial myocytes. Selective β1-AR blockade has been 
shown to enhance the activity of Gαs protein in human atrial tissue
160;334 and the 
sensitivity of β2-AR
152;338 without any demonstrable increase in numbers of β-AR 
or of cAMP responsiveness152;342;343, is suggestive of enhanced coupling of the β-
AR to adenylyl cyclase via Gαs or perhaps an inhibition of PKA phosphorylation of 
Gαs. Wang et al
160 among others measured the α subunit of Gαs and Gαi and the β 
subunit of G proteins expression at protein and mRNA levels and found no 
significant difference in human atria from BBY v BBN patients, however Gαs 
function was found to be significantly (2 fold) enhanced in BBY patients. 
 
There are 4 types of adenylate cyclase found in human atrium (IV-VII)343. β-AR 
activation rapidly activates BAR kinase which phosphorylates β-AR resulting in 
subsequent loss of G-protein coupling343 and there was no significant difference in 
the absolute levels of gene expression among adenylate cyclase subtypes in BBY 
v BBN. As the inotropic effects of synthetic cAMP152 or forskolin291 are not 
augmented following chronic β-B therapy then perhaps a possible role for altered 
amplification of receptor coupling via Gs proteins exists
344. 
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Desensitisation of β-AR occurs via a family of serine threonine kinases called 
GPRC Kinases (GPRCK) abbreviated to GRK- GRK the ones specific to β-AR are 
named βARK. These are similar in structure to other serine threonine kinases such 
as PKA and PKC. When the receptor is phosphorylated by the βARK the β-AR is 
desensitised345. GRK2 is βARK1 and GRK3 is βARK2 and in the myocardium they 
only recognise and thus phosphorylate agonist occupied receptors346. The Gβγ 
subunit which remains from the ‘splicing’ of the G protein complex then interacts 
with the carboxyl terminal of the cytosolic βARK resulting in the translocation of the 
GRK to the membrane where it phosphorylates the activated receptor347. 
Desensitisation in the presence of persistent agonism such as catecholamine 
elevation in heart failure (termed homologous desensitisation) requires not only 
GRK but also β-arrestin which prevents Gαs coupling to the catecholamine bound 
β-AR348. Reduced β-AR density and function in failing hearts is in contrast to 
βARK which is significantly increased in patients with CHF349, hypertension350 and 
myocardial ischaemia351. The premise that elevated βARK1 is protective is being 
suggested by in-vitro studies, as reduced βARK expression levels post myocardial 
infarction have been associated with an increased inotropic response to ISO352 - 
analogous to the interruption of neurohumoural remodelling of CHF by β-B 
therapy- indeed β-B therapy is associated with a reduction in βARK1, β-AR 
downregulation increasing agonist sensitivity and improving cardiac function in 
vivo353. As β-ARK preferentially phosphorylates the β2-AR rather than β1-AR
354, yet 
another possible mechanism for selective inactivation of the β2-AR exists. β1-AR 
blockade with selective β-B therapy will inhibit β-ARK activity in β2-AR resulting in 
more non-phosphorylated β2-AR as a result of background autonomic tone. 
 
The lack of effect of chronic CCB therapy on beta adrenoceptor density is less 
controversial. Published reports confirm that CCB has no effect on adrenoceptor 
density in human right atrium330;335;337;355;356. Two previous reports in humans 
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described a decrease in ICaL associated with chronic pre-operative CCB 
therapy155;282, however a larger study comprised of data from this laboratory and 
three other investigators found no such association144;223;281;287. In animal models 
most studies reported no association between chronic CCB therapy and ICaL and 
indeed in one study an increase in ICaL was described
357-360. It is not clear why the 
difference in results from human atrial myocytes occurred, however the initial 
reports described results with significant methodological differences between the 
studies. 
 
There has been only one published report of the acute effect of the ACE-I drug, 
enalapril, to increase ICaL
282, but the present study is in total agreement with four 
previously published reports demonstrating no association with chronic ACE-I 
therapy and altered ICaL characteristics
144;223;281;287. 
 
There have been no studies published to date demonstrating an association 
between pre-existent hypertension and altered human atrial ICaL characteristics. If 
true, one possibility, discussed above, is elevated levels of βARK350. At first glance 
this would seem counterintuitive as reduced levels of βARK were associated with 
an increased inotropic response to ISO352. However there may indeed be a 
confounder at play. Most patients from whom we received atrial tissue were 
undergoing cardiac surgery for CHD and were receiving chronic β-B therapy which 
is associated with a reduction in βARK1, increasing agonist sensitivity in vivo353. In 
retrospect, pooled data from our own laboratory, with a much larger sample size 
and following multivariate analysis similarly does not identify any such association 
between pre-existent hypertension and altered human atrial ICaL 
characteristics144;284, suggesting that this is a type 1 error due to the small sample 
size. 
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Although the L-type calcium current recorded in canine ventricular myocytes from 
the infarct border zone is reduced with altered kinetics and response to adrenergic 
stimulation following MI in vitro361-363, no such association has been documented in 
human atrial myocytes144;284. 
 
The acute effects of sympathomimetics are blunted in patients with CHF and this 
has been thought to be related to any or all of the following effects: a CHF induced 
down regulation of β-AR, internalisation of the receptor ligand complex with out 
downstream cellular effects, depletion of intracellular stores of secondary 
messengers or impaired phosphorylation of intracellular messengers126;364;365. 
 
The positive inotropic and lusitropic effects of β1-AR and β2-AR ligand binding 
persists in human atrial tissue from failing hearts152;331-333. Despite similar levels of 
expression of β1-AR and β2-AR
339, however, the effects of β2-AR binding E are 
preserved but the β1-AR mediated inotropic effect of NE was reduced fourfould in 
tissue preparations from patients with CHF with no change in lusitropy. Reports of 
reduced ICaL response to β-AR stimulation are controversial, and may reflect 
altered β-AR availability and response in myocytes from CHF patients rather than 
impaired intracellular signal transduction mechanisms114;279;366;367. This hypothesis, 
that β2-AR linked to Gαi proteins
232;309 may oppose the effects of Gαs stimulation in 
human atria, particularly in patients with CHF312, due to the relative downregulation 
of β1-AR as compared to β2-AR
342 remains unsubstantiated330;332;340;342. One report 
has suggested that the ISO induced stimulation of adenylate cyclase activity was 
weaker in atrial tissue compared to ventricular specimens from failing hearts301. 
There appeared only a weakly positive correlation of increasing β-AR receptor 
concentration and adenylate cyclase activity in right atrial specimens301. Very 
recently human atrial myocytes with very small detectable “down-regulated” ICaL at 
baseline from patients in sinus rhythm suffering from LVSD, said to be at high risk 
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of developing AF, were observed to display an exaggerated response to 
stimulation with ISO299. This is on stark contrast to the current work and pooled 
data from our laboratory performed under more physiological conditions. 
 
We, and others, have found, following multivariate analysis, that there were no 
detectable differences in ICaL peak current, I: V relationship or kinetics under basal 
conditions nor following stimulation with ISO at the approximate EC50 (50 nM) 
between cells from patients with as opposed to without LVSD144;279;284;300;368. 
 
Some of the original studies examining inward calcium current in human atrial 
myocytes linked calcium overload via increased ICaL, either alone or as a function 
of tachycardia, to the subsequent development of AF81;82;104;369. It is widely 
accepted that the response to AF, that is the electrophysiological remodelling that 
occurs as a result of the presence of AF or as a result of the pathophysiology 
which has also allowed AF to supervene is associated with an approximate 70% 
reduction in ICaL
69;79;82;98;100;370. In contrast to early data which demonstrated an 
association between large ICaL and post-operative AF, but not the magnitude of an 
adrenergic increase in ICaL
81, Dinanian et al299 report that the smaller the 
magnitude of baseline ICaL the greater the adrenergic response to ISO. However 
no information regarding the subsequent development of AFpcs was available. In 
contrast neither the baseline magnitude of ICaL nor the adrenergic response to ISO 
was predictive of subsequent AFpcs in this study nor in pooled data from this 
laboratory284. 
 
3.6.4 Anti-adrenergic effect of acute superfusion with ET-1 
ET-1 alone, a mixed ET-A and ET-B receptor agonist, at the maximal concentration 
tested (10 nM), had no discernible effect on peak ICaL. Similarly, 10 nM Sarafatoxin 
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S6-c, a selective ET-B receptor agonist had no significant effect on peak ICaL 
indicating that there was no apparent effect rather than a balance of two opposing 
effects on peak ICaL. In contrast, ET-1, in a concentration dependent fashion from 
0.01 to 10 nM, had an anti-adrenergic effect on peak ICaL prestimulated by 0.05 µM 
ISO. This anti-adrenergic effect was partially reversible, both by washout and also 
by either a priori or co-application with the selective ET-A receptor antagonist FRA 
at 10 nM. Sarafatoxin S6-c at 10 nM had no effect on prestimulated peak ICaL, nor 
did it prevent the anti-adrenergic effect of 10 nM ET-1 on peak ICaL which had been 
pre-stimulated with 0.05 µM ISO.  
 
In human atrial myocytes, ET-1 alone was found to increase199, decrease199;200 or 
have no effect199;200 on ICaL under control conditions. It is not immediately apparent 
why this should be. Initial reports in animal models described 
stimulatory196;248;258;259, inhibitory195;196;248;260-263 or no effect203;247;249;264 of ET-1 
directly on ICaL, with an EC50 between 1 and 10 nM, mediated via ET-A 
receptors195;196;203;248;249;258-264. In addition to the possible direct effects on ICaL, 
activation of NHE265 and NCX266-268 via PKC have also been described, but such 
activation would be expected to reduce ICaL as a result of calcium induced 
inactivation which was not observed. 
 
ET-1 has been noted to inhibit IK1 via PKC in human atrial myocytes at 
physiological temperature using whole cell patch clamp371 resulting in a 
hyperpolarised resting membrane potential270;272. ET-1, at a concentration 
observed in patients with severe CHF372, induced maximal inhibition of outward K+ 
and NCX currents in human atrial but not ventricular myocytes similar to 
experience in animal models268;271;273;373. Whether these effects, not directly 
measured herein, could in some way compensate for a direct effect of ET-1 on ICaL 
rendering the net effect to be zero cannot completely be discounted. However ICaL 
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was recorded with caesium in the pipette blocking K+ currents in the cells studied 
and the TCC experiments discount a time dependency of opposing effects 
reported199;200. 
 
Differing methodologies may explain apparently contradictory results. The 
requirement for ET-1 to convey it’s signalling via temperature sensitive secondary 
messengers may result in a population of cells unable to respond conventionally 
depending on the level of oxidation or phosphorylation of the cell cytosol 
proteins84;161;374-379. A similar paradox of apparently opposing effects of ANP on 
ICaL was resolved by ensuring the availability of second messengers, in this case 
cGTP, in the pipette during ruptured patch experiments199;380;381. 
 
Initial experiments investigating potential arrhythmogenic effects of ET-1 in animal 
models were contradictory confounded by the peptide’s vasoconstrictor induced 
ischaemic pro-arrhythmic effects54-60, however several groups began to identify 
acute electrophysiological effects apparently directly attributable to ET-1 in the 
absence of ischaemia56;61-64. 
 
Historically a clearer consensus began to emerge regarding ET-1 having a positive 
inotropic effect and influencing arrhythmogenesis in human tissues although no 
obvious mechanism was initially apparent191. Initially this apparent positive 
inotropic effect was assumed to be related to a direct augmentation of ICaL by ET-
1. However the positive inotropic effect of ET-1 has been demonstrated to occur in 
the absence of an increase in ICaL
179;197;382-384 or the calcium transient suggestive 
of increased myofibrillar sensitivity to calcium195;385;386. In addition the effect of ET-
1 via ET-A receptors in tissue preparations removed from failing hearts varied 
considerably and was thought to relate to altered ET-1 receptor expression rather 
than any changes in ICaL
175;184;372;387;388. 
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The positive inotropic effect of ET-1 in human atrial preparations175;177-
179;188;193;387;388 has now been identified to be mediated by ET-A receptors via InsP3/ 
DAG/ PKC177;184;187;188;193;387;388 in the presence179;188 and absence of any effect on 
NHE177;388. Of note is that the positive inotropic effect of ET-1 was apparently 
independent of patient age, gender, pre-operative drug therapy and LVSD which 
have previously been associated with altered GPCR status and ICaL
386. 
 
In animal models evidence exists for an additional three possible mechanisms by 
which ET-1 can exert a positive inotropic effect in cardiac myocytes in the absence 
of an augmentation of ICaL: stimulation of NHE resulting in increased myocyte [pH]i 
sensitising troponin C to calcium, increasing the [Na]i resulting in mode reversal of 
NCX and PLC activation induced InsP3 formation causing increased SR calcium 
uptake, storage and release187;194;197;241;265;267;389-392. 
 
The above experiments described the effects of acute exposure to ET-1, however 
one study has described the effects of chronic (≥5 days) exposure of rat myocytes 
to ET-1 which resulted in blunting of the positive inotropic effect of both ISO and 
increased [Ca2+]ec mediated by ET-A, via PKC and NHE
393. 
 
In one of the three studies examining the receptor mediated effects of ET-1 alone 
on ICaL
199, an intrinsic stimulatory effect of ET-1 on ICaL was prevented by pre-
treatment of the atrial myocytes with the ET-B receptor agonist BQ-788. In human 
tissue BQ-788 has been shown to have low affinity for and little selectivity for ET-B 
receptors394. This observation could be explained by a lack of effect of ET-1 alone 
which would be consistent with that observed in the other two published 
reports200;322. No additional data other than ICaL current density at baseline was 
provided to explain this apparent dichotomous effect199. This group have published 
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data obtained at room temperature with variable effects dependent on small initial 
ICaL density without clearly identifying an obvious mechanism
92;299.  
 
Evidence exists for a basal constitutive cAMP/ ICaL activity level in human atrial 
myocytes281;287;288;395 which is counterbalanced by type 1 and type 2A 
phosphatases (PP1 and PP2A)91 and it may be that two populations of cells with 
differing phosphatase activity or perhaps altered basal levels of cAMP may explain 
the dichotomous results. In human right atrium ET-1 was demonstrated to have 
little or no effect on cAMP under basal conditions, but inhibited the action of 
adenylate cyclase to produce cAMP due to ET-A receptor/ Gαi/ IP3 formation 
independent of ICaL and PKC
187;200. Indeed the anti-adrenergic effect of ET-1 was 
abolished during simultaneous intracellular application of 8-Br-cAMP200. 
 
In human atrial myocytes, ET-1 alone was found to increase199, decrease199;200 or 
have no effect199;200 on ICaL under control conditions. Following pre-stimulation with 
ISO, ET-1 consistently had an anti-adrenergic effect mediated via ET-A receptors 
coupled to Gαi
199;200. Numerous groups have developed a theme of ET-1 whether 
via crosstalk in  intracellular messengers or via direct antagonism demonstrates an 
anti-adrenergic effect on chronotropy, inotropy and ICaL
245-249. 
 
Adrenergically prestimulated ICaL was inhibited by 10 nM ET-1 via ET-A receptors 
acting on Gαi (pertussis sensitive) GPCRs
245;247;262 which reduced cAMP via PDE 
in guinea-pig ventricular myocytes262 and human atrial myocytes200 in the absence 
of any direct effect on the L-type calcium channel itself198;200. Similar to human 
atrial ICaL, ET-1 binding to ET-A receptors had no effect on basal ICl in animal 
models, however ET-1 with an EC50~ 1 nM, activating Gαi had an anti-adrenergic 
effect reducing ISO prestimulated ICl via reducing intracellular cAMP (PDE)
205;273. 
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ET-1 binding to ET-A receptors on animal cardiac myocytes has a number of 
biological effects mediated via stimulation of Gαi
396-398. ET-1 had an anti-adrenergic 
negatively chronotropic effect mediated via ET inhibition of formation of cAMP both 
under basal conditions and following adrenergic stimulation with ISO399 and ET-1 
prevented apoptosis induced by 10 µM ISO downstream to the β-AR and Gαi 
induced alterations in cAMP mediated intracellularly via phosphatidylinositol and 
protein phosphate kinases400. As apoptosis is a recognized sequel following the 
development of AF or atrial dilation96, whether ET-1 has a direct effect to promote 
apoptosis or has an anti-adrenergic effect to oppose apoptosis mediated by 
catecholamines remains to be determined. 
 
The selective ET-A receptor antagonist FR139317 inhibited the binding of ET-1 to 
ET-A receptors in a concentration dependent, monophasic fashion with an IC50 of 
0.53 nM in the absence of agonist activity401. The possibilities for ET-1 mediated 
anti-adrenergic effect on human atrial ICaL are as follows: ET-1 stimulates calcium 
release from the SR reducing the electrochemical gradient producing calcium 
mediated inactivation of ICaL
195;197;258, ET-1 stimulates IP3 formation and in so doing 
inhibits cAMP formation by adenylate cyclase reducing the ability of cAMP 
dependent kinases to activate ICaL
187;188;200;262;273;399, or that ET-1 stimulates cyclic 
nucleotide phosphodiesterase via cGMP hydrolyzing cAMP antagonizing the 
adrenergic effect of β-AR stimulation187;199;200;242 on ICaL but not NCX
402;403. The 
apparent contradiction in an inhibitory effect on ICaL but a positive inotropic effect 
could be explained by the relative efficacy of the differing second messenger 
systems effected by ET-1 binding to ET-A receptors: sensitising the SR and 
increasing cytosolic calcium during diastole will oppose calcium entry via 
ICaL
195;197;258, PLC activation and IP3/ DAG stimulation produces a positive inotropic 
effect but the associated inhibition of cAMP will reduce ICaL 
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amplitude187;188;200;262;273;399 and activation of NHE265 and NCX266-268 via PKC will 
result in a positive inotropic effect with little or no direct inhibitory effect on ICaL. 
 
If one accepts that ET-1 is a positive inotrope but a negative lusitrope, it is 
accepted that the PIE of ET-1 differs from that of beta-adrenergic agonists such as 
isoproterenol which is positively inotropic but also positively lusitropic. ET-1 
increases the calcium transient and is thought to do this via NHE and ICaL
404. 
Stimulation of NHE causes intracellular alkalinisation and an increase in 
intracellular Na265;405;406 which reverses the normal direction of the sarcolemmal 
NCX and thus increases intracellular calcium407. This may explain why for a given 
PIE ET-1 requires a smaller increase in intracellular Ca and also the different 
lusitropic effects when compared to beta adrenergic agonists407. Additionally 
alkalinisation of the cardiac myocytes increases the affinity of troponin C for 
calcium, sensitising actomyosin ATP-ase to calcium resulting in a positive inotropic 
effect and decreases the rate of dissociation of calcium from the troponin C-ca 
complex resulting in negative lusitropy. 
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4 RESULTS (ii) 
Single atrial myocyte action potential studies 
4.1 Introduction and aims 
The primary function of the heart is to pump blood around the body. In order for 
this to occur effectively a coordinated cycle of excitation, contraction and 
relaxation in cardiac myocytes must occur. The action potential is a time 
dependent integration of multiple ionic currents present on the cell membrane 
which not only initiates intracellular excitation-contraction coupling but also 
provides the excitatory stimulus for adjacent myocytes. This electrical stimulus, 
when normally propagated around the heart, permits coordinated 3-D contraction 
forcing blood through the cardiac chambers and out into the blood vessels. 
 
In human atrial myocytes action potentials are generated by the rapid inward influx 
of fast sodium current (INa) depolarising the cell membrane. This depolarisation 
opens long lasting L-type calcium channels (ICaL) permitting calcium to enter the 
cell triggering mechanical activation of the contractile apparatus within the cell and 
forming the electrical plateau phase characteristic of cardiac myocytes to oppose 
rapid repolarisation by potassium currents (ITO). Action potential repolarisation 
electrically resets the myocytes in a rate dependent manner permitting the 
electrical cycle to be repeated and the ensuing refractoriness ensures sufficient 
time for intracellular processes to complete in time for the subsequent action 
potential.  
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Propagation of an action potential between neighbouring myocytes transmits 
stimuli from one region of the heart to another. The action potential is modulated 
by the physiological environment surrounding the cell, the cell membrane voltage, 
the membrane ion channels and intracellular regulatory molecules in a complex 
fashion. Up until this point we have limited our investigation to one ion channel, 
ICaL. It is important not only to place the effects of ET-1 on ICaL characteristics in 
context within the action potential but also to translate these changes into myocyte 
functional properties, that is repolarisation and refractoriness, in addition to 
identifying any other changes in action potentials which may indicate the possibility 
of ET-1 effecting cardiac ion channels other than ICaL.  
 
The effect of catecholamines to elevate the plateau phase of mammalian cardiac 
action potentials were described in detail many years ago227;408-412. Although the 
cellular basis of this plateau elevation took some time to fully be investigated it 
became clear that this adrenergic effect was the result of cAMP mediated 
increased conductance of ICaL
227;408-416. However, despite these numerous reports, 
relatively little has been published in detail regarding the effect of ISO specifically 
on human atrial isolated myocyte action potentials at physiological temperature161. 
 
Initial experiments investigating potential arrhythmogenic effects of ET-1 in animal 
models were contradictory, confounded by the peptide’s vasoconstrictor induced 
ischaemic pro-arrhythmic effects54-60. However, several groups began to identify 
acute electrophysiological effects apparently directly attributable to ET-1 in the 
absence of ischaemia producing focal activity56;61-64. 
 
Endothelin has been reported to have a direct effect on INa
176;200;261, IK
62;269-272;417, 
ICaL
195;196;248;258-261;263;399, ICl
273, NHE265 and NCX266-268 ionic currents in cardiac 
myocytes in various animal and human studies. In contrast, very little is known 
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about the effects of ET-1 on human atrial myocyte action potentials. In this report 
we have described an absence of effect of ET-1 alone on ICaL but observed 
powerful anti-adrenergic effects of ET-1 to completely reverse the effect of ISO on 
ICaL in human atrial isolated myocytes. 
 
Adrenergic stimulation is recognised to be pro-arrhythmic in both human atrium 
and ventricle via automaticity, triggered activity and reentrant mechanisms69;162;418. 
What is not known is whether ET-1 would modify human atrial myocyte action 
potential characteristics in such a way as to be anti-arrhythmic, as suggested by 
its effect on ICaL, or if it would be observed to have other pleiotropic effects which 
could promote arrhythmogenesis. 
 
In view of the fact that initial reports described stimulatory196;248;258;259, 
inhibitory195;196;248;260-263 or no effect203;247;249;264 of ET-1 on ICaL we wished to 
confirm whether the anti-adrenergic effects of ET-1 on ICaL would translate into 
alterations in action potentials. In addition, using concentrations similar to those 
observed to have electrophysiological effects in animal models195;196;203;248;249;258-
264 and reported to be present in human patients suffering from CHF123;125;128;255 
we hoped to gain some mechanistic insight into arrhythmogenesis in heart failure. 
 
The aims of these experiments were as follows: 
• To establish that human atrial isolated myocyte action potentials could be 
reliably recorded using the nystatin perforated patch clamp technique under 
“physiological” conditions 
• To investigate whether patient characteristics, chronic pre-operative drug 
therapy or pre-operative comorbidity was associated with altered 
electrophysiological properties such as depolarisation, repolarisation and 
refractoriness. 
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• To determine the effects of ISO, at the EC50 previously demonstrated to 
reliably augment ICaL, on action potential characteristics and spontaneous 
depolarisations. 
• To investigate the effect(s), if any, of ET-1 on action potential 
characteristics and spontaneous depolarisations. 
• To compare and contrast the effect(s) on action potential characteristics of 
ET-1 and ISO in combination. 
 
4.2 Methods 
Myocytes were isolated and superfused with solutions as previously described 
(See Methods 2.3.1). Experiments were performed in current-clamp mode 
whereby a constant or pre-specified time-varying current is applied to the myocyte 
and the resultant change in membrane potential, the action potential, is recorded 
(See Methods section 2.4.1). 
  
Myocytes in the resting state were current clamped to -80± 5 mV and 
subsequently the holding current was maintained <150 pA thereafter. Action 
potentials were stimulated at 75 beats per minute (bpm) using 5 ms current pulses 
of 120% threshold strength. 
 
The APD was calculated as the interval between the action potential upstroke and 
repolarisation to the level of 50% (APD50), 75% (APD75) and 90% (APD90) of the 
upstroke amplitude in all cells (See Figure 4.1). Additionally, in order to further 
investigate the effect of CCB drugs action potential repolarisation at 60% (APD60) 
was also calculated. A representative example of the measurements made to the 
raw current tracings to calculate phase 0 characteristics and repolarisation (Figure 
4.1A) and refractoriness in Figure 4.1B. 
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Figure 4.1 Diagrammatic representation of measurements of A) repolarisation and B) refractoriness 
in human atrial isolated myocyte action potential recordings. a= amplitude, b= overshoot, c= MDP, 
d= time to peak amplitude (a/d= Vmax), e= APD50, f= APD60, g= APD75, h= APD90, i= full 
repolarisation, j= 80% amplitude threshold, k= ERP. 
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4.3 Protocols 
Both ERP and REP protocols were performed under control conditions once an 
appreciation of the occurrence of spontaneous depolarisations was realised (See 
Methods 2.4.1). Both ERP and REP protocols were performed under control 
conditions and subsequently acute superfusion with ISO at 0.05 µM or 10 nM ET-1 
alone was performed as soon as stable action potential recordings (ERP and 
REP) had been completed. Following exposure to ISO or ET-1 for 90 seconds and 
3 minutes respectively, based on time to peak effect on earlier ICaL experiments 
and assuming stable action potential recordings were observed, the addition of 
other subsequent reagents to the superfusate occurred. A diagramatic 
representation of action potential experiment is given in Figure 4.2. 
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Figure 4.2 A representative schema of the order and timing of recordings of human atrial isolated 
myocyte action potentials made during acute superfusion with both 0.05 µM Isoproterenol and 10 nM 
ET-1 in combination. 
 
4.4 Statistics & data analysis 
Data were recorded and analysed off-line as described in Methods section 2.5.1.. 
The action potential characteristics of the entire dataset followed a normal 
distribution and therefore the paired Student’s t test was employed to determine 
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the degree of difference between sub-analysed samples under control conditions. 
This test was selected as it is the most valid, accepted test with which to assess 
the probability of a similar or more extreme result being arrived at by chance in 
samples of small size79;144;161;223. Where a comparison between two differing 
populations of data are presented the variance of the two groups has been 
assessed to permit the use of the unpaired Student’s t test was employed. As 
previously stated this report is based on all available information in order to 
maximise utility. 
 
4.5 Results 
4.5.1 Human atrial myocyte action potential morphology and 
phase 0 characteristics under control conditions 
Action potentials were characterised by rapid upstrokes with depolarisation 
consistently reaching positive potentials (overshoot). We recorded only type 1 and 
2 action potentials demonstrating a brief rapid repolarisation phase followed by a 
plateau phase prior to full repolarisation back to the diastolic potential. In order to 
quantify differences in action potential morphology a number of measurements of 
phase 0 characteristics, repolarisation and later, refractoriness, were made. The 
numerical values of the various electrophysiological characteristics are 
represented in Table 4.1. A representative action potential recording is displayed 
in Figure 4.3. 
 
Cellular action potential characteristics followed a normal distribution. In order to 
determine whether samples from a particular patient were consistently more than 
2 SD outwith the single myocyte distribution curve patient means were also 
calculated and comparison with mean data were made. No cells from any patient 
required to be excluded. There was no significant difference in the maximal 
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diastolic potential (MDP) nor of phase 0 of the action potential depolarization 
characteristics of single myocytes as compared to patient mean (Figure 4.4 A-D). 
The mean MDP of all myocytes following hyperpolarisation was -83.62± 0.6 mV as 
compared with -83.35± 0.7 mV (n= 78 cells from 20 patients, mean± s.e.m., Figure 
4.4A). The mean maximal rate of depolarization (Vmax) observed in cells was 
208.7± 5.6 V/s which was not significantly different from patient mean 206.8± 6.8 
V/s (n= 78 cells from 20 patients, mean± s.e.m., Figure 4.4B). The action potential 
overshoot was similar regardless of cellular or patient mean: cell mean 60.7± 0.9 
mV compared to 60.6± 1.2 mV (n= 78 cells from 20 patients, mean± s.e.m., Figure 
4.4C). As expected the total amplitude of the phase 0 response of the action 
potential did not significantly differ between cells or patients. Mean amplitude of 
phase 0 response recorded from cells was 144.6± 0.9 mV and was 143.8± 1.2 mV 
(n= 78 cells from 20 patients, mean± s.e.m., Figure 4.4D) from patients. 
 
4.5.2 Action potential duration under control conditions 
Early, mid and late repolarisation are referred to as APD at 50% 75% and 90% 
respectively calculated as indicated in Figure 4.1 using phase 0 upstroke 
amplitude as the denominator. Action potentials were not triangular with an 
obvious plateau during early and mid repolarisation. In an attempt to confirm that 
cells were similar between and within patients a comparison between cell and 
patient means was performed and, as with MDP and phase 0 characteristics no 
significant difference was observed (Figure 4.5).  
 
Mean action potential repolarisation at 50% (APD50) observed from cells was 
20.8± 2.6 ms compared to patient mean of 21.4± 3.5 ms (n= 78 cells from 20 
patients, mean± s.e.m., Figure 4.5A). Action potential repolarisation at 75% 
(APD75) observed from cells was 144.4± 7.8 ms and in patients was 147.7± 9.4 ms 
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(n= 78 cells from 20 patients, mean± s.e.m., Figure 4.5B). Similarly action potential 
repolarisation at 90% (APD90) observed from cells was 216.3± 9.3 ms compared to 
mean patient APD90 of 215± 9.8 ms (n= 78 cells from 20 patients, mean± s.e.m., 
Figure 4.5C). 
 
4.5.3 Effective refractory period (ERP) under control conditions 
There were no significant differences observed between cellular atrial myocyte 
refractoriness and patient mean ERP recorded in 10 ms increments (Figure 4.6). 
The mean cellular ERP was 210.0± 8.1 ms compared to a patient mean of 213± 
8.8 ms (n= 74 cells from 20 patients, mean± s.e.m., Figure 4.6A). The relationship 
of refractoriness to repolarisation (ERP/APD90) was similar between cells and 
patients: mean myocyte ERP/APD90 ratio of 1.007± 0.03 compared to 1.042± 0.05 
(n= 74 cells from 20 patients, mean± s.e.m., Figure 4.6B). 
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Figure 4.3 Representative human atrial isolated myocyte action potential recording made under 
control conditions. 
 Parameter Mean data Published range to 2008 
Phase 4 MDP -83.62 ± 0.6 mV -71 to -86 mV 
Phase 0 Vmax 208.7 ± 5.6 V/s 149 to 244 V/s 
 Overshoot 60.7 ± 0.9 mV 48 to 53 mV 
 amplitude 144.6 ± 0.9 mV >90 mV 
Repolarisation APD50 20.8 ± 2.6 ms 12 to 62 ms 
 APD75 144.4 ± 7.8 ms 118 to 138 
 APD90 216.3 ± 9.3 ms 176 to 447 ms 
Refractoriness ERP 210 ± 8.1 ms 184 to 233 ms 
 ERP/ APD90 1.007 ± 0.03  
 
Table 4.1 Comparison of mean action potential characteristics data under control conditions from 
this study (nc=78, np=20 for phase 0 and repolarisation data, nc=74, np=20 for refractoriness data) 
with reported ranges in the literature (see text for references). 
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Figure 4.4 Comparison of cell mean with patient mean of phase 1 of the action potentials recorded 
under control conditions. A) Mean Diastolic Potential. B) upstroke maximum velocity. C) action 
potential overshoot. D) action potential amplitude (n= 78 cells from 20 patients). 
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Figure 4.5 Comparison of cell mean with patient mean action potential duration. A) Action potential 
duration at 50% repolarisation (APD50) B) Action potential duration at 75% repolarisation (APD75) C) 
Action potential duration at 90% repolarisation (APD90) (n= 78 cells from 20 patients). 
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Figure 4.6 Comparison of cell mean with patient mean refractoriness. A) Effective refractory period 
(ERP) B) Ratio of ERP to APD90 (n= 74 cells from 20 patients). 
 
4.5.4 Impact of methodology on atrial myocyte action potentials 
and refractoriness 
4.5.4.1 Lack of effect of method of electrical access to the cell on 
action potential characteristics relating to depolarisation 
 
There was no significant difference in the maximal diastolic potential (MDP) nor of 
phase 0 of the action potential depolarization characteristics of those myocytes in 
which the seal was obtained via a ruptured patch as compared with those cells in 
which the seal was a perforated patch. The mean MDP obtained with a ruptured 
seal was -85.1± 0.7 mV (n= 10 cells from 7 patients, mean± s.e.m.) as compared 
with -83.4± 0.7 mV (n= 68 cells from 13 patients, mean± s.e.m.). The maximal rate 
of depolarization (Vmax) observed in cells in which a ruptured seal was obtained 
was 211.8± 14.9 V/s (n= 10 cells from 7 patients, mean± s.e.m.) which was not 
significantly different from those cells in which a perforated seal was obtained 
208.3± 6.1 V/s (n= 68 cells from 13 patients, mean± s.e.m.). The action potential 
overshoot was similar regardless of the method of electrical access:  ruptured seal 
formation was associated with a mean overshoot of 59.4± 3.0 mV (n= 10 cells 
from 7 patients, mean± s.e.m.) compared to 60.9± 0.9 mV (n= 68 cells from 13 
patients, mean± s.e.m.). Consistent with these results the total amplitude of the 
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phase 0 response of the action potential did not significantly differ according to the 
method of electrical access to the cell. Mean amplitude of phase 0 response 
recorded from cells via a ruptured patch was 144.8± 2.7 mV (n= 10 cells from 7 
patients, mean± s.e.m.) and was 144.6± 0.9 mV (n= 68 cells from 13 patients, 
mean± s.e.m.) from cells via a perforated patch. 
 
 
4.5.4.2 Lack of effect of method of electrical access to the cell on 
repolarisation characteristics 
There was no significant difference in the action potential repolarisation 
characteristics of those myocytes in which the seal was obtained via a ruptured 
patch as compared with those cells in which the seal formed was perforated. 
Action potential repolarisation at 50% (APD50) observed from cells in which the 
seal ruptured during formation was 24.6± 8.5 ms (n= 10 cells from 7 patients, 
mean± s.e.m.) compared to 20.2± 2.8 ms (n= 68 cells from 13 patients, mean± 
s.e.m.) that observed from cells in which the seal formed via perforation. Action 
potential repolarisation at 75% (APD75) observed from cells in which a ruptured 
patch formed was 164.6± 17.7 ms (n= 10 cells from 7 patients, mean± s.e.m.) 
compared to 141.4± 8.5 ms (n= 68 cells from 13 patients, mean± s.e.m.) observed 
from cells in which the seal formed via perforation. Similarly action potential 
repolarisation at 90% (APD90) observed from cells in which the seal ruptured 
during formation was 234.7± 22.6 ms (n= 10 cells from 7 patients, mean± s.e.m.) 
compared to 213.6± 10.1 ms (n= 68 cells from 13 patients, mean± s.e.m.) 
observed from cells in which the seal formed via perforations. 
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4.5.4.3 Lack of effect of method of electrical access to the cell on 
myocyte refractoriness 
There were no significant differences observed in atrial myocyte refractoriness 
associated with ruptured as compared with perforated patch formation. The mean 
effective refractory period (ERP) recorded from cells in which the seal ruptured 
during formation was 223.0± 19.3 ms (n= 10 cells from 7 patients, mean± s.e.m.) 
compared to 207.3± 8.9 ms (n= 64 cells from 13 patients, mean± s.e.m.) observed 
from cells in which the seal formed via perforations. The relationship of 
repolarisation to refractoriness (ERP/APD90) was similar regardless of the method 
of electrical access to the cell: recordings performed via ruptured patch (NR) 
demonstrated an ERP/APD90 ratio of 0.968± 0.03 (n= 10 cells from 7 patients, 
mean± s.e.m.) compared to 1.013± 0.04 (n= 64 cells from 13 patients, mean± 
s.e.m.) from recordings obtained via a perforated patch (NP). 
 
 
4.5.5 Impact of patient senescence and gender on human atrial 
isolated myocyte action potentials and refractoriness 
4.5.5.1 Lack of effect of patient age (dichotomised) on action potential 
characteristics 
There were no significant differences in the action potential characteristics relating 
to depolarisation, repolarisation or refractoriness under control conditions between 
those myocytes isolated from tissue excised from the right atrial appendage of 
patients aged 75 or over (elderly) as compared with patients aged less than 75 
years (young).  
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4.5.5.2 Impact of patient gender on action potential characteristics 
 
There were no significant differences in the MDP nor Vmax of phase 0 of the action 
potential, however a significantly greater amplitude of the action potential 
upstroke, with similarly greater overshoot that did not reach statistical significance, 
was observed in atrial myocytes isolated from tissues excised from the RAA of 
male patients (Figure 4.7 A-D). The mean MDP observed from myocytes 
emanating from female patients was -83.4± 0.8 mV (n= 15 cells from 4 patients, 
mean± s.e.m.) compared to -83.7± 0.7 mV (n= 57 cells from 15 patients, mean± 
s.e.m., Figure 4.7A) from male patients. The maximal rate of depolarization (Vmax) 
observed in cells from female patients was 193.9± 10.3 V/s (n= 15 cells from 4 
patients, mean± s.e.m.) which was not significantly different from that observed in 
cells from male patients 208.8± 6.7 V/s (n= 57 cells from 15 patients, mean± 
s.e.m., Figure 4.7B). The action potential overshoot was similar regardless of 
patient gender: mean overshoot of 57.5± 2.1 mV (n= 15 cells from 4 patients, 
mean± s.e.m.) in cells from female patients compared to 61.4± 1.0 mV (n= 57 cells 
from 15 patients, mean± s.e.m., p= 0.08. Figure 4.7C) in cells from male patients. 
However the total amplitude of the phase 0 response of the action potential was 
significantly larger in cells originating from male patients. Mean amplitude of phase 
0 response recorded from cells obtained from female patients was 140± 1.6 mV 
(n= 15 cells from 4 patients, mean± s.e.m.) and was 145.8± 0.9 mV (n= 57 cells 
from 15 patients, mean± s.e.m., p= 0.006. Figure 4.7D) from cells obtained from 
male patients. 
 
In contrast, there were no significant differences in the action potential 
repolarisation nor refractoriness of those atrial myocytes originating from female 
as compared with male patients. 
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Figure 4.7 Effect of patient gender on resting membrane potential and phase 0 action potential 
characteristics of human atrial isolated myocytes under control conditions.   = myocytes obtained 
from female patients (n= 15 cells from 4 patients)   = myocytes obtained from male patients (n= 57 
cells from 15 patients). Values are mean± s.e.m., asterisk* indicates p< 0.05. 
 
 
 
4.5.6 Impact of chronic pre-operative drug therapy on human 
atrial isolated myocyte action potentials and refractoriness 
4.5.6.1 Lack of effect of chronic pre-operative beta-adrenoceptor 
blocker therapy on isolated atrial myocyte action potential 
characteristics 
There were no significant differences in the characteristics of depolarisation, 
repolarisation nor refractoriness under control conditions when myocytes isolated 
from tissue excised from the right atrial appendage of patients chronically 
receiving β-B therapy pre-operatively (BBY) were compared to those from patients 
who were not receiving β-adrenoceptor blocking drug therapy (BBN). 
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4.5.6.2 Effects of chronic pre-operative calcium channel blocker (CCB) 
therapy on atrial myocyte action potential characteristics 
 
There were no significant differences in the maximal diastolic potential (MDP) nor 
of phase 0 of the action potential depolarization characteristics of those myocytes 
isolated from tissue excised from the right atrial appendage of patients chronically 
receiving calcium channel blocking drug therapy pre-operatively (CCBY) as 
compared to those patients who were not receiving calcium channel blocking drug 
therapy (CCBN) (Figure 4.8 A-D). 
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Figure 4.8 Lack of effect of chronic preoperative calcium channel blocking drug therapy on resting 
membrane potential and phase 0 action potential characteristics of human isolated atrial myocytes 
under control conditions.   = myocytes obtained from CCBN patients (n= 47 cells from 14 patients)  
 = myocytes obtained from CCBY patients (n= 25 cells from 5 patients). Values are mean± s.e.m. 
In contrast, atrial myocytes isolated from RAA preparations obtained from patients 
who were chronically receiving CCB therapy pre-operatively demonstrated 
significantly accelerated action potential repolarisation under control conditions. 
There were significant differences in early, mid and late action potential 
repolarisation in comparison to those atrial myocytes originating from patients who 
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were not chronically receiving CCB pre-operatively (Figure 4.9 A-D). Early 
repolarisation (APD50) observed from cells from CCBN patients was 25± 4 ms (n= 
47 cells from 14 patients, mean± s.e.m.) not significantly different than that 
observed in CCBY patients, 15.6± 3.2 ms (n= 25 cells from 5 patients, mean± 
s.e.m., Figure 4.9A).  
 
However a significant difference in early repolarisation was demonstrated at 60% 
repolarisation, mean (APD60) recorded from cells from CCBN patients was 89.3± 
7.5 ms (n= 47 cells from 14 patients, mean± s.e.m.) significantly different than that 
observed in CCBY patients, 65.2± 8.4 ms (n= 25 cells from 5 patients, mean± 
s.e.m., p= 0.049. Figure 4.9B). Action potential repolarisation at 75% (APD75) 
observed from cells from CCBN patients was 162.4± 10.3 ms (n= 47 cells from 14 
patients, mean± s.e.m.) significantly different in comparison to 116.9± 11.8 ms (n= 
25 cells from 5 patients, mean± s.e.m., p= 0.0078. Figure 4.9C) in cells from 
CCBY patients.  
 
Similarly this effect was maintained from early and mid- repolarisation to late 
repolarisation (APD90). Recordings from cells originating from patients who were 
not receiving CCB drugs pre-operatively APD90 was found to be 233± 12 ms (n= 
47 cells from 14 patients, mean± s.e.m.) significantly longer than the 188.2± 15.6 
ms (n= 25 cells from 5 patients, mean± s.e.m., p= 0.029. Figure 4.9D) observed 
from cells obtained from patients who were receiving CCB drugs pre-operatively. 
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Figure 4.9 Effect of chronic preoperative calcium channel blocking drug therapy on human atrial 
isolated myocyte action potential repolarisation under control conditions.   = myocytes obtained 
from CCBN patients (n= 47 cells from 14 patients)   = myocytes obtained from CCBY patients (n= 
25 cells from 5 patients). Values are mean± s.e.m., asterisk* indicates p< 0.05. 
 
There were no significant differences observed in single cell refractoriness in atrial 
myocytes isolated from tissue preparations obtained from patients chronically 
receiving CCB therapy pre-operatively (CCBY) as compared to those patients who 
were not (CCBN) (Figure 4.10 A and B). The mean ERP recorded from cells 
obtained from CCBN patients was 214.5± 10 ms (n= 47 cells from 14 patients, 
mean± s.e.m.) compared to 200.4± 14.9 ms (n= 25 cells from 5 patients, mean± 
s.e.m., Figure 4.10A) observed from cells obtained from CCBY patients. The 
relationship of repolarisation to refractoriness (ERP/APD90) was similar regardless 
of CCB status pre-operatively: recordings made from cells obtained from CCBN 
patients demonstrated an ERP/APD90 ratio of 0.97± 0.02 (n= 47 cells from 14 
patients, mean± s.e.m.) compared to 1.076± 0.08 (n= 25 cells from 5 patients, 
mean± s.e.m., Figure 4.10B) from recordings of cells obtained from CCBY 
patients. 
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Figure 4.10 Lack of effect of chronic preoperative calcium channel blocker therapy on human atrial 
isolated myocyte refractoriness under control conditions.   = myocytes obtained from CCBN 
patients (n= 47 cells from 14 patients)   = myocytes obtained from CCBY patients (n= 25 cells from 
5 patients). Values are mean± s.e.m. 
 
 
4.5.6.3 Impact of chronic pre-operative Angiotensin Converting 
Enzyme Inhibitor (ACE-I) therapy on atrial myocyte action 
potential characteristics 
There were no significant differences in the MDP, amplitude nor overshoot of the 
action potential upstroke, however a significantly greater Vmax of phase 0 of the 
action potential was observed in atrial myocytes isolated from RAA preparations 
obtained from patients chronically receiving ACE-I therapy (ACE-IY) compared to 
myocytes from those patients who were not (ACE-IN) (Figure 4.11 A-D). 
 
The mean MDP observed from myocytes obtained from ACE-IN patients was -83± 
1 mV (n= 24 cells from 6 patients, mean± s.e.m.) compared to -83.9± 0.8 mV (n= 
48 cells from 13 patients, mean± s.e.m., Figure 4.11A) from ACE-IY patients. The 
maximal rate of depolarization (Vmax) observed in cells from ACE-IN patients was 
187.6± 9.6 V/s (n= 24 cells from 6 patients, mean± s.e.m.) which was significantly 
different from that observed in cells from ACE-IY patients 214.7± 6.9 V/s (n= 48 
cells from 13 patients, mean± s.e.m., p= 0.025. Figure 4.11B). Neither the action 
potential overshoot nor overall phase 0 amplitude were associated with pre-
operative ACE-I therapy induced effects: the mean overshoot in cells from ACE-IN 
patients was 59.5± 2.7 mV (n= 24 cells from 6 patients, mean± s.e.m.) compared 
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to 60.9± 0.9 mV (n= 48 cells from 13 patients, mean± s.e.m., Figure 4.11C) in cells 
from ACE-IY patients. The total amplitude of the phase 0 response of the action 
potential recorded from cells obtained from ACE-IN patients was 142.9± 1.6 mV 
(n= 24 cells from 6 patients, mean± s.e.m.) and was 145.4± 1.0 mV (n= 48 cells 
from 13 patients, mean± s.e.m., Figure 4.11D) from cells obtained from ACE-IY 
patients. 
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Figure 4.11 Effect of chronic preoperative angiotensin converting enzyme inhibitor (ACE-I) therapy 
on resting membrane potential and phase 0 action potential characteristics of human atrial isolated 
myocytes under control conditions.   = myocytes obtained from ACE-IN patients (n= 24 cells from 
6 patients)   = myocytes obtained from ACE-IY patients (n= 48 cells from 13 patients). Values are 
mean± s.e.m., asterisk* indicates p< 0.05. 
 
 
There were no significant differences observed in action potential repolarisation 
nor refractoriness from single atrial myocytes isolated from tissue preparations 
obtained from patients chronically receiving ACE-I therapy pre-operatively (ACE-
IY) as compared to those patients who were not (ACE-IN). 
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4.5.7 Impact of patient comorbidity on human atrial isolated 
myocyte action potential characteristics 
4.5.7.1 Impact of pre-operative left ventricular systolic dysfunction 
(LVSD) on atrial myocyte action potential characteristics 
Atrial myocytes isolated from RAA tissue preparations obtained from patients with 
LVSD (LVSDY) were significantly more polarized in the quiescent state under 
control conditions as compared to recordings made from atrial myocytes obtained 
from patients diagnosed as free from LVSD (LVSDN) pre-operatively (Figure 
4.12A). There were, however, no significant differences detected in the observed 
amplitude nor the overshoot of the action potential upstroke, nor in Vmax of phase 0 
of the action potential (Figure 4.12 B-D). The mean MDP observed from myocytes 
obtained from LVSDN patients was -82.1± 0.7 mV (n= 35 cells from 10 patients, 
mean± s.e.m.) significantly different as compared to -84.8± 0.9 mV (n= 43 cells 
from 10 patients, mean± s.e.m., p= 0.025. Figure 4.12A) from LVSDY patients. 
The maximal rate of depolarization (Vmax) observed in cells from LVSDN patients 
was 208.5± 9.4 V/s (n= 35 cells from 10 patients, mean± s.e.m.) which was not 
significantly different from that observed in cells from LVSDY patients 209± 6.9 V/s 
(n= 43 cells from 10 patients, mean± s.e.m. Figure 4.12B). Neither the action 
potential overshoot nor overall phase 0 amplitude were associated with pre-
operative LVSD status: the mean overshoot in cells from LVSDN patients was 
60.2± 1.1 mV (n= 35 cells from 10 patients, mean± s.e.m.) compared to 61.4± 1.5 
mV (n= 43 cells from 10 patients, mean± s.e.m., Figure 4.12C) in cells from 
LVSDY patients. The total amplitude of the phase 0 response of the action 
potential recorded from cells obtained from LVSDN patients was 145± 1.1 mV (n= 
35 cells from 10 patients, mean± s.e.m.) and was 144± 1.5 mV (n= 43 cells from 
10 patients, mean± s.e.m., Figure 4.12D) from cells obtained from LVSDY 
patients. 
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Figure 4.12 Effect of pre-operative left ventricular systolic dysfunction (LVSD) on resting membrane 
potential and phase 0 action potential characteristics of human atrial isolated myocytes under control 
conditions.   = myocytes obtained from patients without LVSD (n= 35 cells from 10 patients)   = 
myocytes obtained from patients with LVSD (n= 43 cells from 10 patients). Values are mean± s.e.m., 
asterisk* indicates p< 0.05. 
 
 
There were no significant differences observed in action potential repolarisation 
nor refractoriness from single atrial myocytes isolated from tissue preparations 
obtained from patients suffering pre-operative LVSD as compared to those 
patients who were not (Figure 4.13 A-C and 4.14 A and B). 
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Figure 4.13 Lack of effect of pre-operative left ventricular systolic dysfunction (LVSD) on human 
atrial isolated myocyte action potential repolarisation under control conditions.   = myocytes 
obtained from patients without LVSD (n= 35 cells from 10 patients)   = myocytes obtained from 
patients with LVSD (n= 43 cells from 10 patients). Values are mean± s.e.m. 
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Figure 4.14 Lack of effect of pre-operative left ventricular systolic dysfunction (LVSD) on human 
atrial isolated myocyte refractoriness under control conditions.   = myocytes obtained from patients 
without LVSD (n= 35 cells from 10 patients)   = myocytes obtained from patients with LVSD (n= 43 
cells from 10 patients). Values are mean± s.e.m. 
 
4.5.7.2 Lack of effect of prior myocardial infarction (MI) on atrial 
myocyte action potential characteristics 
There were no significant differences in the characteristics of depolarisation, 
repolarisation nor refractoriness observed in recordings made from those 
myocytes isolated from tissue excised from the right atrial appendage of patients 
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who had suffered a myocardial infarction (MI) pre-operatively (MIY) as compared 
to those patients who had not suffered a prior MI (MIN).  
 
4.5.8 Effect of 0.05 µM isoproterenol alone on human atrial 
isolated myocyte action potentials and refractoriness 
 
4.5.8.1 Effect of 0.05 µM ISO on human atrial isolated myocyte action 
potential characteristics relating to depolarisation 
Isoproterenol, at 0.05 µM, had no significant effect on action potential upstroke, 
amplitude nor on phase one overshoot of the action potential but was associated 
with a small but statistically significant depolarisation of the myocyte during 
diastole as illustrated in Figure 4.15 and 4.16. 
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Figure 4.15 A representative example of the effect of acute superfusion with 0.05 µM Isoproterenol 
on a human atrial isolated myocyte action potential waveform. 
 
The mean MDP under control conditions was -83.6± 0.7 mV whereas following 
acute superfusion with 0.05 µM ISO the mean MDP was observed to be 
significantly different at -78.9± 1.3 mV (n= 22 cells from 12 patients, mean± s.e.m., 
paired data, p< 0.05, Figure 4.16A). The maximal rate of depolarization (Vmax), 
however, was not significantly different following acute superfusion with ISO at 
0.05 µM (control Vmax 194.1± 9.1 V/s vs 196.9± 11.3 V/s following 0.05 µM ISO, n= 
22 cells from 12 patients, mean± s.e.m., paired data, Figure 4.16B). The action 
potential overshoot was also similar regardless of the presence of 0.05 µM ISO in 
the superfusate (55.6± 1.5 mV vs 57.3± 1.6 mV (n= 22 cells from 12 patients, 
mean± s.e.m., paired data Figure 4.16C). Similarly the total amplitude of the phase 
1 response of the action potential did not significantly differ during acute 
superfusion with ISO at 0.05 µM: mean amplitude of phase 1 response recorded 
from cells under control conditions was 140.6± 1.6 mV compared to 136.6± 2.0 
mV during exposure to ISO (n= 22 cells from 12 patients, mean± s.e.m., Figure 
4.16D). 
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Figure 4.16 Effect of acute superfusion with 0.05 µM Isoproterenol on resting membrane potential 
and phase 1 action potential characteristics of human atrial isolated myocytes.   = control   = 
0.05 µM Isoproterenol (ISO) (n= 22 cells from 12 patients, paired data). Values are mean± s.e.m., 
asterisk (*) p< 0.05. 
 
 
4.5.8.2 Effect of ISO on human atrial isolated myocyte action potential 
repolarisation 
Isoproterenol, at 0.05 µM, significantly prolonged the early and mid repolarisation 
of human atrial myocyte action potentials resulting in elevation of the action 
potential plateau, but had no such effect on later repolarisation or effective 
refractory period (Figures 4.17 and 4.19). The APD50 significantly increased from 
28± 5 ms under control conditions to 54± 10 ms following the application of ISO, 
an increase of 93% (n= 22 cells from 12 patients, p< 0.05 Figure 4.17). Neither the 
APD75 (control 154± 13 ms vs 163± 21 ms post ISO, n= 22 cells from 12 patients 
Figure 4.17) nor the APD90 (control 220± 14 ms vs 204± 16 ms post ISO, n= 22 
cells from 12 patients Figure 4.17) was significantly affected.  
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Figure 4.17 Effect of acute superfusion with 0.05 µM Isoproterenol on action potential repolarisation 
characteristics of human atrial isolated myocytes.   = control   = 0.05 µM Isoproterenol (ISO) (n= 
22 cells from 12 patients, paired data). Values are mean± s.e.m., asterisk (*) p< 0.05. 
 
 
4.5.8.3 Effect of ISO on human atrial isolated myocyte refractoriness 
An example of the effect of acute superfusion with 0.05µM ISO on human isolated 
atrial myocyte refractoriness can be seen in Figure 4.20 and mean data in Figure 
4.19. Although 0.05µM ISO did not have a significant effect on the ERP directly 
(control ERP 208.9± 16.7 ms vs ISO ERP 227.9± 28.8 ms, n= 19 cells from 10 
patients Figure 4.19), the combination of this non significant increase in ERP and 
the non significant decrease in the APD90 (see section 4.5.8.2) resulted in a small 
but statistically significant increase in the ERP/ APD90 ratio (control ERP/APD90 
0.976± 0.02 vs ISO ERP/APD90 1.04± 0.03 ms, n= 19 cells from 10 patients, p< 
0.05 Figure 4.19). 
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Figure 4.18 Representative example of the effect of acute superfusion with 0.05 µM Isoproterenol on 
human atrial isolated myocyte action potential waveforms, A) under control conditions and B) during 
acute superfusion with ISO. 
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Figure 4.19 Effect of acute superfusion with 0.05 µM Isoproterenol on human atrial isolated myocyte 
refractoriness.   = control   = 0.05 µM Isoproterenol (ISO) (n= 19 cells from 10 patients, paired 
data). Values are mean± s.e.m., asterisk (*) p< 0.05. 
 
 
4.5.8.4 Effect of ISO to induce spontaneous depolarisations 
During the repetitive stimulation protocol designed to evaluate the effective 
refractory period following superfusion with ISO, but not under control conditions, 
low amplitude sub-threshold spontaneous depolarisations would frequently 
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interrupt the stimulation train. These ‘spontaneous depolarisations’ (SD) most 
frequently occurred during phase 3 and 4 of the action potential and only 
occasionally reached threshold (see Figure 4.20). The occurrence of SDs was 
significantly associated with exposure to ISO and was not observed under control 
conditions (control SD 0% vs ISO SD 64%, n= 11 cells, 3 patients, χ2 test, p< 
0.05). 
 
4.5.9 Effect of 10 nM endothelin-1 alone on human atrial 
isolated myocyte action potentials and refractoriness 
4.5.9.1 Effect of ET-1 alone on human atrial myocyte action potential 
characteristics related to depolarisation 
 
Acute superfusion of human atrial myocytes with 10 nM Endothelin-1 had no 
apparent effect on the MDP, amplitude nor on phase one overshoot of the action 
potential but was associated with a significant reduction in action potential 
upstroke velocity (Figure 4.21). Under control conditions the MDP was -84.8± 1.5 
mV and following acute superfusion with 10 nM ET-1 was observed to be -83.6± 2 
mV (n= 21 cells from 5 patients, mean± s.e.m., paired data, Figure 4.21A). The 
maximal rate of depolarization (Vmax), however, was significantly reduced following 
exposure to 10 nM ET-1 (control Vmax 211± 12.3 V/s vs 165± 11.9 V/s following 10 
nM ET-1, n= 21 cells from 5 patients, mean± s.e.m., paired data, Figure 4.21B). 
The action potential overshoot was similar regardless of the presence of ET-1 in 
the superfusate (61.9± 1.7 mV vs 55.9± 2.9 mV (n= 21 cells from 5 patients, 
mean± s.e.m., paired data, Figure 4.21C). The total amplitude of the phase 1 
response of the action potential did not significantly differ during acute superfusion 
with 10 nM ET-1: mean amplitude of phase 1 response recorded from cells under 
control conditions was 146.9± 1.6 mV compared to 139± 4.3 mV during exposure 
to ET-1 (n= 21 cells from 5 patients, mean± s.e.m., paired data, Figure 4.21D). 
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 Control 
 
Figure 4.20 A representative example of the effect of acute superfusion with 0.05 µM Isoproterenol 
on a human atrial isolated myocyte action potentials stimulated during a repetitive stimulation 
protocol demonstrating phase 3 spontaneous depolarisations (*). 
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Figure 4.21 Effect of acute superfusion with 10 nM ET-1 on resting membrane potential and phase 1 
action potential characteristics of human atrial isolated myocytes.   = control   = 10 nM ET-1 (n= 
21 cells from 5 patients, paired data). Values are mean± s.e.m., asterisk (*) p< 0.05. 
* * * * * 
* 
* 
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Calum Jon Redpath  Chapter 4-154 
4.5.9.2 Effect of ET-1 alone on action potential repolarisation 
 
The acute superfusion of human atrial myocytes with 10 nM ET-1 had no 
discernible effect on action potential repolarisation (Figures 4.22 and 4.24). The 
APD50 was similar under control conditions compared to during superfusion with 
ET-1 (12.8± 1.9 ms vs 13.8± 1.8 n= 21 cells from 5 patients, Figures 4.22 and 
4.24). Neither the APD75 (control 132.4± 13.1 ms vs 141.8± 13.2 ms post ET-1, n= 
21 cells from 5 patients, Figure 4.22) nor the APD90 (control 210.1± 17.1 ms vs 
226.2± 19.7 ms post ET-1, n= 21 cells from 5 patients) was significantly different 
during exposure to 10 nM ET-1 (Figure 4.22).  
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Figure 4.22 Effect of acute superfusion with 10 nM ET-1 on action potential repolarisation 
characteristics of human atrial isolated myocytes.   = control   = 10 nM ET-1 (n= 21 cells from 5 
patients, paired data). Values are mean± s.e.m. 
 
4.5.9.3 Effect of ET-1 alone on effective refractory period 
 
An example of the effect of acute superfusion with 10 nM ET-1 on human 
refractoriness can be seen in Figure 4.23 and mean data in Figures 4.23 & 4.24. 
Superfusion of myocytes with 10 nM ET-1 did not have a significant effect on the 
ERP (control ERP 190.6± 14.9 ms vs ET-1 ERP 207.5± 15.5 ms, n= 16 cells from 
5 patients Figures 4.23 and 4.24), nor the ERP/ APD90 ratio (control ERP/APD90 
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0.903± 0.03 vs ET-1 ERP/APD90 0.957± 0.04 ms, n= 16 cells from 5 patients, 
Figure 4.23). 
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Figure 4.23 Effect of acute superfusion with 10 nM ET-1 on human atrial isolated myocyte 
refractoriness.   = control   = 10 nM ET-1 (n= 16 cells from 5 patients, paired data). Values are 
mean± s.e.m. 
 
4.5.9.4 Effect of ET-1 alone on spontaneous depolarisations 
 
Acute superfusion with 10 nM ET-1 alone was not significantly associated with SD 
occurrence (control SD 0% vs ET-1 SD 15%, n= 13 cells, 5 patients, χ2 test, p= 
ns). 
 
4.5.10 Effect of 0.05 µM ISO alone and in combination (co-
application) with 10 nM ET-1 on human isolated atrial 
myocyte action potentials and refractoriness 
4.5.10.1 Effect of ET-1 on adrenergically prestimulated action 
potential characteristics relating to depolarisation 
 
Acute superfusion of human atrial myocytes with 0.05 µM Isoproterenol followed 
by the addition of 10 nM Endothelin-1 to the superfusate (co-application) after 5 
minutes had no apparent effect on the MDP, action potential upstroke velocity, 
amplitude nor on phase one overshoot of the action potential (Figure 4.25). Under 
control conditions the MDP was -83.3± 0.8 mV, following acute superfusion with 
0.05 µM ISO the MDP was -79.8± 1.1 mV and was -79.5± 1.3 mV following the 
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Figure 4.24 Lack of effect of ET-1 on basal action potential repolarisation and ERP. A, Action 
potential waveform and mean APD50, and B, Restitution and mean ERP, in absence of a drug (
 
) 
and following 10 nM ET-1 (
 
). Upper panels: superimposed responses to (A) 7th conditioning pulse 
and (B) in a different cell, to the 7th and 8th conditioning pulses followed by premature test pulses. 
Horizontal bars=ERP. Lower panels: paired means of APD50 (21 cells, 5 patients) and ERP (16 cells, 
5 patients). Values mean ± s.e.m. Figure taken from Redpath et al, JMCC 2006; 40: 717-724. 
 
 
addition of 10 nM ET-1 to the superfusate (n= 15 cells from 10 patients, mean± 
s.e.m., paired data, Figure 4.25A). The maximal rate of depolarization (Vmax) did 
not significantly change following superfusion with ISO, nor with ISO and ET-1 in 
combination (control Vmax 191.4± 11.3 V/s, ISO Vmax 203.4± 9.6 V/s and ISO/ET-1 
Vmax 182.9± 15.6 V/s, n= 15 cells from 10 patients, mean± s.e.m., paired data, 
Figure 4.25B). The action potential overshoot was similar regardless of the 
presence of ISO or subsequently simultaneous ISO and ET-1 in the superfusate 
(control overshoot 56.9± 1.8 mV vs ISO 59.1± 1.5 mV vs ISO/ET-1 59.5± 2.5 mV, 
n= 15 cells from 10 patients, mean± s.e.m., paired data, Figure 4.25C). The total 
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amplitude of the phase 1 response of the action potential did not significantly differ 
following superfusion with 0.05 µM ISO alone or in combination with 10 nM ET-1: 
mean amplitude of phase 1 response recorded from cells under control conditions 
was 140.5± 1.9 mV compared to 139.1± 1.1 mV during exposure to 0.05 µM ISO 
alone and was 138.9± 2.3 mV during superfusion with ISO and ET-1 (n= 15 cells 
from 10 patients, mean± s.e.m., paired data, Figure 4.25D). 
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Figure 4.25 Effect of acute superfusion with 0.05 µM ISO alone and then 0.05 µM ISO in 
combination with 10 nM ET-1 on resting membrane potential and phase 1 action potential 
characteristics of human atrial isolated myocytes.   = control   = 0.05 µM ISO      = 0.05 µM ISO 
and 10 nM ET-1 co-application (n= 15 cells from 10 patients, paired data). Values are mean± s.e.m. 
 
 
4.5.10.2 Effect of ET-1 on adrenergically prestimulated action potential 
repolarisation (APD) 
As described in sections 4.5.8.2 and 4.5.8.3, 0.05 µM Isoproterenol significantly 
prolonged the early and mid repolarisation of human atrial myocyte action 
potentials resulting in elevation of the action potential plateau, but had no such 
effect on later repolarisation or effective refractory period, the “adrenergic effect” 
on action potentials (Figures 4.17 to 4.19). In cells in which the adrenergic effect of 
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ISO alone was recorded prior to addition of 10 nM ET-1 to the superfusate the 
APD50 significantly increased from 30± 6.3 ms under control conditions to 45.7± 
6.9 ms following the application of ISO, an increase of 52% (n= 15 cells from 10 
patients, paired data, p< 0.05, Figure 4.26) was then significantly reversed to 
19.8± 3.3 ms during superfusion of myocytes with 0.05 µM ISO and 10 nM ET-1 in 
combination (n= 15 cells from 10 patients, paired data, p< 0.05, Figure 4.26).  
 
Neither the APD75 (control 144.9± 16 ms vs 137.3± 14.9 ms post ISO vs 111± 13 
ms post ISO and ET-1, n= 15 cells from 10 patients) nor the APD90 (control 210.3± 
17.3 ms vs 187.9± 16.1 ms post ISO vs 173.5± 13.2 ms post ISO and ET-1, n= 15 
cells from 10 patients) was significantly affected either by ISO alone nor ISO in 
combination with ET-1 (Figure 4.26). 
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Figure 4.26 Effect of acute superfusion with 0.05 µM ISO alone and then 0.05 µM ISO in 
combination with 10 nM ET-1 on action potential repolarisation of human atrial isolated myocytes.   
= control   = 0.05 µM ISO      = 0.05 µM ISO and 10 nM ET-1 co-application (n= 15 cells from 10 
patients, paired data). Values are mean± s.e.m., asterisk (*) and hash (#) indicate p< 0.05. 
Figure taken from Redpath et al, JMCC 2006; 40: 717-724. 
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4.5.10.3 Effect of ET-1 on adrenergically prestimulated action potential 
effective refractory period 
An example of the effects of acute superfusion with 0.05 µM ISO alone and 
subsequent co-application of 0.05 µM ISO with 10 nM ET-1 on human 
refractoriness can be seen in Figure 4.27 and mean data in Figures 4.28 & 4.29. 
Superfusion of myocytes with ISO alone and in combination with 10 nM ET-1 did 
not have a significant effect on cellular ERP (control ERP 204± 19 ms vs ISO ERP 
198.7± 15.9 vs ISO/ET-1 ERP 180± 15 ms, n= 15 cells from 10 patients Figures 
4.27 and 4.28), nor the ERP/ APD90 ratio (control ERP/APD90 0.962± 0.03 vs ISO 
ERP 1.078± 0.04 vs ISO/ET-1 ERP/APD90 1.04± 0.04 ms, n= 15 cells from 10 
patients, Figure 4.27). 
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Figure 4.27 Effect of acute superfusion with 0.05 µM ISO alone and then 0.05 µM ISO in 
combination with 10 nM ET-1 on human atrial isolated myocyte refractoriness.   = control   = 
0.05 µM ISO      = 0.05 µM ISO and 10 nM ET-1 co-application (n= 15 cells from 10 patients, paired 
data). Values are mean± s.e.m. 
 
4.5.10.4 Effect of ET-1 on adrenergically prestimulated spontaneous 
depolarisations 
During repetitive stimulation protocol testing to evaluate the effective refractory 
period following superfusion with ISO, but not under control conditions, low 
amplitude sub-threshold phase 3 and 4 spontaneous depolarisations frequently 
occurred, as described in section 4.5.8.4 (Figures 4.20 and 4.29). These SDs did  
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Figure 4.28 Anti-adrenergic effect of ET-1 on action potential early repolarisation, but not refractory 
period. A, Action potential waveform and duration at 50% repolarisation (APD50) and B, Restitution 
and effective refractory period (ERP) in atrial cells, in absence of a drug (
 
), following 0.05 µM ISO 
(
 
) and subsequent co-application of 10 nM ET-1 (
 
). Upper panels: original, superimposed action 
potentials, each from the same cell, produced by (A) the 7th of a train of conditioning current pulses 
(75 beats/min) and (B) 7th and 8th conditioning pulses followed by progressively premature test 
pulses. Horizontal bars= cell ERP. Lower panels: histogram data; paired means (n=15 cells, 10 
patients). Values are mean± s.e.m. Figure taken from Redpath et al, JMCC 2006; 40: 717-724. 
 
 
not occur under control conditions, were significantly associated with exposure to 
ISO and following the co-application of 10 nM ET-1 with 0.05µM ISO were 
significantly abolished (control SD 0% vs ISO SD 100% vs ISO/ET-1 SD 0%, n= 5 
cells, 3 patients, χ2 test, p< 0.05 Figures 4.20 & 4.29). 
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Figure 4.29 Spontaneous depolarisation-induction by isoproterenol, and anti-adrenergic effect of ET-
1. A, Original action potentials (APs) evoked by trains of current pulses (75 beats/min) in the 
absence of a drug (
 
), with 0.05 µM ISO (
 
) and subsequent 10 nM ET-1 (
 
) in (i) a cell with a 
normal AP plateau, and (ii) a cell with relatively large plateau. Arrows indicate “spontaneous 
depolarisations” (SDs): any AP phase 3 transient depolarisation or phase 4 depolarisation >3 mV. 
Dots indicate driven beats. iii, typical absence of response to ET-1 without ISO. All initial APs are 
post-rest. B, Histograms showing significant production of SDs by ISO (i), abolition of SDs by ET-1 
(ii), and lack of significant (NS) SD-induction by ET-1 alone (iii). Numbers within columns=n cells 
displaying SDs/total studied. Figure taken from Redpath et al, JMCC 2006; 40: 717-724. 
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4.6 Discussion 
4.6.1 Methodological considerations and action potential 
morphology 
Action potential characteristics as displayed were in accordance with those 
published previously. There have previously been a number of descriptions of 
differing human atrial myocyte action potential morphologies381. More recently a 
consensus is emerging of three types of action potential morphologies 
demonstrated in human atrial RAA specimens has been reached381;419-426.  
 
Type 1 or typical adult human atrial myocyte action potentials demonstrate a spike 
and dome morphology and have been previously reported to have a maximal 
diastolic potential (MDP) of -71 to -86 mV broadly in line with characteristics 
mathematically modeled from ion current data421;427.  
 
A second type of action potential morphology was described as having a spike but 
no dome, reported to be due to the continued presence of ITO but reduced IKr, 
related to the enzymatic isolation method419;420;422-425. At physiological stimulation 
rates of 60 bpm there were no significant electrophysiological difference in 
electrophysiological characteristics between these two action potential 
morphologies425. Mathematical modelling of the human atrial myocyte action 
potential provides support for this assertion and determines that at physiological 
heart rate and temperature the action potential morphology is primarily effected by 
ICaL, ITO and IKsus
421;427.  
 
A third, infrequent action potential of triangular morphology (absent spike and 
dome), previously associated with infants with congenital heart disease420 and 
described in ventricular myocytes from hearts removed at cardiac transplantation, 
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was not identified in this study425. It was expected that had cells displaying this 
action potential morphology been encountered they would likely be excluded as at 
stimulation rates greater then 60 bpm, these myocytes have previously been found 
to become unresponsive due to the prolonged APD at rest exceeding the PCL425. 
 
Initial depolarisation, or phase 0 characteristics, of atrial myocyte action potentials 
have varied among investigators: Vmax of 149 V/s to 244 V/s, an upstroke 
amplitude >90 mV and an overshoot of 48 to 53 mV have been 
reported79;144;284;419;420;422-425;428-435. Mean data for phase 0 characteristics in this 
study are within this published range (See Table 1). 
 
Repolarisation and refractoriness characteristics of human atrial isolated myocytes 
are particularly susceptible to methodological variation; the APD and ERP 
physiologically adapt to changes in the cycle length of stimulation and a reduction 
in environmental temperature accelerates human atrial myocyte repolarisation at 
identical PCL72;79;161;419;436.  At physiological stimulation rates of 60-75 bpm the 
range of repolarisation was found to be APD50 of 12 to 62 ms, an APD75 of 118 to 
138 ms, an APD90 between 341 and 447 ms and refractoriness (ERP) of 184-244 
ms79;144;284;419;420;422-425;428-435. Our data, obtained with a stimulation rate of 75 bpm 
with the myocytes maintained at physiological temperature, was within this 
published range (See Table 1). 
 
The two differing morphologies of action potential, although similar, could 
potentially be explained by heterogeneity in IKr and ITO as a result of enzymatic 
isolation or between cells from differing regions of the heart437, albeit that in the 
present study all cells were isolated using identical methodology and all tissue 
samples were obtained from the RAA of consenting patients undergoing corrective 
cardiac surgery. No direct measurements of IKr and ITO were made in this study 
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and further work will be required to resolve this issue. Alternative explanations 
such as varying disease states and pharmacological therapy will be discussed 
below. 
 
4.6.2 Patients’ characteristics and action potential characteristics 
This study was not prospectively powered to determine potential associations 
between patients’ clinical characteristics and human atrial isolated myocyte 
electrophysiology. The data emanating from this study were pooled with data from 
colleagues in our laboratory and forms the results section of our recently published 
manuscript300. What has been presented herein represents univariate analysis of 
the data solely from this project which was performed in order to inform 
multivariate analysis of our laboratories collective efforts. This, limited, data has 
been discussed in order to generate hypotheses which were later tested as part of 
the collective effort300. 
 
Patient senescence had no significant effect on human atrial action potential 
characteristics in line with previously published reports from this laboratory79;144;284. 
This is supported by data from experiments examining INa activation suggesting 
little if any data supports an alteration in INa as a function of age bar small shift in 
the half inactivation potential towards less negative potentials381;438-440.  
 
Male gender was associated with an increased phase 0 amplitude, however there 
exists no precedent for this in the literature. Gender has not been identified in 
previous work on human atrial action potentials, and in pooled data from this 
laboratory the association of male gender and an increased phase 0 amplitude 
has not been replicated, suggesting that this may be a type 2 error79;144;284. 
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The effects of chronic therapy with β-B on ICaL and action potential repolarisation 
and refractoriness have recently been described in humans144;284. The 
prolongation of APD90 and ERP in the absence of an effect on ICaL was identified 
on univariate analysis, persisted on multivariate analysis and was found to be 
independent of heart rate144. However, in this smaller patient dataset, although the 
recorded measurements of repolarisation and refractoriness in this study are 
consistent with that published by our laboratory, no statistical difference myocyte 
repolarisation or refractoriness was observed. Thus apparent inconsistency may 
be explained by the lack of a significant decrease in heart rate related to β-B use 
(heart rate BBY 58.8± 2.8 v. BBN HR 64.7± 2.8 bpm p= ns, Np= 13 BBY and Np= 7 
BBN). The lack of a significant heart rate response may be a corollary for 
underdosing, medication error or non compliance with chronic β-B therapy pre-
operatively rather than any absence of effect of β-B on ITO, APD90 or ERP
144. 
Another explanation is that this inability to reject the null hypothesis represents a 
type 1 error as pooled data from our laboratory including data from this study, with 
a significantly larger dataset has maintained the association between β-B therapy 
and an approximate 20% reduction in APD90 and ERP
300. 
 
Pre-operative CCB drug therapy was associated with more rapid early (APD60), 
mid (APD75) and late (APD90) repolarisation but no effect on ERP in the absence 
of a direct effect on ICaL. The apparent effect of chronic CCB therapy on mid and 
late repolarisation, combined with a possible effect on APD50 which approached 
statistical significance (p= 0.051) prompted the measurement of APD60. Both 
Diltiazem and Verapamil have previously been associated with acutely reducing 
the AP plateau as recorded by APD50
430;441. Chronic pre-operative therapy with 
CCB has also been associated with reduced ICaL and accelerated repolarisation
282. 
However, in contrast, a larger study in this laboratory confirmed a lack of effect of 
chronic CCB therapy on ICaL
144. In addition no significant effect on APD or ERP 
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was observed144. Patients in both studies form this laboratory were predominantly 
receiving dihydropyridine (Amlodipine or Nifedipine) CCBs pre-operatively at 
similar dosages. After merging the datasets the apparent effect of CCB therapy on 
action potential repolarisation ceased to be statistically significant on univariate 
analysis.  
 
ACE-I therapy was associated with a small increase in action potential upstroke 
velocity (Vmax) during phase 0 depolarisation but no other significant effects on 
action potential characteristics. Data from multicellular recordings in animal 
models suggestive of a role for AII antagonism reducing cellular and structural 
remodelling such as atrial fibrosis may suggest a link, however there is no data 
from single cellular recordings to suggest a direct effect of ACE-I therapy on 
INa
118;442-446. However INa was not measured in this study and thus would require 
further work to determine the presence of any direct effect on INa and the 
reproducibility of any effect on Vmax in human atrial myocytes. 
 
Initial reports describing human atrial action potentials correlated diseased, dilated 
atria with a depolarized MDP, however no specific associations between atrial AP 
characteristics and disease processes have been identified115;430;432;433;447;448. Data 
on atrial dimensions were not available for this study, however an analysis of the 
effect of LVSD was made and a small but significant hyperpolarisation of the MDP 
was observed. This had no apparent effect on phase 0 depolarisation 
characteristics and this has not previously been reported. No effect was identified 
for LVSD nor prior MI on any other action potential characteristic in this study. 
 
The possible effects of LVSD on human atrial myocyte repolarisation and 
refractoriness are controversial with previous reports describing no change in 
early449;450 or late451 repolarisation, accelerated early and late repolarisation451 and 
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prolongation of APD90
449;450. The present study failed to identify any significant 
association with altered repolarisation or ERP but in order to resolve the 
controversy, pooled data from our lab, subject to multivariate analysis and 
incorporating data relating to patients with objective assessments of LVSD 
identified that LVSD is associated with abbreviated APD90 and ERP by 
approximately 10-20%.  
 
Similarly controversial to the possible impact of LVSD on atrial ICaL and atrial 
action potential characteristics is the possible interplay of effects of ISO and ET-1 
on ICaL and action potentials in the presence and absence of LVSD. The next 
Results chapter will build on the data presented in this chapter on action potentials 
under control conditions by investigating the effects of acute superfusion of ISO 
and ET-1, alone and in combination, on human atrial action potentials. 
 
4.6.3 Effect(s) of ISO on action potentials 
The first experimental recordings of human atrial action potentials almost 50 years 
ago were able to demonstrate that adrenergic stimulation with epinephrine or 
isoproterenol increased the action potential plateau and caused 
afterdepolarisations without alteration of phase 0 characteristics419;428;429;452 as 
observed in this study. The presence or absence of β-B therapy was not 
associated with alteration in action potential characteristics, also consistent with 
our findings (See Chapter 3 Results section). Due to the small sample of 
recordings further sub-analysis of the association with prior β-B therapy 
modulating either the ability of ISO to elevate the action potential plateau or to 
induce SDs is not possible. The lack of effect on later repolarisation and cellular 
ERP, in combination with the known effect of ISO to augment ITO and IKur suggests 
that in addition to increasing APD50 there must also be ‘compensation’ of late 
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repolarisation in order to fully repolarise ‘on time’ and to preserve ERP164;165;424;453. 
It also suggests that SDs are related to elevated ICaL rather than some hithertofore 
unappreciated effect on K repolarising currents as the SDs occur in cells in which 
there has not been lengthening of ERP. This suggests that, at least insofar as 
human atrial isolated myocytes in vitro can be described to undergo 
arrhythmogenesis, triggered activity, traditionally associated with arrhythmia 
initiation, is a potential arrhythmogenic effect of adrenergic stimulation. 
 
4.6.4 Effect(s) of ET-1 on action potentials 
ET-1 has been noted to enhance INa in animal studies and a small number of 
human atrial myocytes associated with a hyperpolarized resting membrane 
potential and an increased amplitude and upstroke velocity of phase 0 of the 
human atrial action potential176;200;261. In contrast a small but significant reduction 
in Vmax in the absence of an effect on MDP was detected in this the largest study 
to date of the direct effect of ET-1 on human atrial myocyte action potentials at 
physiological temperature with preserved cellular integrity. As no recordings of INa 
were made in this study we can only speculate as to a potential reduction in INa 
associated with acute superfusion with 10 nM ET-1. Methodological differences 
such as a 10 mV less depolarized holding potential in this study as compared to 
prior studies of INa may, in part, explain the difference in results. Further direct 
measurements of the effect of ET-1 on INa would be required to resolve this 
question. 
 
Initial reports described stimulatory196;248;258;259, inhibitory195;196;248;260-263 or no 
effect203;247;249;264 of ET-1 on ICaL, with an EC50 between 1 and 10 nM, mediated via 
ET-A receptors in animal models
195;196;203;248;249;258-264. In human atrial myocytes, 
ET-1 alone was found to increase199, decrease199;200 or have no effect199;200 on ICaL 
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under control conditions. The action potential data in this study confirms the earlier 
finding (See Results Chapter 3) that under conditions of physiological temperature 
with a ruptured patch preserving human atrial myocyte integrity 10 nM ET-1 alone 
has no effect on ICaL. In human right atrium ET-1 was demonstrated to have little or 
no effect on cAMP under basal conditions, but significantly inhibited adenylate 
cyclase due to ET-A receptor/ Gαi/ IP3 formation independent of ICaL and PKC 
following adrenergic stimulation187;200. Indeed the anti-adrenergic effect of ET-1 is 
abolished during simultaneous intracellular application of 8-Br-cAMP200. 
 
4.6.5 Effect(s) of ISO and ET-1 in combination on action potentials 
In accordance with the data presented herein, adrenergically prestimulated ICaL 
has been consistently found to be inhibited by 10 nM ET-1 via ET-A receptors 
acting on Gαi (pertussis sensitive) GPCRs
245;247;262 reducing cAMP in human atrial 
myocytes in the absence of any direct effect on the L-type calcium channel 
itself198-200. 
 
In addition to an anti-adrenergic effect of on ICaL, ET-1 has been reported to 
activate NHE179;241;265;393 and NCX241;266;268;393 via PKC and inhibit ICl via reducing 
intracellular cAMP205;273. This would be expected to indirectly affect ICaL because of 
increasing intracellular calcium levels which may explain the positive inotropic 
effect of ET-1174;197;265;271;382-384;454;455 in the absence of a simultaneous increase in 
ICaL
179;197;382-384. However an increased intracellular calcium 
transient192;197;264;267;392;456;457 despite the sensitisation of myofibrils to calcium265;384 
has previously been associated with the generation of SDs319;391;392;457;458. The 
data presented do not support this, however again in the absence of direct 
measurements of the ion currents this possibility cannot be discounted. 
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Endothelin has also been reported to have direct effects on in human atrial 
myocyte repolarising potassium channels371 which also contribute to determining 
the amplitude and duration of the action potential459. ET-1 induced marked 
inhibition of IK1 via PKC in human atrial myocytes at physiological temperature 
using whole cell patch clamp371. A reduction in an inward rectifying current 
necessary for maintaining the resting membrane potential of atrial myocytes may 
induce early or delayed afterdepolarisations and abnormal automaticity270;272. In 
animal studies ET-1 modulation of K+ outward currents is conflicting62;269-272. In 
various models ET-1 was observed to increase the delayed rectifier IK
264;456, and 
IKss
271;454 however also to inhibit IK
62;271, IKss
271;454, ITO
417, IKACh
269;460 and IKATP via 
ET-A receptors. Data on the resulting effects on action potential repolarisation are 
also mixed with no change454, an increase383 and a decrease61 in APD reported. 
The present study does not support, but cannot exclude, a direct effect of ET-1 on 
K+ currents in human atrial myocytes. The lack of change in action potential 
repolarisation with superfusion of ET-1 alone, the lack of spontaneous 
depolarisations following exposure of myocytes to ET-1 and the ‘symmetrical’ anti-
adrenergic effect of ET-1 co-application following exposure to ISO all would 
suggest an ET-1 effect predominantly limited to ICaL. 
 
In summary, in contrast to ISO, 10 nM ET-1 did not appear to be associated with 
any arrhythmogenic effect on human atrial isolated myocytes in vitro. Indeed ET-1 
could be viewed as being anti-arrhythmic as the pro-arrhythmic effect(s) of ISO 
were abolished by the addition of 10 nM to the ISO containing superfusate. It is 
appealing, but premature, to ascribe all the anti-arrhythmic effects of ET-1 as a 
direct translation of the anti-adrenergic effect on ICaL through to early repolarisation 
and SDs. 
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5 GENERAL DISCUSSION 
5.1 Main Conclusions 
The data presented herein confirm that under these experimental conditions ET-1 
modulates the effects of ISO on ICaL and action potentials via ET-A receptors in 
human atrial isolated myocytes. There was no apparent effect of ET-1 alone on 
either ICaL or action potential repolarisation or refractoriness and the anti-
adrenergic effects of ET-1 were not modified by chronic pre-operative β-B therapy. 
Whether the anti-adrenergic effects of ET-1 are anti-arrhythmic in humans is yet to 
be determined. 
The anti-adrenergic effect of ET-1 on ICaL was observed at concentrations of ET-1 
which have been reported in the venous blood of patients suffering from severe 
CHF. This ET-1 effect was prevented by the ET-A receptor anatagonist, FRA, and 
was partially reversible both by washout and subsequent superfusion with FRA. 
ET-1 alone was associated with a reduction in Vmax but not repolarisation or 
refractoriness. ET-1 did however reverse the adrenergically induced increase in 
APD50 and spontaneous depolarisations. 
The possible physiological mechanisms of these effects, such as secondary 
messenger systems and interactions with other atrial ion channels, and their 
potential implications for arrhythmogenesis in human atria will be discussed. 
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5.2 Possible physiological mechanisms of the effects of 
ET-1 in human atrial myocytes 
ET-1, binding to ET-A receptors expressed on cardiac myocytes has a number of 
biological effects mediated via stimulation of Gαi
396-398: ET-1 was found to directly 
inhibit or reduce cAMP187;246;261;399 and increase InsP3187;384;391;392;455;458 with direct 
experimental evidence for anti-muscarinic269 and anti-adrenergic 
effects187;246;249;261;262 in a number of animal models. 
 
In human atrial myocytes evidence exists for a basal constitutive cAMP/ ICaL 
activity281;287;288;395. Upon binding to β-AR, ISO rapidly induces a threefold rise in 
cAMP activity which, via PKA-induced phosphorylation of ICaL results in a 
sustained elevation of long lasting inward calcium current90;238;239;302-307. ET-1, with 
an EC50 of 1-10 nM, binds to the ET-A receptor on human atrial myocytes rapidly 
stimulating Gαq activating PLC which hydrolyses phosphatidylinositol present in 
the plasmalemma. The resultant 1,4,5-inositol triphosphate (InsP3) enters the 
cytosol and diacyl-glycerol (DAG) remains in the plane of the 
membrane327;457;458;461;462. In human right atrial specimens, ET-1 was not found to 
have any effect on cAMP levels under basal conditions but could reversibly inhibit 
an adrenergically-activated adenylate cyclase/ cAMP cascade187;200 the effects of 
which were not limited to ICaL
199;200. In addition, within seconds, PKC (δ and ε)313 is 
activated462;463 and translocates close to the membrane to activate small Ras G 
proteins and extracellular signal related kinase (ERK) within 3 minutes464. InsP3 
also stimulates SR calcium release resulting in a rapid increase in [Ca2+]i, 
independent of external calcium, followed by a sustained increase in [Ca2+]i 
facilitated by increased SR calcium uptake457;458;465-467. 
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ET-1 binding to ET-A also activates phospholipases A and D, altering arachidonic 
acid metabolism and providing sufficient supply of DAG for sustained PKC 
activation468;469. PKC then selectively phosphorylates the α1c subunit of ICaL 
resulting in decreased calcium entry90. Recently, the possibility that ET-1 induced 
upregulation of PKC may play a role in the augmentation of constitutive IKACh, 
increased in AF and a cause of APD abbreviation, and IKATP has been raised
470-473. 
 
Alternative second messenger systems may be activated by ET-1 directly. 
Evidence is accumulating that, in addition to an inhibitory action on cAMP via 
Gi/o
396-398, the anti-adrenergic effect of ET-1 is via stimulation of a phosphatase 
which opposes the PKA-phosphorylation of calcium handling regulatory 
proteins242;245 independent of PKC activation242;248. Human atrial ICaL has been 
shown be modulated via the cGMP cascade, albeit that the overall effect varies 
with the relative balance of the three cGMP effector proteins281;287;288;380;395. 
Modest activation of cGMP increases cAMP via inhibiting PDE3 resulting in a 
positive inotropic effect and an increase in ICaL, however strong activation of cGMP 
produces both an activation of PDE2, opposing PDE3, and activation of PKG 
resulting in an overall inhibitory effect on ICaL
287. 
 
A further level of complexity in understanding the effects of ET-1 is due, in part, to 
the crosstalk present between the angiotensin, adrenergic and endothelin 
receptors’ secondary messenger systems243;248;474;475. Endothelin is synthesised, 
stored and released in human atrium and crosstalk between AII and ET-1 as an 
autocrine phenomenon has been described474. 
 
In summary it appears that the possibilities for an ET-1 mediated anti-adrenergic 
effect on ICaL and subsequently action potentials are as follows: ET-1 stimulates 
calcium release from the SR producing calcium mediated inactivation of 
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ICaL
195;197;258, ET-1 stimulates IP3 formation and in so doing inhibits cAMP formation 
by adenylate cyclase reducing the ability of cAMP dependent kinases to activate 
ICaL
187;188;200;262;273;399, or that ET-1 stimulates cyclic nucleotide phosphodiesterase 
via cGMP hydrolyzing cAMP antagonizing the adrenergic effect of β-AR 
stimulation187;199;200;242 on ICaL but not NCX
402;403. The apparent contradiction in an 
inhibitory effect on ICaL but a positive inotropic effect could be explained by the 
relative efficacy of the differing second messenger systems effected by ET-1 
binding to ET-A receptors: sensitizing the SR and increasing cytosolic calcium 
during diastole will oppose calcium entry via ICaL
195;197;258, PLC activation and IP3/ 
DAG stimulation produces a positive inotropic effect but the associated inhibition 
of cAMP will reduce ICaL amplitude
187;188;200;262;273;399 and activation of NHE265 and 
NCX266-268 via PKC will result in a positive inotropic effect with little direct effect on 
ICaL. 
 
5.3 The potential effects of ET-1 on the fundamental 
mechanisms of arrhythmogenesis in human atria 
The three fundamental mechanisms underpinning arrhythmogenesis are triggered 
activity, reentry and abnormal automaticity. The occurrence of these fundamental 
mechanisms is promoted by several pathophysiological remodelling processes 
(Figure 1.1). The potential for ET-1, alone or in combination with ISO, to affect 
human atrial arrhythmogenesis could be modified by the duration of exposure, 
local concentration and tissue exposure within the heart, pathological disease 
states, pharmacological therapy and the presence of physiological stress. 
Evidence suggesting a possible role of ET-1 in any of these three fundamental 
processes, and impact on AF or CHF induced remodelling will be discussed. 
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5.3.1 Triggered Activity 
ET-1 was, at first, thought likely to predispose to EADs and DADs by reducing IK 
and causing increased intracellular calcium loading50 via augmenting ICaL. 
However the data suggesting that ET-1 decreases IK
62;271 are controversial264;456 
and in the present study and one other ET-1 did not affect APD322;454. ET-1 did 
augment the calcium transient via increased calcium mobilisation from SR and 
perinuclear stores192;197;264;267;392;456;457 activating NHE179;241;265;393 and 
NCX241;266;268;393. This may potentially be pro-arrhythmic, with ET-1 increasing the 
magnitude of calcium sparks sufficiently to induce diastolic calcium waves 
correlating with spontaneous depolarisations319;391;392;458. However, in an open 
chest dog model ET-1 had an anti-adrenergic protective effect on ISO induced 
atrial fibrillation and ventricular arrhythmia476. Although the data presented here 
relate to single myocyte recordings, ET-1 abolished both the early and late 
spontaneous depolarisations initiated by ISO during action potential recordings322, 
directly analagous to the anti-adrenergic phenomenon described in the open chest 
dog model476. Further evidence of a potential anti-arrhythmic effect of ET-1 comes 
from clinical trials in human patients of long term ET-A receptor blockade. Despite 
promising results in animal testing274;275, results of clinical trials in human patients 
with CHF have been disappointing276 with two larger studies being terminated 
prematurely due partly to an unexpected increase in atrial277 and ventricular278 
arrhythmia. 
 
The acute effects of ISO on ICaL and IK translate into altered action potential 
repolarisation and refractoriness. Data from early experiments in line with the data 
presented here confirm that acute superfusion with ISO increased the action 
potential plateau and caused afterdepolarisations without alteration of phase 0 
characteristics419;428;429;452.  The lack of effect on later repolarisation and cellular 
Calum Jon Redpath  Chapter 5-176 
ERP, in combination with the known effect of ISO to augment ITO and IKur suggests 
that in addition to increasing APD50 there must also be ‘compensation’ of late 
repolarisation in order to fully repolarise ‘on time’ and to preserve ERP164;165;424;453. 
It also suggests that SDs are related to elevated ICaL rather than some hithertofore 
unappreciated effect on K repolarising currents as the SDs occur in cells in which 
there has not been lengthening of ERP. This is also suggested by the lack of effect 
of ET-1 alone on ICaL and the absence of a significant effect of ET-1 alone to cause 
SDs. This suggests that, at least insofar as human atrial isolated myocytes in vitro 
can be described to undergo arrhythmogenesis, triggered activity, traditionally 
associated with arrhythmia initiation, is a potential arrhythmogenic effect of acute 
adrenergic stimulation and that this arrhythmogenic effect is opposed by ET-1. 
 
Unopposed β-AR agonism, such as that experienced during decompensated CHF, 
would be expected to increase both ICaL and IKur / IKs and these opposing effects on 
APD may protect against excessive APD prolongation in human atria69;165. Any 
increase in cAMP or PKA activity will result in increased phosphorylation of 
calcium handling proteins and augmentation of CHF induced remodelling69. 
Elevated PKA hyperphosphorylates RyR2 disassociating calstabin and 
CaMKII477;478 in human ventricular preparations resulting in depleted SR calcium 
stores because of diastolic calcium leak from the SR477-479 activating inward NCX 
and potentially culminating in triggered arrhythmia210. The potential 
arrhythmogenic effect of leaky RyR2 in CHF is only beginning to be 
investigated477;480-483, however. Fortunately, although Ca ATP-ase (SERCA2a) and 
phospholamban (PLB) levels remain unaltered, PLB phosphorylation is decreased 
because of subsequent increased phosphatase activity in CHF484-488. This results 
in decreased calcium uptake, SERCA2a function and CaATP-ase 
activity479;485;487;489-494 reducing subsequent calcium transient and rate of decay, 
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culminating in a reduced force frequency relationship491;495 and a lower probability 
of triggered activity. 
 
Despite this adaptation, in animal models adrenergic stimulation and altered 
phosphorylation status of PKA and CaMKII in combination appear to result in 
sufficiently leaky SR calcium release channels to produce diastolic calcium waves 
which can result in triggered arrhythmia43;496;497 with evidence of altered CaMKII 
activity in human CHF479, despite reduced myocyte calcium stores210;496 because 
of hyperphosphorylated SR calcium release channels, the electrogenicity of 
calcium extrusion by NCX and the increased membrane resistance due to 
decreased IK1 resulting in greater depolarisation for any given inward current
69. 
 
AF-induced electrical remodelling is accompanied over a longer time course by 
cellular remodelling98. AF has been associated with human atrial myocyte 
apoptosis96 and the surviving atrial myocytes demonstrate significant ultra-
structural abnormalities97;498;499. Atrial myocyte degeneration with sarcoplasmic 
reticulum fragmentation, marked collagen formation, widening of the intercalated 
discs and replacement of myofibrils results in patchy fibrosis, atrial dilatation and 
myopathy97;498;499. More frequent calcium sparks and calcium waves were 
observed in atrial myocytes isolated from patients in AF when compared to those 
from patients in sinus rhythm despite apparently similar levels of SR calcium 
loading and greater NCX activity suggesting a direct role for the calcium release 
channel16. Elevated levels of PKA induced hyperphosphorylation of RyRs resulting 
in dissociation of calstabin2 (FK506) and thus increasing the Po due to calcium 
hypersensitivity could also contribute to increased leak of calcium from the SR in 
human atria initiating AF via triggered activity or supporting arrhythmia 
maintenance in patients already suffering AF16;477;500. 
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5.3.2 Intra-atrial Reentry 
Intra-atrial reentry is promoted by any factor which reduces conduction velocity 
and refractoriness or increases path length or conduction time. Thus decreased 
INa/ Vmax, decreased ICaL or increased IK, decreased APD and ERP, atrial dilation 
and stretch all promote reentry. We did not measure INa or IK directly and therefore 
can only speculate on the direct effect of ET-1 on these ion currents. The small 
reduction in Vmax following acute superfusion with 10 nM ET-1 in this study 
suggests a possible decrease in INa, however this is contrary to previous reports in 
human right atrial myocytes176;200;261 and should interpreted with caution. The lack 
of effect of ET-1 on APD suggests that in the present model ET-1 does not acutely 
affect IK. However, one study of human atrial myocytes reported that ET-1 induced 
a marked inhibition of IK1
371. In view of the absence of an ET-1 effect on APD and 
ERP in this study, at the very least it can be said that using this model of 
arrhythmogenesis there is little or no evidence for ET-1 alone to promote intra-
atrial reentry via a direct effect on ion channels or refractoriness in human atrial 
isolated myocytes. 
 
Heart Failure, whether acute501 or chronic502 results in left atrial stretch and 
dilatation which has been associated with reductions in ICaL, APD shortening and 
plateau depression115. Myocytes isolated from dilated human atria are larger with 
smaller ICaL and demonstrate abbreviated APD, perhaps due to elevated levels of 
ANP, altered redox state or kinase/ phosphatase activity84;115;199;299;379;503. Whether 
this reduced ICaL translates into a reduction in atrial ERP is unclear
115;117 however 
the relationship between atrial dilatation, altered atrial electrophysiology and 
prognosis appears robust115;504;505. Certainly atrial dilatation and calcium overload 
as a result of tachycardia will result in oxidative stress, as indicated by glutathione 
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depletion and increased NADPH activity which have been linked with impaired 
contractility, reduced ICaL and IKur AF in man
97;375;377;379;506-508. 
 
Altered phosphorylation as a result of stretch-induced oxidative stress can also 
modulate the response of ICaL and cellular calcium processing to adrenergic 
stimulation84;379;509;510 perhaps directly via the RyR and L-type calcium 
channels374;376;379;395;511. This mechano-electric feedback512;513, demonstrated in 
humans514 and animal models515-517 via vagal efferent stimulation, results in 
electrical instability by accelerated repolarisation and ERP shortening518 further 
predisposing to arrhythmia519. Acute atrial stretch may have variable effects 
throughout the atria thereby generating non uniformity of conduction and this 
combined with increased atrial size is more likely to permit accommodation of the 
multiple daughter wavelets seen in fibrillating atria520 promoting reentry or enhance 
the automaticity of arrhythmogenic foci448. 
 
CHF, in addition to direct cardiac electrophysiological remodelling 
effects69;114;115;117;119;158;449, is associated with increased levels of circulating 
catecholamines and adrenergic tone which in turn can have profound effects on 
human cardiac performance122;151;255;331;332;521-523. In human atrial myocytes acute 
exposure to ISO has a concentration dependent effect via β-AR stimulation 
increasing ICaL, IK and IKur via PKA/ cAMP, and α-AR stimulation by Phenylephrine 
decreases IKur and Ito via PKC
165. This indicates that the repolarisation prolonging 
effect of ISO by increasing ICaL and inhibition of Ito outweighs opposition by 
stimulatory effects on IKur
164;165;321;424. 
 
In the present study, no measurements of K+ currents were made but acute 
superfusion with ISO augmented ICaL in a concentration dependent manner without 
altering the I:V relationship, activation or inactivation kinetics in human atrial 
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isolated myocytes. This adrenergic increase in ICaL has previously been attributed 
to an increased mean channel opening time and an increased Po
90;238;239;302-307. 
 
The acute effects of ISO on ICaL and IK translate into altered action potential 
repolarisation and refractoriness. Data from early experiments in line with the data 
presented here confirm that acute superfusion with ISO increased the action 
potential plateau and caused afterdepolarisations without alteration of phase 0 
characteristics419;428;429;452.  The lack of effect on later repolarisation and cellular 
ERP, in combination with the known effect of ISO to augment ITO and IKur suggests 
that in addition to increasing APD50 there must also be ‘compensation’ of late 
repolarisation in order to fully repolarise ‘on time’ and to preserve ERP164;165;424;453. 
 
5.3.3 Abnormal Automaticity 
Abnormal automaticity in the atrium occurs when atrial or pulmonary vein 
myocytes, which are not normally pacemaker cells, begin to spontaneously fire at 
a faster rate than the SAN as a result of accelerated phase 4 depolarisation (See 
Section 1.2.3).Although fractionation or fibrillatory conduction has been observed 
in patients, no direct evidence for a role of abnormal automaticity has been 
identified to date in patients67-69. Currently there is no data to suggest that ET-1 
has an effect on If or phase 4 of the human atrial action potential. 
 
5.4 Limitations of this work 
Despite the obvious scientific benefits, there are inherent practical and theoretical 
limitations in studying human tissues. The availability of tissue is limited, by virtue 
that cardiac tissue is only available at the time of cardiopulmonary bypass during 
cardiac surgery, a small sample of tissue is obtained and thus fewer cells are 
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available for experiments. In addition the confounding effects of competing 
comorbidities and pharmacological therapies, effects of age and gender and 
hithertofore unknown other factors can potentially limit the applicability of some 
experimental results. 
 
The enzymatic dissociation method is recognised to result in cells which are 
depolarised at rest after experimentation. Furthermore, despite strenuous attempts 
to maintain and protect the myocytes, prolonged recording protocols are limited, 
despite the success of perforated patch recordings. 
 
5.5 Future Directions 
AF remains the most common disorder of cardiac rhythm1;524-526, affecting more 
than half a million people in the UK alone527 and estimated to cost the UK NHS 
more than £1 Billion in 2000527. The prevalence of AF in the UK has risen528 and 
will continue to do so as the population ages1;529 and improvements in the 
management of associated conditions such as CHF are implemented530 
 
AF results in several deleterious, yet reversible, effects on cardiac physiology: loss 
of Atrio-Ventricular synchrony and rapid irregular ventricular systole negatively 
effect cardiac output2;3;531-535 increasing the risk of atrial536 and ventricular 
tachycardiamyopathy537 and ultimately CHF538-540. Even in the absence of 
coronary atheroma, AF increases myocardial oxygen demand whilst 
simultaneously decreasing coronary perfusion resulting in myocardial 
ischaemia541;542 and hence potentially precipitating further arrhythmia543. 
 
These experiments have prompted me to consider investigating the links between 
the intracellular calcium handling effects of ET-1 and alterations of ICaL and action 
potential characteristics at the plasmalemma. Experiments performed with 
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confocal microscopic measurements would provide further insight into the effects 
of neurohormonal activation on human atrial myocytes but also the multifaceted 
process of atrial excitation contraction coupling. This work would enhance our 
knowledge of the generation of EADs and DADs. Expansion to multicellular 
preparations would allow further assessment of the ability of adrenergically 
induced afterdepolarisations to be propagated linking to arrhythmogenesis. The 
interaction between other neurohormones, such as ANP and AII, and 
catecholamines and ET-1 may prove another fruitful piece of experimental work. 
Do these autocrine/ paracrine substances interact at the receptor level, crosstalk, 
or within the cell at the level of secondary messengers or indeed via 
complementary or opposing effects on calcium handling, or indeed all of the 
above. If such interaction exists is this pro or anti arrhythmic? 
 
Expanding the area of interest into the K+ currents involved in repolarisation may 
also permit further insight into atrial myocyte electrophysiology. Although 
investigation of IKr and IKs in human atrial myocytes is difficult due to the chunk 
method of isolation544, an investigation into the impact of ET-1 on these important 
repolarising currents is much needed. 
 
Investigation of a potential role for tyrosine phosphorylation and PKC in the 
modulation of ICaL in human atrial myocytes, whether membrane bound or 
cytosolic, warrants further examination. Interest in reports of a role of Ca2+/ 
calmodulin dependent protein kinase II (CAMKII) activity in modulating ICaL and 
RyR function have been aroused by the data relating to the role of protein 
phosphatases in AF and CHF induced structural remodelling84;483;496;497;545-547. 
 
By the very nature of the experimental method, studies of an acute exposure of 
myocytes to single, biologically plausible, contender molecules, such as ISO and 
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ET-1 in this study, have commonly been performed. The possibility of performing 
integrated physiology experiments in animal models examining the effect(s) of 
chronically elevated ET-1 levels on atrial and ventricular electrophysiology should 
be explored. A comparison with those electrophysiological effects occurring in 
cardiac tissue following an induced heart failure syndrome would assist in the 
understanding of the links between CHF, AF, ion currents and calcium handling. 
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Appendices 
(i) Patient consent form 
 
Right atrial appendage 
 
Glasgow Royal Infirmary University N.H.S. Trust 
 
PATIENT INFORMATION AND CONSENT FORM 
 
Title of Project: Electrophysiological and molecular properties of isolated human 
cardiac myocytes. 
 
Summary: 
You are shortly to undergo a heart operation. The reasons for this, and the type 
of operation to be performed, will have been discussed with you by your 
cardiologist and by the heart surgeon. 
We are undertaking research into why some patients have abnormal heart 
rhythms and how these cardiac arrhythmias affect the heart cells. In order to 
understand the biological properties of heart cells we would like to obtain a 
small sample of your heart muscle.  
During the operation, the surgeon routinely makes a small cut in the heart to 
allow the operation to proceed. Many surgeons perform this by removing a small 
piece of heart tissue (about the size of a pea), which would normally be 
discarded. Some surgeons do not routinely remove this piece of tissue, but are 
willing to do so, since they know that such a procedure would not do you any 
harm. We are asking for your consent to use this small piece of the heart to 
obtain heart cells for our study. Part of the tissue will be studied directly for 
electrical activity and then discarded, and the remainder will be deep-frozen at 
the hospital for future analysis of molecular activity, after which it will be 
destroyed. Participation in our study will not change the operation or result in 
additional risk or discomfort to you. 
In addition, we would ask your permission to obtain details of your condition 
from your medical records. These details will be kept confidential and your 
identity will be concealed by the use of a coding system. Such information will 
be retained for comparison with the results of the tissue analysis, and will not be 
disclosed to anyone outside the hospital. 
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This research project will not be of direct benefit to you, but the results may 
help other patients in the future. If you are unwilling to take part, you are 
entirely at liberty to refuse permission. This would not affect your medical 
treatment in any way. 
 
Consent: 
I, (Name) ………………………………………………………………………………. 
of (Address) …………………………………………………………………………… 
agree to take part in the Research Project described above. 
Dr …………………………………………….. has explained to me what is involved, how it 
might affect me and the purpose of the Research Project. 
 
Signed …………………………………………………………… Date …………….. 
 
Witness ….……………………………………………………… Date …………….. 
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